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CHAPTER 1 
Cardiovascular pharmacology of purines: a general introduction 

General introduction 
Background 
Since the beginning of this century, the cardiovascular actions of extracellular 
nucleosides and nucleotides have been recognized [1-4]. Only recently, understanding of 
their interstitial formation, degradation and mode of action has been increased and their 
significance in (patho)physiology has been identified [5]. Apart from their cardiovascular 
actions, they appear to be involved in modulation of the central nervous system, immune 
function, thrombocyte aggregation and regulation of renal and gastro-intestinal functions 
[6-14]. Via their interactions with the autonomic nervous system [15.16], they probably 
interfere with almost any body function. This thesis will focus on two purines: adenosine 
and adenosine-5'-triphospate (ATP). In this introduction section, we will primarily discuss 
in-vitro and animal data on the role of purines in the modulation of the cardiovascular 
system. For a discussion of human in-vivo studies, we refer to the other chapters in this 
thesis. Interaction with other systems will only be considered as far as it interferes with 
the cardiovascular system. Since endothelium is thought to play an important role in the 
vascular effects of purines, some general properties of the endothelium with regard to the 
regulation of vascular tone will be discussed First. 
The role of the endothelium in the regulation of vascular tone 
In vitro experiments on the effect of endothelium removal have indicated that a 
variety of classical pharmacological vasodilators induce their effect in an endothelium-
dependent way [17-19]. Among these vasodilators are acetylcholine, adenine nucleotides, 
histamine, serotonin, thrombin, bradykinin and substance P. These substances stimulate 
the endothelium to release a labile substance called 'endothelium-derived relaxing factor' 
(EDRF) [20]. Both nitrovasodilators, with nitric oxide (NO) as active principle, and 
EDRF stimulate the soluble guanylate cyclase in the smooth muscle cell to form cyclic 
guanosine monophosphate (cGMP), a second messenger inducing relaxation in smooth 
muscle cells [21]. Based on this and other similarities Furchgott assumed that EDRF was 
identical to NO. This has been experimentally confirmed by Moncada's group [22,23] and 
Ignarro et al. in 1987 [24]. NO is formed from L-arginine [25,26]. This stereospecific 
reaction is catalyzed by NO-synthase and can be competitively antagonized by L-arginine 
analogues like Nf!-monomethyl-L-arginine (L-NMMA) [27,28]. Two types of NO-
synthase are known: a constitutive Ca2+-dependent NO-synthase and an inducible Ca2+-
independent NO-synthase [29]. The first type is present in the endothelial cells and in 
adventitial nerve endings where it may play a role in non-adrenergic and non-cholinergic 
nerve stimulated vasodilation [30,31]. The second type is expressed in endothelial cells, 
smooth muscle cells, granulocytes, Kupffer cells and hepatocytes after induction by lipo-
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polysaccharides (LPS), interferon gamma or interleukin-1 [32] Under physiological cir-
cumstances the Ca'+-dependent NO-synthase is the most important one in regulation of 
vascular tone [33] The second type may play an important role in sepsis mediating the 
vasodilation and shock [34] 
In vitro the basal vascular tone is increased by removal of the endothelium or by 
incubation with L-NMMA, indicating the basal release of endothelium-denved NO 
[27,28,35] Vallance et al have shown that this L-NMMA-induced forearm vasoconstric-
tion is reversed by infusion of L-arginine but not by D-arginine, indicating that NO is 
also released in basal conditions in humans in vivo [36] Intravenous infusion of L-
NMMA in rats induces an increase in blood pressure suggesting that endothelial basal 
NO-release has an important function in blood pressure regulation [37] However, a 
central mechanism due to decreased NO mediated inhibition of the sympathetic nervous 
system may play a role in the pressor response to systemic infusion of L-NMMA in rats 
[30,38,39] 
Hypoxia and shear stress stimulate the NO release providing a mechanism to adapt 
the circulation to local demands [40,41] Besides direct effects of these factors on the 
endothelial NO release, local stimulation of the release of endothehum-dependent 
vasodilator substances from passing erythrocytes (adenosine triphosphate (ATP)) or from 
endothelial cells (ATP, acetylcholine, substance P, serotonin) may account for the 
increased NO-release during hypoxia or shear stress [42,43] 
Both adrenergic nerve stimulation- and phenylephnne-induced vasoconstriction are 
inhibited in the presence of endothelium [44,45] indicating an interaction between the 
sympathetic nervous system and endothelium This interaction is accomplished by an 
alpha-receptor-mediated norepinephrine induced release of EDRF [46] Besides this 
interaction, an endothelmm-denved factor may have a presynaptic inhibiting influence on 
norepinephrine release [47] However, the literature is not unequivocal on this issue [48] 
The majority ot endothehum-dependent vasodilators, like serotonin, acetylcholine and 
ATP, are able to elicit vasoconstriction in the absence ot endothelium, probably by 
interacting with specific smooth muscle cell receptors [49-51] Like norepinephrine, these 
compounds may play a role as a neurotransmitter in the sympathetic nervous system [49]. 
Endothelium-denved nitric oxide is not only a potent vasodilator Like smooth 
muscle cells, thrombocytes possess a soluble guanylate cyclase [52] Acetylcholine-
induced EDRF release stimulates the soluble guanylate cyclase of passing thrombocytes 
[53] Endothelium-denved NO inhibits thrombocyte adhesion and aggregation by 
stimulation ot thrombocyte soluble guanylate cyclase [54-56] Thrombocyte NO-synthase 
is stimulated during thrombocyte aggregation providing a negative feedback control 
[52,57] Prostacyclme potentiates the effect ot NO on thrombocyte aggregation [58] 
During aggregation thrombocytes release vasoactive substances which induce an endothe-
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hum-dependent vasodilation (ATP, ADP, possibly serotonin), or vasoconstriction in the 
absence of endothelium (thromboxane A2, serotonin) [59-61]. These thrombocyte-denved 
vasoactive substances may also be involved in an EDRF-mediated inhibition of thrombo-
cyte aggregation. 
Many questions still remain to be answered in research on endothelial physiology. 
For instance, other endothelium-denved substances like prostacycline and 'endothelium 
derived hyperpolanzing factor' may be involved in the endothelium-dependent vasodila-
tion [62-67]. Their relative importance may vary in different vascular beds, different 
species and different physiological and pathophysiological circumstances [68,69] 
Besides EDRF the endothelium is able to release endothelium-denved contracting 
factors (EDCF's) like endothelin-1, thromboxane A, and prostaglandin H2 [70] Many 
stimuli that induce release ot EDRF also induce the release of endothelin-1 [71-73] 
Furthermore, endothelin-1 itself is able to stimulate the release of endothelium-denved 
NO and prostacycline [74-77] The physiological importance of these interactions is 
speculative, but it is suggested that the endothelin-1 -induced release of NO and prosta-
cycline exerts a negative feedback on endothelin production via cGMP- and cAMP-
dependent mechanisms [70] The physiological relevance of the inhibition of autogenesis 
and proliferation of smooth muscle cells by NO and the opposite effect of endothelin-1 is 
unknown [78,79]. 
Formation, release and degradation of adenosine and ATP 
Within the cell, adenosine is pnmanly formed by two metabolic routes [80]. First, 
it is formed from ATP by degradation via adenosine-5'-diphosphate and adenosine-5'-
monophosphate (AMP) to adenosine This pathway is accelerated when there is a 
mismatch between energy supply and demand and probably represents the main route of 
adenosine formation during ischemia The hydrolysation of AMP is catalysed by 5'-
nucleotidase, which is present both in the intracellular (cytosolic form) as well as the 
extracellular space (membrane bound form) Second, adenosine is formed by hydrolysati-
on of ATP via S-adenosylmethionine to S-adenosylhomocysteine which in tum is 
hydrolysed to adenosine This reaction is catalysed by S-adenosylhomocysteine-hydrolase 
This route is oxygen insensitive and is probably of minor importance during ischemic 
conditions Adenosine diffuses through the cellular membrane between the extracellular 
and intracellular space This bidirectional process [81] is concentration gradient dependent 
and is facilitated by a nucleoside transporter that is located in the outer membrane of 
many cells among which the endothelial cells, erythrocytes, cardiomyocytes and vascular 
smooth muscle cells. 
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Apart from a cellular source of adenosine, adenosine formation may occur from 
extracellular ATP that can rapidly be degraded to adenosine by widespread ecto-nucleoti-
dases which are present at the extracellular surface of vascular smooth muscle cells and 
endothelium [82-86]. The endothelium appears to play a key role in uptake and metabo-
lism of luminally applied adenosine [87-89], but it is also a major source of endogenous 
adenine nucleosides and nucleotides. The endothelial release of adenine nucleosides and 
nucleotides is increased by beta-adrenergic stimulation [85]. Norepinephrine-induced 
activation of 5'-nucleotidase may play a role in this interaction between endothelial 
adenosine formation and the sympathetic nervous system [90]. 
Adenosine-5'-triphosphate is released by exocytosis from aggregating thrombocytes 
and from sympathetic nerve endings where it is coreleased with norepinephrine [15]. In 
most cells, cytoplasmatic ATP concentrations are high and simple diffusion of ATP 
through the cell membrane may partly account for extracellular ATP. During increased 
blood flow [42,72,91], sympathetic nerve stimulation [92], or application of well known 
vasodilators like bradykinin and acetylcholine [93], endothelial cells appear to release 
ATP. Cardiac ischemia evokes an increase in plasma nucleotide concentration in the 
venous effluent which is underestimated by vascular ecto-nucleotidase activity [85]. Under 
hypoxic conditions, erythrocytes release ATP [94]. 
As mentioned above, extracellular ATP is rapidly degraded to adenosine by ecto-
nucleotidases. During normal oxygenation, intracellular adenosine and AMP concentrati-
ons are low. In this situation, extracellular adenosine will rapidly be transported to the 
intracellular compartment where it is further inactivated by phosphorylation to AMP or 
deamination to inosine. An extracellular form of adenosine deaminase exists. The relative 
importance of extracellular versus intracellular adenosine deaminase differs between 
species [95]. In man, intracellular deamination after uptake is probably of most importan-
ce [95]. 
Purinergic receptors 
Cardiovascular responses to purines are thought to be mediated by membrane 
bound receptors that interact with their extracellular ligand to evoke an intracellular signal 
(increase or decrease in concentrations of Ca2+, cAMP or cGMP for example) that 
ultimately changes cellular function (i.e. smooth muscle cell relaxation or contraction, 
reduction or increase in neuronal firing rate or neurotransmitter release) [96]. Several 
lines of evidence support this view and point towards a subdivision in P,- and P2-
purinergic receptors. This subdivision is based on the potency order of agonists (ATP > 
ADP > AMP > adenosine and adenosine > AMP > ADP > ATP for the P2- and P,-
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purinergic receptor respectively) and the P,- but not P2-punnergic receptor antagonistic 
properties of xanthine derivatives [6] 
The existence of P|-punnergic receptors has been demonstrated using adenosine 
analogues that are less or not attected by degradation, specific antagonists derived from 
the methylxanthines caffeine and theophylline, (ìntra)cellular measurement of second 
messenger systems (cAMP, intracellular Ca2+ concentrations, ion currents, membrane 
potentials), receptor ligand labelling studies, receptor purification and DNA cloning 
studies [97] Based on ligand specificity and effect on intracellular cAMP levels, P,-
punnergic receptors are subdivided in A,- and A2-adenosine-receptors. This differentiation 
has been verified by molecular techniques [98,99] Both receptors are linked to so called 
G proteins A|-receptor stimulation evokes a G.-mediated decrease in adenylate cyclase 
activity with subsequent reduction in intracellular cAMP levels The A,-receptor is 
associated with a Gs binding protein and stimulation of this receptor increases adenylate 
cyclase activity with a subsequent increase in intracellular cAMP levels Apart from this 
adenylate cyclase mediated response to P,-receptor stimulation, both receptor subtypes 
have been associated with a variety ot other second messenger systems [5] like for 
instance an ATP-dependent potassium channel (KA1I.-channel). A,-receptor-mediated 
opening of K,U|.-channels may play a role in the phenomenon of ischemic preconditioning 
(see below) Recently, the existence of a distinct Añádenosme receptor has been sugges-
ted [100] Advances in molecular biology will probably reveal many other subclasses of 
the adenosine receptor Whether stimulation ot these receptors give rise to a specific 
pharmacological or physiological effect, distinct from A,- or A,-receptor stimulation 
remains to be elucidated 
Based on rank order differences in agonist potencies and different vascular effects, 
the vascular P,-purinergic receptor has been subdivided in the P3x- and P2>-punnergic 
receptors [101,102] P,4-purinergic receptors are located on vascular smooth muscle cells 
and mediate vasoconstriction The Ρ,,,-purinergic receptor mediates a vasodilator response 
either via stimulation ot the endothelium to produce endothelium-denved relaxing factors 
(nitric oxide, prostacychne) or via a direct effect on the smooth muscle cell 
[62,69,103-106] Apart from these two receptor subtypes, the existence of separate 
vascular 'pynmidine' or 'nucleotide' receptors has been suggested [107-111]. A more 
definite characterization of cardiovascular Ρ,-receptors continues to be hindered by the 
lack of selective, competitive receptor antagonists [108,109] The P2x-punnergic receptor 
agonist alpha,beta-methylene ATP, has been successfully applied to perform radioligand 
studies on P2-punnergic receptors [112] and to desensitize P,x-punnergic receptors [113]. 
However, repeated application ot alpha,beta-methylene ATP not only inhibits the 
vasoconstrictor etlecl ot ATP, but may also attenuate the vasoconstrictor effect of norepi­
nephrine, angiotensin II and vasopressin [114] In addition, the potency of alpha.beta-
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methylene ATP to inhibit ATP-induced effects varies enormously [115]. To date, P2-
purinergic receptors have not been isolated with molecular techniques. The second 
messenger systems that are involved in mediating its effects are not exactly known but 
phospholipase С activation, inositol phosphate production and subsequent increases in 
intracellular Ca2+ concentrations appear to be involved [104]. 
Apart from vascular P2-purinergic receptors, specific P2T-purinergic receptors have been 
demonstrated on thrombocytes [116]. Adenosine-5'-diphosphate is the most potent 
endogenous agonist for this receptor and receptor stimulation results in thrombocyte 
activation and subsequent thrombus formation. Adenosine-5'-triphosphate is an endoge­
nous antagonist for this receptor. 
Effects of cardiovascular purinergic receptor stimulation 
Vascular wall 
Adenosine-5'-rriphosphare may exert two opposite vascular actions that are 
mediated by two distinct P2-purinergic receptors located on endothelium and vascular 
smooth muscle cells (see figure 1). The endothelial receptor evokes an endothelium-
mediated vasodilator response. Apart from nitric oxide, prostacycline and/or 'EDHF' 
(endothelium-derived hyperpolarizing factor) may be involved as endothelium-derived 
relaxing factor [63,103,104]. Since the endothelium plays an important role in degrada­
tion and uptake of purines, only a minor part of luminally applied ATP will probably 
reach the vascular smooth muscle cells [82,83]. Indeed, if endothelial function is intact, 
ATP as released during thrombocyte aggregation induces a vasodilator response [59]. 
On vascular smooth muscle cells, P2„-purinergic receptor stimulation results in a 
vasoconstrictor response [117]. For reasons as mentioned above, this receptor will 
preferentially be stimulated by interstitially released ATP as occurs from sympathetic 
nerve endings. 
In most vessels, adenosine induces a vasodilator response via A2-adenosine 
receptor activation (see figure I) [118]. The A, receptor can mediate vascular relaxation 
as well [119] although this receptor subtype is generally believed to be involved in a 
vasoconstrictor action of adenosine in some vascular beds (see below). In the absence of 
an intact endothelium, the vasodilator response is still present indicating that an intact 
endothelium is not obligate for adenosine to establish its effect [120]. However, some 
studies show a reduced vasodilator response to adenosine when the endothelium is 
removed, indicating that adenosine receptors may be present on the endothelial cells 
[106]. Furthermore, inhibition of NO-synthase has been shown to inhibit adenosine-
mediated vasodilation [121]. Recently, A2-adenosine receptors have been 
16 
General introduction 
Sympathetic пвг ф 
ADO K¿> 
ATP NE 
•р=а R 
*мт**/я* j j j ^
 А Т
р 
Figure 1. A simplified presentation of the proposed interactions (based on in vitro studies and animal in 
vivo studies) between the purines adenosine (ADO) and adenosine-5'-triphosphate (ATP) and the sympathe­
tic nervous system and endothelium with respect to the regulation of vascular tone. Squares represent P,-
purinergic receptors (P^-purinergic receptor: shaded boxes, P^-purinergic receptors: black boxes); Circles 
represent Ρ,-purinergic receptors (Α,-purinergic receptor: shaded circle, A
:
-purinergic receptor: black 
circle); Triangle represents the alpha adrenoceptor; V.S.M. cell: vascular smooth muscle cell; NO: nitric 
oxide; EDRF: endothelium derived relaxing factor; NE: norepinephrine. 
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demonstrated on human endothelial cells [122]. There is some debate with regard to the 
functional significance of these endothelial adenosine receptors [123]. Facing the key role 
of the endothelium in purine degradation and uptake, the site of adenosine application or 
formation may determine whether the vasodilator response is mediated by a direct effect 
on the vascular smooth muscle cells (interstitial adenosine) or whether the endothelium is 
involved (luminal adenosine) [124]. 
Although adenosine induces a vasodilator response in most vessels, two important 
exceptions are known: the pulmonary vascular bed [125] and the preglomerular afferent 
arterioles in the kidney (see below). In these vessels adenosine induces a vasoconstrictor 
response that is thought to be mediated by A,-purinergic receptors. In the lung, this effect 
might be implicated in hypoxia-induced vasoconstriction, and in the kidney adenosine-
induced afferent vasoconstriction may be involved in the autoregulation of the glomerular 
filtration rate (see below). 
Apart from its direct influence on vascular tone, purines have been shown to affect 
norepinephrine release from sympathetic nerve endings by presynaptic modulation (see 
figure 1). Most studies on this matter point towards an adenosine-induced A^purinergic 
receptor-mediated response. ATP, via a yet unclassified purinergic receptor subtype, may 
be involved as well [126,127]. 
Based on the above mentioned experimental data, Burnstock hypothesized that 
ATP is co-released with norepinephrine by sympathetic nerve endings, induces a 
vasoconstrictor response in concert with norepinephrine and is rapidly degraded to 
adenosine which presynaptically inhibits sympathetic neurotransmitter release thus 
providing a negative feedback loop [15,128]. The activity of this feedback loop may be 
controlled by ecto-nucleotidase activity [129]. 
Heart 
Apart from coronary vasodilation and presynaptic inhibition of norepinephrine 
release (see above), purines have negative chronotropic, dromotropic and inotropic effects 
in isolated heart preparations. ATP is thought to induce its negative chronotropic and 
dromotropic effects after degradation to adenosine [130,131]. However, under certain 
experimental conditions, atropine or vagotomy can attenuate the negative chrono/dromo-
tropic actions of ATP, suggesting that the ATP effect is at least partially vagally mediated 
[132,133]. 
Negative chronotropic actions. Adenosine depresses sinoatrial node activity and 
shifts the earliest site of atrial activation from the SA node towards the crista terminalis 
region. At high concentrations, adenosine may even cause a SA exit block. Adenosine 
may also depress atrioventricular and ventricular escape rhythms. In patients with a 
ventricular escape rhythm, heart rate is reduced in response to adenosine, especially when 
18 
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the escape rhythm is accelerated with isoproterenol. These effects are probably mediated 
by Α,-adenosine receptor stimulation [134]. In the intact organism, the adenosine-induced 
stimulation of reflex mechanisms may result in an increase in heart rate, which strongly 
contrasts with its effect on the SA-node (see chapter 2) 
Negative dromotropic actions. From the beginning of purine research, adenosine is 
known to induce heart block [1]. Adenosine prolongs atrioventricular conduction time 
dose-dependently. Its site of action is probably the proximal portion of the AV junction. 
Based on the rank order of potency of different adenosine analogs, A,-adenosine receptors 
are thought to be involved [135]. This action of adenosine is used clinically to terminate 
supraventricular tachycardias, especially in situations where calcium antagonists are 
contra-indicated [136,137]. 
(Anti)arrhythmic properties. Adenosine has been shown to attenuate ischemia- and 
catecholamine-induced arrhythmias [138-140]. This action is mediated by A, adenosine 
receptors, probably by preventing catecholamine-induced calcium influx and subsequent 
afterdepolarizations [134]. Adenosine-5'-triphosphate also inhibits isoproterenol-induced 
calcium influx, probably by stimulating Α,-adenosine receptors after degradation to 
adenosine [134]. When ATP alone (i.e. without isoproterenol pretreatment) is applied to 
isolated myocardial cells, calcium influx is increased. This effect is supposed to be related 
to P2-purinergic receptor stimulation [141] and may contribute to ATP-induced automati-
city. Alternatively, in isolated myocardial cells ATP hydrolysis may activate the chlori­
de/bicarbonate exchanger. The subsequent intracellular acidification may induce 
arrhythmic activity, providing a P2-purinergic receptor-independent mechanism [142]. 
Negative inotropic actions. Adenosine has a negative inotropic effect on both atrial 
and ventricular myocardium when contractility is increased with isoproterenol probably by 
antagonizing the isoproterenol-induced increase in intracellular cAMP [134,143]. In the 
atrium, adenosine also has a direct, i.e without isoproterenol pretreatment, negative 
inotropic action probably by increasing potassium efflux and subsequent hyperpolarizati-
on. These effects are mediated by Α,-adenosine receptor stimulation [134]. In contrast to 
adenosine, ATP has a positive inotropic action in both atrial and ventricular myocardial 
cells [144] by increasing intracellular calcium concentration. 
Kidney 
In contrast to most other vascular beds, adenosine induces a vasoconstrictor 
response in the outer renal cortex which appears to be confined to the glomerular afferent 
arterioles and which is mediated by Α,-adenosine receptors. Simultaneously, adenosine 
dilates the efferent glomerular arterioles via A2-adenosine receptor stimulation [145]. 
Acting in concert, these effects of adenosine result in a reduction of glomerular filtration 
rate. The vasoconstrictor effect occurs immediately upon adenosine infusion, while the 
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vasodilator response develops more slowly. These opposing effects of adenosine may 
explain the Diphasic response of renal blood flow but a constant depression of glomerular 
filtration rate during infusion of adenosine in the renal artery [145,146]. Adenosine-
ïnduced release of EDRF probably contributes to the efferent arteriolar vasodilation 
[145,146]. The adenosine-mediated reduction in glomerular filtration rate has been 
proposed to be involved in tubuloglomerular feedback. This term has been ascnbed to the 
phenomenon that an increase in the perfusion rate of fluid in the distal nephron results in 
a vasoconstrictive response of the afferent arteriole such that the glomerular filtration rate 
of that nephron is diminished. An increased tubular volume load would be sensed by the 
macula densa evoking a paracrine signal to the glomeruli and a subsequent reduction in 
glomerular filtration rate. Inhibition of the tubuloglomerular feedback by selective 
adenosine receptor antagonists and adenosine deaminase as well as stimulation of the 
phenomenon by adenosine deaminase inhibition and nucleoside transport inhibition serve 
as important evidence in favour of adenosine as a mediator of this phenomenon [5] 
Adenosine also affects tubular function resulting in an increased water and sodium 
excretion (although an increased sodium reabsorption has also been observed). In the 
nanomolar range, adenosine and its analogs stimulate A,-adenosine receptors resulting in 
reduced intracellular cAMP concentrations, providing a mechanism to attenuate the effects 
of vasopressin and parathyroid hormone, which are both acting via stimulation of 
adenylate cyclase [14]. In addition, adenosine inhibits renal renin release via Α,-adenosine 
receptor stimulation [147-154], resulting in reduced angiotensin II production. Renal 
erythropoietin production is increased by A2-adenosine receptor stimulation [155]. 
The renal effects of ATP are less well assessed. In the rat, ATP induces a 
vasoconstrictor response that appears to be most pronounced in the afterent (preglomeru-
lar) arterioles. The efferent arterioles are not aifected by ATP [156]. 
Adenosine: a natural defense against the sequelae of ischemia 
Extracellular formation of adenosine is increased during hypoxia and ischemia 
[157-160]. The sympathetic nervous system may play a role in this hypoxia or ischemia-
induced adenosine release [161-163]. Several effects of this locally formed adenosine are 
assumed to be beneficial in situations of reduced oxygen supply [164]. In the heart, the 
negative inotropic and chronotropic effects will reduce oxygen demand. The electrophysi­
ological effects of adenosine will reduce the risk of ischemia-induced arrhythmias. 
Presynaptic inhibition of norepinephrine release will attenuate the possible deleterious 
effects of norepinephrine like arrhythmogenesis, vasoconstriction, thrombocyte aggregati­
on and direct cytotoxicity [165] However, the relation between adenosine, cardiopro­
tection and sympathetic nervous system is complex since norepinephrine is able to 
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augment ischemia-induced adenosine formation by activation of 5'-nucleotidase [90] 
Furthermore, norepinephrine (like adenosine) has been shown to induce ischemic 
preconditioning (see below) [90] Adenosine-induced vasodilation will increase oxygen 
supply In addition, adenosine inhibits thrombocyte aggregation [166] and attenuates 
neutrophil function [Π,167] possibly reducing the formation of leucocyte-derived free 
radicals during ischemia and reperfusion In several animal models, adenosine has been 
shown to reduce myocardial infarct size and to prevent ischemia-induced cardiac 
arrhythmias [168-174] Adenosine appears to be involved in preconditioning defined as 
the increased tolerance of myocardium to a prolonged ischemic insult achieved by an 
initial briet exposure to ischemia and reperfusion [175] In humans, preconditioning has 
also been suggested [176-179] In animals, adenosine-induced preconditioning is mediated 
by A|-adenosine receptor stimulation An A^-adenosine receptor may also be involved 
[180,181] Protein kinase С and ATP-dependent potassium channels appear to play a key 
role in the postreceptor mechanism of preconditioning [182,183] 
In the kidney, adenosine only marginally attects renal blood flow (due to a 
combination ot afferent arteriolar contraction and efferent vasodilation) but reduces 
tubular oxygen demand by attenuating glomerular filtration rate and tubular function In 
contrast to this theoretical beneficial effects of adenosine in renal ischemia, the adenosine 
receptor antagonist theophylline prevented renal ischemic damage in rabbits [184] 
In the brain, adenosine can attenuate the synaptic release of the exocytotic 
aimnoacids glutamate and aspartate by stimulation of presynaptic Α,-adenosine receptors 
Postsynaptically, adenosine depresses membrane Ca , + permeability and increases K+ and 
CI permeability resulting in hyperpolansation, and a reduced oxygen demand [185] 
Endogenous adenosine prevents the occurrence of convulsions [186] Dilation of cerebral 
arterioles will increase oxygen supply Adenosine receptor stimulation and elevation of 
endogenous adenosine levels appear to reduce cerebral infarct size in animals [187] 
Pharmacological interventions 
To date, pharmacological interventions are primarily directed towards adenosine-
mediated effects An increasing number of more or less selective P,- and P2-punnergic 
receptor agonists and antagonists have been described For a detailed description, the 
reader is referred to some excellent reviews on this matter [6,97,116] 
Apart from compounds that directly interact with the adenosine receptor, some 
drugs have been developed with an indirect action More specifically, these drugs enhance 
adenosine release (AICA riboside [188-190]) or reduce adenosine degradation by 
inhibiting cellular uptake of adenosine (nucleoside transport inhibitors nitrobenzylthi-
oinosine, dipyridamole, dilazep and mioflazine derivatives like draflazine [191,192]) or 
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by inhibiting adenosine deaminase activity (deoxicoformycin). In addition, some com-
pounds have been described that facilitate the binding of adenosine to its receptor through 
an allostenc mechanism These allostenc enhancers may have the theoretical advantage of 
a possible adenosine receptor subtype specificity [193] These indirectly acting drugs have 
in common that they affect adenosine-mediated effects only at sites of endogenous 
adenosine release, providing a tool to prevent systemic side effects that are associated 
with systemic infusion of adenosine or its analogues 
Outline of this thesis 
In most studies that are presented in this thesis, the 'perfused forearm technique' is 
used With this technique, it is possible to quantify the effect of vasoactive substances on 
the forearm circulation without interference by possible systemic effects of the used 
compounds like baroreflex activation 
After cannulation of the brachial artery (an anatomical end artery), vasoactive 
substances can be infused using highly accurate perfusion pumps The resulting changes 
m forearm blood flow can be quantified by strain gauge plethysmography [194] To 
confine the measurements to the muscle vascular bed as much as possible, all measure-
ments are performed during occlusion of the hand circulation which is largely determined 
by the skin vasculature [195] Simultaneous measurements of forearm blood flow in the 
non-infused arm, permit us to detect possible changes in forearm blood flow that do not 
reflect local effects of the intra arterial infusions 
In the first part of this thesis (chapters 2-4), the effects of endogenous adenosine 
are investigated In particular, its interaction with the sympathetic nervous system is 
explored First, the effects of various grades of systemic nucleoside transport inhibition, 
as induced with draflazine, on plasma catecholamines, some hemodynamic parameters and 
ventilation are investigated (chapter 2 and 3) The hypothesis is tested that systemic 
nucleoside transport inhibition at a grade without any effect on catecholamines, blood 
pressure or heart rate still potentiates the forearm vasodilator response to exogenous 
adenosine. Next, the role of endogenous adenosine in modulation of forearm norepi-
nephrine release is investigated in baseline conditions and during stimulation of the 
sympathetic nervous system (chapter 4) This study tests the hypothesis that increased 
extracellular concentrations of endogenous adenosine results in a reduced norepinephrine 
release in response to sympathetic nerve stimulation 
The second part of this thesis focuses on the interaction between two purines 
(adenosine and adenosine-5'-triphosphate) on the one hand and the endothelium of the 
forearm vascular bed on the other In a pilot study, the ability of NG-monomethyl-L-
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arginine-acetate (L-NMMA) is investigated to reduce the formation of nitric oxide in our 
experimental setting. Acetylcholine is used as an endothelium-dependent vasodilator since 
this compound has been shown to induce vasodilation via stimulation of nitric oxide in the 
human forearm vascular bed [36]. The interaction between methacholine and L-NMMA is 
also studied because this compound has frequently been used as a substitute for acetylcho-
line in pharmacological studies of the human forearm vascular bed [196-199] without 
comparing the two substances with respect to their ability to stimulate NO-synthase 
(chapter 5). Searching for possible P2x-purinergic receptors in the human forearm 
vasculature, the forearm vascular response to adenosine-5'-triphosphate (ATP) is further 
characterized (chapter 6). To this end, theophylline and L-NMMA are used to reduce P,-
purinergic receptor activation and NO-formation as possible mechanisms of ATP-induced 
vasodilation. In a final attempt to demonstrate ATP-induced forearm vasoconstriction as a 
possible marker of P2x-purinergic receptor activation, the effect of extremely high ATP 
dosages are studied. 
As outlined in the introduction section, nitric oxide may play a role in the 
vasodilator response to luminally applied adenosine. To assess this possibility in the 
human forearm vascular bed, the interaction between L-NMMA and adenosine is studied 
(chapter 7). Additionally, the role of potassium channels in signal transduction after 
adenosine receptor stimulation by luminally applied adenosine is investigated using 
tolbutamide and quinidine as K-channel blockers. 
Impaired adenosine responsiveness, as suggested in animal studies [200,201], 
could contribute to the devastating sequelae of ischemic disease in patients with diabetes 
mellitus. To explore this possible mechanism in humans, the forearm vasodilator response 
to adenosine is studied in patients with uncomplicated insulin-dependent diabetes mellitus 
and compared with healthy age-matched control subjects (chapter 8). 
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Adenosine transport inhibition in humans 
ABSTRACT 
In 12 healthy male volunteers (27-53 years), a placebo-controlled randomized 
double blind cross-over trial was performed to study the effect of the intravenous injection 
of 0.25, 0.5, 1, 2, 4 and 6 mg draflazine (a selective nucleoside transport inhibitor) on 
hemodynamic and neurohumoral parameters and ex vivo nucleoside transport inhibition 
(ΝΤΓ). We hypothesized that an intravenous draflazine dosage without effect on hemody­
namic and neurohumoral parameters would still be able to augment the forearm vasodila­
tor response to intra-arterially infused adenosine. Heart rate (electrocardiography), 
systolic blood pressure (Dinamap 1846 SX; Critikon, Portanje Electrónica BV, Utrecht, 
The Netherlands), plasma norepinephrine and epinephrine increased dose-dependently and 
could almost totally be abolished by caffeine pretreatment indicating the involvement of 
adenosine receptors. Draflazine did not affect forearm blood flow (venous occlusion 
plethysmography). Intravenous injection of 0.5 mg draflazine did not affect any of the 
measured hemodynamic parameters but still induced a significant ex vivo nucleoside-
transport inhibition of 31.5+4.1 % (P<0.05 versus placebo). In a subgroup of ten 
subjects the brachial artery was cannulated to infuse adenosine (0.15, 0.5, 1.5, 5, 15 and 
50 μg/100 ml forearm per min) before and after intravenous injection of 0.5 mg draflazi­
ne. Forearm blood flow amounted 1.9+0.3 ml/100 ml forearm per min for placebo and 
1.8±0.2, 2.0±0.3, 3.8±0.9, 6.3±1.2, 11.3±2.2 and 19.3+3.9 ml/100 ml forearm per 
min for the six incremental adenosine dosages, respectively. After the intravenous drafla­
zine infusion, these values were 1.6+0.2 ml/100 ml forearm per min for placebo and 
2.1±0.3, 3.3±0.6, 5.8+1.1, 6.9±1.4, 14.4+2.9 and 23.5±4.0 ml/100 ml forearm per 
min, respectively (Friedman ANOVA: Ρ < 0.05 before versus after draflazine infusion). 
In conclusion, a 30-50 % inhibition of adenosine transport significantly augments the 
forearm vasodilator response to adenosine without significant systemic effects. These 
results suggest that draflazine is a feasible tool to potentiate adenosine-mediated cardio­
protection in man. 
INTRODUCTION 
Adenosine has important cardioprotective properties that are mediated by stimulati­
on of adenosine receptors, located on the outer cell membrane. In animals, infarct size is 
reduced when adenosine is infused either before ischemia or during the reperfusion period 
[168,169,202]. Infusion of a selective adenosine receptor antagonist increases infarct size, 
indicating a role for endogenous adenosine as a cardioprotective autacoid [169]. Adenosi­
ne is a mediator of ischemic preconditioning [168,169,171], defined as the increased 
tolerance of myocardium to a prolonged ischemic insult achieved by an initial brief 
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exposure to ischemia and reperfusion [203]. This phenomenon has originally been 
described in animals [175]. Also, in humans a preconditioning effect has been suggested 
[176,177]. At present, many potentially cardioprotective effects of adenosine are known, 
like inhibition of neutrophil activation with subsequent reduced free radical formation, 
inhibition of thrombocyte aggregation, vasodilation, presynaptic inhibition of norepi-
nephrine release, opening of potassium channels, and repletion of purine stores [204]. 
From a pharmacological point of view it seems of interest to develop agents with a 
comparable local effect on the myocardium [205]. Within this concept, long-acting 
adenosine receptor agonists are not useful because these drugs elicit pharmacological 
effects, not only during ischemia but continuously, and not only in the myocardium but in 
nearly all organ systems, resulting in a large list of side effects [206,207]. Inhibition of 
the cellular uptake of extracellular adenosine might be an alternative approach to 
circumvent the disadvantages of intravenous adenosine infusions [208]. In animals, this 
concept has been evaluated by the use of adenosine transport inhibitors like, for instance, 
dipyridamole. Dipyridamole appears to potentiate myocardial preconditioning [209]. In 
humans, dipyridamole is not a suitable tool to potentiate the cardioprotective effect of 
endogenous adenosine [210,211] and this might be due to its nonspecific actions like 
stimulation of prostacycline release and inhibition of phosphodiesterase [212,213]. 
Recently, a new adenosine transport inhibitor, called draflazine, has become 
available for human investigation. This active (-)-enantiomer of the piperazine derivate R 
75231 is a highly specific adenosine transport inhibitor with a tighter binding to the 
transporter and looser binding to plasma proteins when compared with dipyridamole 
[192]. In rabbits, R 75231 has shown to prevent death from catecholamine-induced 
cardiac toxicity [214] and to improve functional recovery after cardiac ischemia [215]. In 
pigs, R 75231 reduces ischaemia-induced arrhythmias [216]. The present study explores 
the hemodynamic and neurohumoral effects of various grades of adenosine transport 
inhibition in man. Our results convincingly show that inhibition of adenosine transport by 
70% or more increases blood pressure, heart rate and plasma catecholamines. In contrast, 
low grade inhibition to 30-50 % does not evoke any systemic hemodynamic changes but 
still potentiates the vasodilator effects of adenosine at a site of increased supply. These 
observations should be taken into account when draflazine is used as an 'on demand' drug 
to potentiate the beneficial effects of adenosine as released during ischemia. 
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SUBJECTS AND METHODS 
Subjects 
After approval of the local ethics committee, twelve normotensive nonsmoking 
healthy Caucasian male volunteers signed written informed consent before participation in 
the study. Demographic data are shown in table 1. They had no history of hypertension, 
diabetes mellitus or drug allergy, and did not use concomitant medication. In all volun-
teers a physical examination, routine laboratory investigation, and a twelve-electrocardio-
graphy lead were performed to exclude cardiovascular, pulmonary, renal, liver, or 
neurologic disease. 
TABLE 1: Demographic characteristics 
N=12 mean (range) 
age (years) 41 (27-53) 
weight (kg) 73.3 (62.3-88.5) 
length (cm) 179.5 (172.0-189.0) 
systolic blood pressure (mmHg)* 129 (112-140) 
diastolic blood pressure (mmHg)* 75 (62-88) 
heart rate (bpm)* 63 (48-72) 
* Auscultatory measurements with sphygmomanometer alter 5 minutes of supine rest (systolic blood 
pressure: Korotkoff I; diastolic blood pressure: Korotkoft V) 
* Measured by pulse frequency counting after 5 minutes ot supine rest 
Methods 
'Critical dose' finding (part I) 
In this study, the circulatory effects of six dosages of draflazine were investigated 
(0.25, 0.5, 1, 2, 4 and 6 mg). 
First, in a double-blind randomized cross-over design, the hemodynamic and 
neurohumoral effects of placebo and 1, 2 or 4 mg draflazine were studied during four 
sessions per volunteer, that were separated by at least one week. At least one week there-
after, and after proven tolerance to the previous dosages, the effect of 6 mg draflazine 
was studied in a single blind fashion. This 6-mg dose was not included in the randomized 
double blind approach for safety reasons, on request of the ethics committee. After the 
randomization code had been broken, data analysis showed that all dosages, including the 
lowest, induced a statistically significant increase in heart rate. Therefore, the trial was 
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prolonged with two visits per volunteer, separated by at least one week, to study the 
hemodynamic effects of 0.25 and 0.5 mg draflazine in a double-blind randomized fashion. 
Each experiment was performed in the morning after a 24-hour abstinence from 
caffeine-containing products and an overnight fast of at least 10 hours. Both arms were 
intravenously cannulated to infuse drug (left arm) and to collect blood (right arm). After 
an equilibration period of at least 45 minutes in supine position, placebo or drug was 
intravenously infused for 15 minutes using an automatic syringe infusion pump (type 
STC-521, Terumo Corporation, Tokyo, Japan). From five minutes before until 60 
minutes after the start of the infusion, heart rate was measured by standard electrocardio-
graphy and continuously recorded on tape (Oxford 9000 with ADgi preamplifier, band 
pass 0.05-40 Hz, (-3 dB); Oxford Medical, Gorinchem, the Netherlands). Starting 
immediately before and continuing until 60 minutes after the start of the drug infusion, 
blood pressure (Dinamap 1846 SX, Critikon, Portanje electrónica BV, Utrecht, The 
Netherlands) and forearm blood flow (FBF) were measured at the left arm at five- and 
fifteen minute intervals, respectively. FBF was registered by electrocardiography-
triggered venous occlusion plethysmography using mercury-in-silastic strain gauges (EC4, 
D.E. Hokanson, Inc., Washington DC, USA). The upper arm collecting cuff was 
inflated using a rapid cuff inflator (E-20, D.E. Hokanson, Inc., Washington DC, USA). 
At least one minute before the FBF measurements, the circulation of the left hand was 
occluded by inflation of a wrist cuff to 200 mmHg. FBF was recorded three times per 
minute during three minutes. 
Before the start of each intravenous injection, blood was collected for the measure-
ment of the plasma caffeine concentration. 
Immediately before and 15, 30 and 60 minutes after the start of the intravenous 
infusion of placebo, 1, 2, 4 or 6 mg draflazine, blood was collected to determine plasma 
epinephrine (EPI), norepinephrine (NE), and adenosine concentration and to measure ex 
vivo adenosine transport inhibition (see Analytical Methods). Additionally, 15, 30 and 60 
minutes after the start of the infusion, blood was collected to measure whole blood 
draflazine concentrations (see Analytical Methods). After administration of 0.25 and 0.5 
mg draflazine, only adenosine transport inhibition and draflazine concentrations were 
determined. 
Effect of the adenosine receptor antagonist caffeine on hemodynamic and neurohumoral 
responses to draflazine (part 2) 
To investigate the contribution of adenosine-receptor stimulation in the hemodyna-
mic and neurohumoral responses to draflazine, in a subgroup of ten subjects, informed 
consent was obtained to repeat the intravenous injection of 4 mg draflazine during 
adenosine receptor blockade with caffeine, an adenosine receptor antagonist in humans 
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[206]. Forty minutes before the start or" the draflazine injection, a ten minute intravenous 
caffeine infusion was started (4 mg/kg), as described previously [217]. Blood pressure, 
heart rate, catecholamines, plasma caffeine concentration and adenosine transport 
inhibition were measured immediately before the start of the caffeine infusion, immediate-
ly before the start of the draflazine infusion and at regular time intervals thereafter as 
mentioned above. Draflazine-induced changes in hemodynamic and neurohumoral parame-
ters were compared with those as obtained in part 1 of this study. 
Effect of 0.5 mg draflazine on the forearm vasodilator response to adenosine (part 3) 
In ten of the twelve subjects informed consent was obtained for a third study part 
to investigate the effect of 0.5 mg draflazine ('critical dose') on the forearm vasodilator 
response to intra-arterially infused adenosine. This dose was chosen because it was the 
highest dose of draflazine which did not affect baseline hemodynamic or neurohumoral 
parameters. Before the start of the study, the subjects were asked to abstain from 
caffeine-containing products for at least 24 hours. All tests were performed in the supine 
position after an overnight fast, starting at 8.00 AM. After administration of a 2% local 
anaesthesia (Xylocaine; Astra Pharmaceutical Products Inc., Worcester, MA), the left 
brachial artery was cannulated with a 20-gauge catheter (Angiocath, Deserei Medical, 
Inc., Becton Dickinson and Co., Sandy, UT) for both intra-arterial adenosine infusion 
(automatic syringe infusion pump, [type STC-521, Terumo Corp.]) and blood pressure 
recording (Hewlett Packard GmbH, Böblingen, Germany). Forearm blood flow was 
registered simultaneously on both forearms by electrocardiography-triggered venous 
occlusion plethysmography as stated above. 
The experiment started with the measurement of baseline FBF during placebo 
infusion (NaCl, 0.9%). The effect of six increasing dosages of adenosine (0.15, 0.5, 1.5, 
5, 15 and 50 /ig/100 ml forearm per min) were compared with placebo (NaCl 0.9%). 
Prolonged occlusion of the hand circulation can cause discomfort with subsequent effects 
on blood pressure and heart rate. Therefore, a 5-minute-rest was allowed between the 
placebo infusion and the first adenosine infusion and between the third and fourth 
adenosine infusion. Forty-five minutes after the last adenosine infusion, the intra-arterial 
placebo infusion was repeated and followed by a fifteen minute intravenous injection of 
0.5 mg draflazine in the right arm. Subsequently, the vasodilator response to adenosine 
was studied again. Additionally, the ex vivo adenosine transport inhibition was measured 
at regular time intervals. During all procedures, total infusion was adjusted to forearm 
volume as measured by water displacement and kept at a constant rate of 100 μ1/100 ml 
forearm per min. Placebo and each adenosine dosage were infused for 4 minutes. 
In a separate group of six healthy nonsmoking male volunteers the same protocol 
was performed except for the intravenous infusion of draflazine (time control study). 
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Analytical methods 
Samples for determination of plasma caffeine concentration were analyzed with a 
reversed-phase HPLC method (limit of detection: 0.2 /ig/ml) [218]. 
Plasma levels of EPI and NE were determined simultaneously by a HPLC method 
with fluorometric detection, in which catecholamines are concentrated from plasma by 
liquid-liquid extraction and derivated with the selective fluorescent agent 1,2-diphenyl-
ethylenediamine prior to chromatography as has been described in more detail elsewhere 
[219]. The interassay coefficients of variation in our laboratory are 7.2% and 8.5% at a 
mean concentration of 0.15 and 1.02 nmol/liter for EPI and NE respectively (N=52). 
To measure plasma adenosine concentration, 2 ml blood was collected and directly mixed 
during collection with 2 ml blocker solution using a specially designed device. The 
blocker solution contained the adenosine deaminase inhibitor erythro-9(2-hydroxy-3-
nonyl)-adenosine (EHNA, 10 /iM), the adenosine transport inhibitor dipyridamole (20 
μΜ) and the thrombocyte aggregation inhibitor indomethacin (2 mg/liter). Immediately 
after blood collection the blood/blocker mixture was centrifuged (model 3200; Eppendorf 
North America, Inc., Madison, WI) at 3000 rpm for 2 minutes and the plasma was 
deproteinated with perchloric acid as described before [220]. The extract was kept frozen 
at -20 °C until the adenosine concentration was determined in duplicate by reversed-phase, 
high performance liquid chromatography using a nonlinear gradient. 
In five subjects 12 ml blood/blocker mixture was collected before administration 
of 0.25 or 0.5 mg draflazine and divided into 6 equal portions. Adenosine standards were 
added to five separate blocker/mixture portions. The six portions were handled as stated 
above. The expected increases in adenosine concentration, as compared with the control 
blood/blocker mixture were 0.029, 0.052, 0.110, 0.210, and 0.405 /*M. The averaged 
recoveries were 115.9 ± 31.3, 144.7 + 24.6, 109.6 ± 11.6, 114.5 ± 15.6 and 126.7 ± 
12.2 % for the five increasing standards, respectively. The detected increase in plasma 
adenosine concentration tended to be overestimated, although this was not statistically 
significant (P=0.3, n=5; Friedman ANOVA). In each individual a maximal correlation 
of 1.0 was observed between expected and measured adenosine concentration. The 
individual regression coefficients ranged from 1.0 to 1.7 (mean±SE: 1.3±0.1). The 
intra-assay variability, calculated as the coefficient of variation in the duplicate determina­
tions at baseline (five duplicate-determinations in 11 subjects) was 16.2±2.2 %. The 
short-term intra-individual variability in measured adenosine concentration, calculated as 
the coefficient of variation of the four measurements during placebo infusion, was 
20.7±7.2 %. 
Ex vivo adenosine transport inhibition was measured by standardized incubation of 
erythrocytes with adenosine. Four ml blood was drawn into a vial containing 1 ml acid, 
citrate, and dextrose (85 mM trisodium citrate, 65 mM citric acid and 20 g/liter glucose) 
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and further handled as described before [216]. The percentage inhibition of adenosine 
transport (ATI %) was calculated as: 
ΑΉ%=(Α1-Α()χ100Ι(1-Α^ 
in which A0 represents the adenosine concentration as proportion of the sum of the 
concentration of adenosine, inosine and hypoxanthine as determined in the sample 
collected just before the drug infusion and A, represents this proportion as determined in 
the sample collected after the start of the drug infusion. 
Whole-blood draflazine concentration was detected by HPLC (limit of detection: 
5.0 ng/ml). 
Drugs and solutions 
Sterile solutions of draflazine or placebo in a formulation with 5 % hydroxypro-
pyl-/3-cyclodextrine (Janssen Pharmaceutica Inc., Beerse, Belgium), were prepared with 
NaCl 0.9% on the morning of the study day by a specially trained research nurse who 
was not otherwise involved in the practical performance of the trial. The randomization 
code was broken at the end of the trial, after all calculations on forearm blood flow were 
performed. Sterile solutions of caffeine (OPG Pharma, Utrecht, The Netherlands) and 
adenosine (Sigma Chemical Co., St Louis, MO) were freshly prepared by the investigator 
with NaCl 0.9% as solvent. 
Statistics 
Heart rate, as derived from continuously recorded R-R intervals, was averaged for 
each consecutive five-minute interval. The five-minute interval just before draflazine or 
placebo infusion was taken as baseline. For the other hemodynamic and neurohumoral 
parameters, the values obtained just before the intravenous infusion were taken as 
baseline. For each experiment, the effect of drug administration was calculated at each 
time point as change from baseline. Since hemodynamic parameters appeared to be 
normally distributed (P>0.1; Shapiro-Wilk test for normality) differences in changes 
from baseline between placebo and draflazine administration were assessed by an 
ANOVA for repeated measurements with the drug dosage and time as within-subject 
factors. The neurohumoral parameters were not normally distributed (P<0.1; Shapiro-
Wilk test for normality). If an overall analysis by Friedman two-way nonparametric 
ANOVA showed significant differences in responses (P<0.05, by means of Chi-square 
approximation), the paired Wilcoxon signed rank test was used to detect which draflazine 
dosages were different from placebo. During the intra-arterial study (part 3), теал 
arterial pressure was measured continuously during each recording of FBF and averaged 
per FBF registration. Forearm vascular resistance (FVR) was calculated from simultane-
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ously measured mean arterial pressure and FBF and expressed as arbitrary units (AU). 
Additionally, the ratio of each simultaneously measured FBF (FBF infused/FBF control 
arm) was calculated. FBFs, the calculated flow ratios and FVRs obtained during each 
four minutes of placebo infusion or during the last two minutes of each drug infusion 
were averaged to one value. Adenosine-induced effects were expressed both as absolute 
and percentage change from preceding placebo infusion. The overall effect of draflazine 
on the adenosine dose response curve was analyzed by Friedman two-way nonparametric 
ANOVA. All results are expressed as mean±SE unless indicated otherwise; Ρ < 0.05 (two 
sided) was considered to indicate statistical significance. 
RESULTS 
Plasma caffeine levels were determined to check the compliance with respect to 
the caffeine abstinence. For part 1 of this study, in four subjects, the plasma caffeine 
concentration was below the limit of detection for all visits. In six subjects the plasma 
caffeine concentration remained below 1 mg/liter. In one subject caffeine was only 
detectable before the infusion of 1 mg draflazine (1.4 mg/liter) and in another subject, 
caffeine was detectable during 5 of the 7 visits ranging from 0.5 to 1.6 mg/liter. For part 
2 of this study, plasma caffeine was detectable in two subjects being 0.2 mg/liter for 
both. In part 3 of this study, plasma caffeine was detectable in 3 subjects being 0.8, 0.3 
and 0.25 mg/liter. These plasma caffeine concentrations indicate a good compliance with 
regard to the caffeine abstinence. In the second part of the study, caffeine was administe­
red in a dose of 4 mg/kg. Thirty minutes after the caffeine infusion and immediately 
before the start of the draflazine infusion, plasma caffeine concentration was on average 
5.7±0.2 mg/liter. 
Subjective side effects to draflazine 
Up to 2 mg draflazine, no subjective side effects occurred. In one subject, the 4-
mg dose induced a slight headache and a feeling of dyspnoea. Previous intravenous 
injection of caffeine completely prevented these complaints. In 8 of the 12 subjects, the 6-
mg dose induced temporary subjective side effects ranging from a feeling of excitement 
(n=4) and/or headache (n=4) to nausea (n=3) that was accompanied by vomiting and 
chest pain (without electrocardiographic changes) in one subject. These subjective side 
effects might have affected the recordings, resulting in less accurate measurements during 
and after the administration of 6 mg draflazine as compared with the lower dosages. 
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Critical dose finding 
Table 2 shows mean baseline values for all measured parameters. Overall, no 
statistically significant differences in baseline values were observed. 
Figure 1 shows the time course of changes in blood pressure and heart rate during 
the varying draflazine infusions as compared with placebo. Up to 0.5 mg, draflazine did 
not induce a significant increase in heart rate. Heart rate increased by maximally 2.0+1.1 
for placebo and 1.8+0.5, 3.3±0.8, 6.1±0.7, 15.2+2.3, 29.2±2.6, and 32.5+2.8 bpm 
for 0.25, 0.5, 1, 2, 4 and 6 mg draflazine respectively (P<0.01 versus placebo for 1, 2, 
4 and 6 mg draflazine, η = 12). Up to 1 mg draflazine, systolic blood pressure was not 
significantly affected. At higher dosages, the maximal mean systolic blood pressure 
response increased dose-dependently by 9.1 + 1.4, 12.5+3.2 and 18.0±3.1 mmHg for 2, 
4 and 6 mg draflazine respectively (P<0.05 versus placebo, n = 12). The most important 
increase in systolic blood pressure occurred during the first 15 minutes after starting the 
draflazine infusion. Neither diastolic blood pressure, mean arterial pressure nor forearm 
blood flow were significantly affected by draflazine. When forearm vascular tone was 
expressed as vascular resistance (ratio of mean arterial pressure and forearm blood flow), 
still no effect of draflazine on forearm vasculature could be observed. 
The effect of draflazine on plasma NE and EPI concentration are shown in figure 
2. Starting with 2 mg, draflazine induced a dose-dependent increase in plasma NE 
concentration that reached a maximum at 30 minutes after starting the infusion. At this 
time point, the increase in NE concentration was 0.7+0.1, 1.0±0.2 and 1.7±0.3 
nmol/liter for 2, 4 and 6 mg draflazine respectively (P<0.05 versus placebo, η = 12). 
After infusion of 1 mg draflazine, the EPI concentration was not significantly 
affected. Infusion of 2 mg draflazine induced a small increase in EPI concentration of 
0.02 ± 0.01 nmol/liter at 15 minutes after starting the draflazine infusion (P<0.05 
versus placebo, η = 12). Up to 60 minutes after the start of the infusion of 4 or 6 mg 
draflazine, the EPI concentration continuously increased maximally by 0.15+0.03 and 
0.31 ±0.06 nmol/liter respectively (P<0.05 versus placebo, η =12). 
The course of ex vivo adenosine transport inhibition is shown in figure 3. Fifteen 
minutes after the start of each draflazine infusion, maximal adenosine transport inhibition 
was achieved being 0.2+0.7 for placebo and 10.2±2.3, 31.5+4.1, 70.4+1.5, 80.6±0.9, 
89.6+1.1, and 92.6±0.6 % for 0.25, 0.5, 1, 2, 4 and 6 mg draflazine respectively 
(P<0.05 for each dosage versus placebo). 
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Figure 1. Effect of draflazine on systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart 
rate. *, Significant difference with placebo (n= 12) 
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Figure 2. Effect of draflazine on plasma catecho­
lamines. *, Significant difference with placebo 
(n=12) 
Figure 3. Effect of draflazine on ex vivo nucleo­
side transport inhibition (top) and plasma-adenosi-
ne concentration (bottom), respectively *, Cur­
ves that were significantly different from placebo 
at all time points (n= 12) 
Sixty minutes after starting the infusion, there still remained a significant adenosine trans­
port inhibition being -0.9±0.8 for placebo and 6.0±0.8, 14.2+1.1, 22.3±3.0, 
42.5 + 1.7, 59.8+1.9 and 68.3+2.0 % for the six draflazine doses, respectively (P<0.05 
for each dosage versus placebo). For each subject, the relation between drug concentrati­
on and ex vivo adenosine transport inhibition was assessed by computer assisted curve 
fitting using the Hill equation (figure 4). For this analysis, minimal and maximal ex vivo 
adenosine transport inhibition was set constant at 0 and 100 % respectively. The best 
fitting drug concentration with 50 % ex vivo adenosine transport inhibition and Hill-
coefficient were 74.1 ±2.4 ng/ml (range: 55.5-88.1 ng/ml; n=12) and 3.2+0.1 (range: 
2.5-4.0; η = 12), respectively. According to this model, 95 ±1 % of the variation in ex 
vivo nucleoside transport inhibition could on average be explained by the blood draflazine 
concentration. 
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Figure 4. Relation between percent inhibition in adenosine transport and whole-blood draflazine concentrati­
on. This relation was evaluated for each subject using the Hill equation. For each individual, the best fitting 
Hill coefficient and IC„ (draflazine concentration that exhibits 50% of the maximal effect) were calculated 
by computer-assisted curve fitting (n= 12). 
For each subject, the relation between draflazine-induced heart rate response 
(difference with response after placebo infusion) and ex vivo adenosine transport 
inhibition was assessed at 15, 30 and 60 minutes after starting the draflazine infusion 
(figure 5). Up to approximately 50 % inhibition of adenosine transport, heart rate was 
unaffected. An equation in the form of Y=AX3 appeared to describe the relation between 
heart rate response and adenosine transport inhibition most accurately. Nonlinear 
regression analysis revealed a mean value for A of (3.0+0.3) 10"\ (6.1+0.4) 10"5 and 
(7.7+0.8) IO"5 at 15, 30 and 60 minutes respectively. With this model, 77±2, 90±2 and 
81 ± 3 % of the intra-individual variation in heart rate response could be explained by ex 
vivo nucleoside transport inhibition at 15, 30 and 60 minutes after starting the draflazine 
infusion, respectively. 
Apart from ex vivo adenosine transport inhibition, figure 3 shows the effect of 
draflazine on plasma adenosine concentration. Draflazine did not induce significant 
changes in plasma adenosine concentration (P>0.5, n = l l ) . 
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Effect of the adenosine receptor antagonist caffeine on hemodynamic and neurohu­
moral responses to draflazine 
Baseline values after caffeine infusion were significantly increased for systolic, 
diastolic and mean arterial pressure and plasma EPI concentration and reduced for heart 
rate when compared with baseline values without caffeine pretreatment (see table 3). 
Figure 6 shows the effect of intravenous caffeine infusion (4 mg/kg) on the course 
of systolic blood pressure, heart rate, EPI and NE after draflazine infusion. Caffeine 
pretreatment reduced the heart rate response to the 4-mg dose of draflazine from 
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TABLE 3: Effect of caffeine on baseline parameters 
N=10 Before placebo Before 4 mg draflazine Before 4 mg drafla-
(without caffeine (without caffeine zine (with caffeine 
pretreatment) pretreatment) pretreatment) 
Systolic blood pressure (mmHg) 108.8±3.4 
Diastolic blood pressure (mmHg) 68.9± 1.9 
Mean arterial pressure (mmHg) 83.8±2.3 
Heart rate (bpm) 59.0±2.2 
Norepinephrine (nmol/L) 1.2±0.1 
Epinephrine (nmol/L) 0.11 ± 0.02 
108.5±3.1 
68.9±2.3 
83.5±2.5 
58.4±1.4 
1.3±0.2 
0.09 ±0.02 
113.0±2.1+* 
73.1±1.6** 
87.3 ±1.7* 
53.9 ±1.4** 
1.0±0.1 
0.14±0.02' 
* and t Significantly different from baseline values before placebo and 4 mg (without caffeine treatment), 
respectively, · Friedman Two-way ANOVA: p = 0.08; Wilcoxon matched-pairs, signed-ranks test: P=0.03 
versus 4 mg draflazine (without caffeine pretreatment). 
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Figure б. Effect of caffeine pretreatment (4 mg/kg) on the draflazine (4 mg)-induced increases in systolic 
blood pressure (SBP), heart rate, norepinephrine and epinephrine. * And #, significant differences with 
placebo or draflazine after caffeine pretreatment, respectively (n= 10). 
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29.3±3.8 bpm (32.6+3.0 %) to 8.8±1.0 (13.9+1.4 %) (P<0.01 versus placebo and 
versus draflazine without caffeine pretreatment). The systolic blood pressure response to 
draflazine was reduced from 11.7 + 3.7 mmHg (10.7+3.3 %) without caffeine pretreat­
ment to 4.9+1.7 mmHg (4.3± 1.5 %) after caffeine pretreatment (P=NS versus 
placebo, Ρ<0.05 versus draflazine without caffeine pretreatment). 
Caffeine pretreatment reduced the increase in NE concentration after the 4-mg 
dose of draflazine from 1.1 ±0.23 nmol/liter (105.6±22.6 %) to 0.2±0.1 nmol/liter 
(23.7±4.1 %) (P=NS versus placebo and P<0.05 versus draflazine infusion without 
caffeine pretreatment). The increase in plasma EPI concentration after 4 nig draflazine 
was reduced from 0.14±0.04 nmol/liter (177.0±42.2 %) without caffeine pretreatment to 
0.09+0.02 nmol/liter (73.1 ±12.9 %) after caffeine pretreatment (P=NS versus placebo 
and Ρ <0.05 versus draflazine without caffeine pretreatment). 
Draflazine induced a significant inhibition of nucleoside transport of 89.3 + 1.1, 
71.5 + 1.3 and 59.4±1.8 % at 15, 30 and 60 minutes after the start of the draflazine 
infusion respectively and these figures did not significantly differ from adenosine 
transport inhibition as observed after infusion of 4 mg draflazine without caffeine 
pretreatment. 
Effect of 0.5 mg draflazine on forearm vasodilator response to adenosine 
Intra-arterial infusion of adenosine increased forearm blood flow dose dependently. 
The baseline forearm blood flow was 1.9+0.3 and 1.6±0.2 ml/100 ml forearm per min 
in the infused and control arm, respectively. During the subsequent six incremental 
adenosine infusions, the forearm blood flow in the infused arm amounted to 1.8+0.2, 
2.0±0.3, 3.8±0.9, 6.3±1.2, 11.3+2.2 and 19.3±3.9 ml/100 ml/min, respectively. In 
the control arm, forearm blood flow remained unchanged. Draflazine did not affect 
forearm blood flow: in the infused arm, forearm blood flow was 1.8+0.2 and 1.6+0.2 
ml/100 ml per min immediately before and after the draflazine infusion, respectively 
(control arm: 1.3+0.1 and 1.2±0.2 ml/100 ml per min). However, draflazine significant­
ly augmented the adenosine-induced changes in forearm blood flow. After the draflazine 
infusion, the forearm blood flow in the infused arm amounted 2.1 ±0.3, 3.3+0.6, 
5.8+1.1, 6.9+1.4, 14.4±2.9 and 23.5±4.0 ml/100 ml forearm per min during the six 
incremental adenosine infusions, respectively (P<0.05 versus adenosine infusions before 
draflazine treatment). In the control arm, forearm blood flow remained unchanged. Figure 
7 shows the effect of draflazine on the forearm vasodilator response to adenosine, 
expressed as percent change in FVR. The same effect of draflazine was observed when 
results were expressed as forearm vascular resistance or flow ratio both expressed as 
absolute as well as percent changes from baseline. The time control study did not reveal a 
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significant change in adenosine-induced forearm vasodilation, excluding significant carry­
over effects (see lower panel of figure 7). 
Infused arm Control arm 
ее 
> 
0 0.15 0.5 1.5 5 15 50 
Adenosln· dosag· (mtcrog/100 ml/mtn) 
0 0.15 0.5 1.5 5 IS 50 
Adsnosln· dosag« (mlcrog/100 ml/mln) 
0 0.15 0.5 1.5 5 15 50 
Adenosine dosag· (mlcrog/100 ml/mln) 
0 0.15 0.5 1.5 5 15 50 
Adtnosln» dosag· (mlcrog/100 ml/mln) 
Figure 7. Adenosine-induced forearm vasodilation expressed <ts forearm vascular resistance (quotient of 
mean arterial pressure and forearm blood flow) in infused- and control arm. Upper panel: effect of 
intravenous draflazine treatment (N=10); — : before draflazine infusion; : after draflazine infusion. 
Lower panel, time control study (N=6), — : first dose response curve; : second dose response curve. 
P-values indicate level of significance for the difference between both curves. 
Heart rate was 57.5±1.7 and 58.4±1.4 bpm immediately before and after 
draflazine infusion, respectively (P>0.2), confirming that the used draflazine dosage did 
not induce systemic effects. 
Ex vivo nucleoside transport inhibition was 47.9±3.2, 21.6±1.6 and 15.0±1.5 % 
at the end of the draflazine infusion, and at the end of the third and sixth intra-arterial 
adenosine dose, respectively. 
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DISCUSSION 
This study was aimed at finding a draflazme dosage without unwanted hemody-
namic and neurohumoral effects that still potentiates the beneficial effects of adenosine at 
sites of increased formation. Therefore, a dose-response trial was performed that revealed 
a dose-dependent increase in systolic blood pressure, heart rate, and plasma catecholami-
nes in subjects that refrained from caffeine-containing products for at least 24 hours. 
Preceding caffeine infusion abolished all draflazine-mediated effects, confirming that they 
were mediated by adenosine receptor stimulation Heart rate appeared to be the most 
sensitive parameter to detect unwanted effects. An intravenous dosage of 0.5 mg 
draflazme did not affect heart rate, but still induced an ex vivo transport inhibition by 
approximately 30 % To test the hypothesis that this 'critical dose' is able to potentiate 
the vasodilatory effects ol adenosine in humans at sites of increased formation, the 
perfused forearm technique was used as a model of local adenosine formation Intrave-
nous infusion of 0.5 mg draflazme appeared to augment the forearm vasodilator response 
to adenosine threefold, suggesting that a low grade adenosine transport inhibition is a 
feasible approach to exploit the beneficial effects of endogenous adenosine in humans. 
Hemodynamic and neurohumoral effects of draflazine 
With regard to the cardiovascular system, adenosine can induce direct and indirect 
effects. The direct effects of adenosine include negative inotropic, chronotropic and 
dromotropic effects [134], relaxation of vascular smooth muscle (except in the pulmonary 
and renal vascular bed where vasoconstriction is observed) [5,221], pre- and postsynaptic 
inhibition of adrenergic neurotransmission [222,223], reduction of renal renin release 
[148,151,153], stimulation of vascular angiotensin II production [224] and inhibitory 
effects on cardiovascular centres in the brain stem except for the nucleus tractus sohtarn 
that is excitated by adenosine, resulting in an increased sensitivity of the baroreflex [225]. 
These effects are thought to be involved in the hypotensive response to intravenously 
administered adenosine as observed in animals and anesthetized humans The indirect 
effects are mediated by adenosine-induced stimulation of afferent nerves, including renal 
[226,227] and myocardial afferent nerves [385], carotid and aortic chemoreceptors 
[207,228] and forearm (muscle) afferent nerves [229] Stimulation of these afférents 
results in activation of the sympathetic nervous system and respiratory system [206,230] 
and a subsequent increase in systolic blood pressure, and plasma renin activity 
[206,207,230-234]. The increase in heart rate is probably mediated by concomitant deac-
tivation of the parasympathetic nervous system since it can be antagonized by atropine but 
not by propranolol [235] These indirect effects of intravenous adenosine infusion are 
dependent on an intact autonomic reflex arc [207], which probably explains why these 
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effects are blunted in anesthetized humans and animals [236-238]. The increase in systolic 
blood pressure is not always observed during intravenous infusion of adenosine in healthy 
volunteers [235,239-241]. This apparent discrepancy in the literature can be explained by 
differences in caffeine abstinence which is always relatively short or totally absent in the 
studies in which no increase in systolic blood pressure is observed. After ingestion of two 
cups of regular coffee, plasma caffeine concentrations are in the range of 4-5 mg/liter 
[242], which is sufficiently high to antagonize the hemodynamic effects of intravenous 
adenosine infusion [206]. The plasma half life time of caffeine after ingestion of two cups 
of coffee ranges from 2 to 8.5 hours [242]. Therefore, a 24 hour period of caffeine 
abstinence is important to prevent underestimation of adenosine-induced hemodynamic 
and neurohumoral effects. An increase in systolic blood pressure, heart rate and plasma 
catecholamines has also been observed in resting man after administration of the adenosi-
ne transport inhibitor dipyridamole [217,243] and could be inhibited by previous admi-
nistration of caffeine or theophylline [217,244], suggesting that adenosine is formed under 
baseline conditions. In addition to the variable oral bioavailability of dipyridamole and its 
lack of specificity [212,213,245,246], these excitatory effects of dipyridamole may be an 
explanation for its disappointing effect on cardiovascular mortality in large trials 
[210,211]. 
It was expected from the previous experiments with adenosine and dipyridamole in 
healthy, conscious human volunteers, that draflazine, too, could induce hemodynamic and 
neurohumoral effects that would be unfavourable in patients with ischemic heart disease. 
The present study indeed confirms most of these observations and substantiates them by 
showing their dependency on the degree of ex vivo adenosine transport inhibition. 
Moreover, we observed an increase in both EPI and NE during high degrees of selective 
adenosine transport inhibition, supporting the involvement of the sympathetic nervous 
system in this excitatory response. The increase in systolic blood pressure without a 
change in mean arterial pressure excludes baroreflex activation as a possible mechanism 
for the increased plasma catecholamine concentrations. Activation of sympathetic tone by 
draflazine-induced myocardial ischemia is very unlikely because the study was performed 
in healthy subjects without a history of cardiovascular disease. Additionally, continuous 
electrocardiography did not demonstrate myocardial ischemia. However, a yet unknown 
direct effect of draflazine on the kinetics of catecholamines can not be excluded. 
Effect of caffeìne pretreatment on draflazine-induced hemodynamic and neurohumo-
ral responses 
Caffeine pretreatment almost completely abolished the effect of draflazine on 
systolic blood pressure, heart rate, and plasma catecholamines. This antagonism occurred 
at a plasma caffeine concentration of 5.7 mg/liter, a concentration that can occur after 
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drinking one cup of coffee [242] The property of caffeine as a competitive adenosine 
receptor antagonist has been well documented in human in vivo studies 
[206,221,247,248]. Therefore, the observed antagonism of draflazine-induced hemodyna-
mic and neurohumoral responses by caffeine indicates the involvement of adenosine 
receptors in draflazine-induced effects. 
Thirty minutes after caffeine pretreatment, baseline values of systolic, diastolic, 
and mean arterial pressure and plasma EPI concentration were increased and baseline 
heart rate was reduced. These findings are in agreement with previous reports about the 
effect of caffeine [218]. The changes in baseline blood pressure, heart rate and EPI that 
were associated with caffeine pretreatment could have interfered with the subsequent 
effects of draflazine infusion. However, the magnitude of the increased baseline levels 
after caffeine are almost neglectable when compared with the effects of draflazine. 
Draflazine-induced adenosine transport inhibition was not significantly affected by 
caffeine pretreatment Therefore, the effect of caffeine on draflazine-induced hemodyna-
mic and neurohumoral responses can not be explained by differences in the degree of 
adenosine transport inhibition 
In theory, inhibition of 5'-nucleotidase by caffeine could have diminished the 
formation of extracellular adenosine [249] However, inhibition of the ecto-5'-nucleotida-
se, as obtained from rat brain, occurs at a caffeine concentration of 1 0 mM which is 
considerably higher than the plasma caffeine concentration of 5.7 mg/hter (equivalent to 
0 03 mM) as observed in this study. Therefore, caffeine-induced inhibition of extracellu-
lar adenosine formation is not likely in the present study. 
Draflazine and plasma adenosine concentration 
Draflazine failed to increase plasma adenosine concentrations. Two possible 
explanations will be discussed {a) the lack of an observed plasma adenosine increase is 
due to a measurement error and (b) adenosine concentrations are increased in the 
interstitium only. 
(a) The precision of the adenosine determinations in the present study does not 
essentially differ from that reported by others [250]. As stated in methods, the recovery 
of adenosine added to plasma was high and appeared to be linear within the physiological 
range. Therefore, a systematic measurement error is unlikely Both German et al. and 
Sollevi et al. observed a doubling in plasma adenosine concentration after administration 
of the adenosine transport inhibitor dipyridamole [244,251]. However, in both studies, 
adenosine formation, uptake and breakdown after blood sampling were not optimally 
antagonized. German et al. did not use a blocker solution [251,252] while Sollevi et al. 
used a blocker solution that was mixed with blood immediately after, in stead ot during, 
blood sampling [244]. Therefore, in these studies, baseline plasma adenosine concentra-
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tions may have been underestimated. The administered dipyridamole may have affected 
adenosine uptake by erythrocytes after blood sampling resulting in an artificial increase in 
measured plasma adenosine concentration. The present study does not rule out a small 
draflazine-induced increase in plasma adenosine levels since intra-subject variability of the 
adenosine detection method is relatively high, especially when compared with detection 
methods of other endogenous compounds like for instance (nor)epinephrine. Plasma 
adenosine concentrations were measured up to 60 minutes after the start of the draflazine 
infusion. Therefore, our data do not exclude a detectable increase in plasma adenosine 
levels after this time point or during more sustained nucleoside transport inhibition. 
(b) The most likely explanation for adenosine receptor-mediated hemodynamic and 
neurohumoral effects without any change in plasma adenosine concentrations is that 
selective adenosine transport inhibition results in accumulation of endogenous adenosine 
within the interstitium. As discussed in detail elsewhere, the vascular endothelium may 
act as a strong barrier against passage of metabolites [88,253,254]. In normal tissue, the 
nucleoside transporter bypasses this barrier but nucleoside transport inhibition may 
transform the endothelium to a functional barrier preventing adenosine to leave the 
interstitial space [254]. Interstitial adenosine may originate from ATP that is released 
from sympathetic nerve endings [102] and subsequently dephosphorylated to adenosine by 
ecto-phosphatases and ecto-5'-nucleotidase located on the membranes of vascular smooth 
muscle cells and endothelium. Since ATP is released from sympathetic nerve endings by 
exocytosis, this source of adenosine is not blocked by adenosine transport inhibition. 
Ex vivo nucleoside transport inhibition in relation to draflazine concentration and 
heart rate response 
The relation between blood drug concentration and ex vivo adenosine transport 
inhibition could well be described by the Hill-equation. Since draflazine concentration was 
measured in whole blood, this is not necessarily a reflection of draflazine concentration at 
the level of the nucleoside transporter in the erythrocyte membrane. Therefore, the 
accuracy and pharmacological importance of the Hill-coefficient and the 50 % inhibiting 
drug concentration, as determined in this study should not be overvalued. Nevertheless, 
the high correlation between ex vivo nucleoside transport inhibition and whole-blood 
draflazine concentration provides an experimental base to use this functional parameter as 
a tool to monitor draflazine treatment. This is further supported by the high correlation 
between ex vivo adenosine transport inhibition and heart rate response. The relation 
between heart rate response and ex vivo nucleoside transport inhibition became steeper 
over time, reflecting a time delay between draflazine-induced ex vivo nucleoside transport 
inhibition and its effect on heart rate. Two processes may account for this delay. First, 
intravenous infusion of draflazine rapidly inhibits nucleoside transport at the erythrocyte 
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membrane while diffusion of draflazine into the interstitial space and inhibition of 
adenosine transport in the vascular wall may take more time. Second, it probably takes 
some time for endogenous adenosine to accumulate and to reach concentrations that are 
sufficiently high to evoke its full effect on heart rate. 
Effect of 0.5 mg draflazine on forearm vasodilator response to adenosine 
The forearm vasodilator response to adenosine was significantly augmented by a 
draflazine dosage that did not induce unwanted hemodynamic or neurohumoral side 
effects. These results indicate that the cellular uptake of luminal adenosine is inhibited, 
and that the increased adenosine concentrations are available for stimulation of adenosine 
receptors that mediate vascular relaxation. The reduced augmentation of adenosine-
mediated vasodilation at the three highest adenosine concentrations, could be the result of 
the decreased nucleoside transport inhibition at the time that the highest adenosine 
concentration was infused. This is supported by the ex vivo nucleoside transport inhibition 
which amounted to only 15 % at the end of the sixth adenosine infusion, compared with 
22 % at the end of the third adenosine infusion. 
Limitations of the study and conclusions 
Three limitations of the study should be mentioned. First, the studies were 
performed in healthy volunteers. We are not informed about the influence of age and 
varying disease states on the systemic effects of draflazine. Therefore, it cannot be 
excluded that in the elderly or in patients with conditions like hypertension and cardiovas-
cular disease, a different dose-response pattern to draflazine exists. Second, the hemody-
namic- and neurohumoral responses to the adenosine transport inhibitor draflazine were 
studied after a 24 hour abstinence from caffeine containing products. This abstinence 
period was included to prevent adenosine antagonism by caffeine. In clinical practice, 
such a situation will almost never occur. Adenosine receptor upregulation during caffeine 
use may have occurred and could have exaggerated the effects of adenosine uptake 
inhibition after short term abstinence from caffeine [255-257]. Third, we studied the acute 
effects of short-term nucleoside transport inhibition. Our data do not exclude the 
development of tolerance to increased levels of endogenous adenosine that may arise 
during long-term nucleoside transport inhibition. 
Before it can definitely be concluded that draflazine is a feasible tool to potentiate 
the cardioprotective effects of adenosine in humans, our findings should be confirmed in 
the coronary vasculature. Furthermore, the present observation of in vivo adenosine 
transport inhibition holds for intra-arterially applied adenosine and should be verified for 
interstitially formed adenosine as during ischemia. 
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In conclusion, in healthy male volunteers, draflazine is able to inhibit adenosine 
transport significantly both ex vivo as well as in-vivo in man. Heart rate appeared to be 
the most sensitive parameter to detect systemic hemodynamic or neurohumoral effects. 
When a draflazine dosage is injected that does not affect heart rate, the forearm vasodila-
tor response to adenosine is still potentiated. Clinical trials are needed to investigate the 
possible beneficial effect of adenosine uptake inhibition in the prevention of ischemic 
injury. In these trials, caffeine intake should be monitored, the optimal draflazine dosage 
can be determined using heart rate as a marker of unwanted systemic effects and ex vivo 
adenosine transport inhibition can be used as a tool to monitor efficacy and compliance. 
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CHAPTER 3 
High-grade nucleoside transport inhibition 
stimulates ventilation in humans. 
Rongen GA, Smits Ρ, Bootsma G, Ver Donck К, de Vries A, Thien Th 
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Adenosine transport inhibition and ventilation 
ABSTRACT 
In six healthy male volunteers a placebo controlled, double-blind, randomized, 
crossover trial was done to assess the effect of 1, 2, 4 and 6 mg draflazine, a specific 
nucleoside transport inhibitor, on ventilation. Draflazine increased thoracic excursions 
dose-dependently by maximally (median with 95% confidence interval) 114.0% (38.3 to 
184.8%) without affecting breathing rate. Ex vivo adenosine transport was inhibited by 
0% (0 to 1%) after placebo, and 70% (59 to 74%), 81% (76 to 85%), 90% (86 to 93%), 
and 93% (90 to 96%) after the four increasing draflazine dosages, respectively (P<0.05 
for each draflazine dosage versus placebo). These results indicate that endogenously 
released adenosine may play a role in the regulation of ventilation. 
INTRODUCTION 
Intravenous injection of adenosine has been reported to stimulate ventilation in 
humans [207,228,234,248]. The adenosine receptor antagonist theophylline does not 
reduce ventilation in healthy volunteers [258], suggesting that endogenous adenosine does 
not play an important role in the regulation of the ventilation. However, theophylline 
crosses the blood-brain barrier, and the contrasting central and peripheral effects of 
adenosine may offer an explanation for the lack of effect of theophylline on ventilation 
[259]. Alternatively, the physiological importance of adenosine can be evaluated by 
inhibiting its cellular uptake. Although dipyridamole augmented the ventilatory effects of 
intravenously injected adenosine [260,261], it did not affect ventilation during isocapnic 
hypoxia when given orally [258]. In contrast, it has recently been reported that intrave-
nously injected dipyridamole stimulates ventilation in humans [262]. Besides the variable 
oral availability of dipyridamole [245], nonspecific actions such as phosphodiesterase 
inhibition and stimulation of prostacycline release [212,213] may have interfered, possibly 
accounting for these contrasting results. Based on these previous observations, we 
hypothesized that endogenously released adenosine is able to stimulate ventilation in man. 
To test this hypothesis, we decided to study the effect of intravenously injected draflazine, 
a specific nucleoside transport inhibitor, on ventilation. Draflazine, the active (-)-
enantiomer of R 75 231, has a tight binding to the nucleoside transporter [192]. Phase I 
studies in man reveal a long duration of action: 50% ex vivo adenosine transport 
inhibition at four hours after a total dose of 10 mg R 75 231 (resembling 5 mg draflazine) 
intravenously [254]. The advantage of using draflazine in stead of dipyridamole is that 
draflazine does not possess nonspecific confounding effects as does dipyridamole. Drug 
efficacy was monitored by measuring ex vivo nucleoside transport inhibition. 
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SUBJECTS AND METHODS 
Subjects 
After approval of the local ethics committee, six normotensive, nonsmoking, 
healthy, Caucasian, nonobese, male volunteers [age: 43.8 (29-53) years; height: 179.9 
(172-189) cm] signed written informed consent before participation. They had no history 
of pulmonary disease and did not use concomitant medication. 
Study design 
The ventilatory effects of placebo and 1, 2, 4 or 6 mg of draflazine were studied 
during five sessions per volunteer, that were separated by at least one week. The 
administration of placebo or draflazine was randomized and double-blind, except for the 
highest dose (6 mg). The 6-mg dose was always given in the final session in a single-
blind way for safety reasons, because at the time of these experiments this dosage had not 
been given before. Each experiment was done in the morning after a 24-hour abstinence 
from caffeine-containing products and an overnight fast of at least 10 hours. Both arms 
were intravenously cannulated to infuse the drug (left arm) and to collect blood (right 
arm). Immediately before and after the 15-minute drug infusion, blood was collected for 
measurement of plasma adenosine [220] and ex vivo nucleoside transport [216]. Ventilati-
on was measured by registration of each thoracic excursion that occurred during three 
minutes before the start of draflazine infusion (baseline period) and immediately after the 
draflazine administration [207]. 
Measurement of ventilation 
Thoracic excursions were measured using mercury-in-Silastic strain gauge 
plethysmography (Hokanson EC4, D.E. Hokanson, Inc.; Washington, DC). A 26-cm 
mercury-in-Silastic strain gauge was wrapped around the thorax at the mid sternal level. 
To bridge the remaining gap, both ends of the Silastic tube were attached to an unextensi-
ble band at the back of the volunteer. As the thorax expands, the length of the gauge is 
changed by a corresponding amount. The resulting variations in the voltage drop across 
the gauge will reflect changes in thoracic circumference. In a separate group of 6 healthy 
nonobese male volunteers [age: 28.5 (22-36) years; height: 179.9 (172-190) cm], this 
method was validated against simultaneous spirometrie recordings (Figure 1). Although 
confidence intervals were considerably higher for the Plethysmographie technique, an 
increase in tidal volume as recorded by spirometry almost always accompanied an 
increase in thoracic excursion for each individual. 
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Figure 1. Six subjects were asked to breath with 
a tidal volume of approximately 600 (baseline), 
800, 1000, 1200, 1400 and 1600 ml. They adjust 
their ventilation by watching a continuous regist­
ration of their tidal volume by spirometry. Chan­
ges in real tidal volume (spirometry) and thoracic 
excursions (strain gauge plethysmography) were 
expressed as percentage change from baseline. 
Upper panel shows the group averaged changes 
in thoracic excursion (plethysmography) in com­
parison with changes in tidal volume (spirometry) 
expressed as median with 95% confidence inter­
val The lower panel shows individual changes in 
these two parameters 
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Analytical methods 
Plasma adenosine concentration and ex vivo adenosine transport inhibition were 
measured as described in chapter 2. 
Drugs and solutions 
Draflazine or placebo solutions in a formulation with 5 % hydroxypropyl-|8-
cyclodextrine (Janssen Pharmaceutica, Beerse, Belgium) were prepared with sodium 
chloride (NaCl 0.9%) by a specially trained research nurse who was not otherwise 
involved in the practical performance of the trial. 
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Statistics 
For each three-minute registration period, the thoracic excursions were averaged to 
one value. Effects of placebo or drug infusion were expressed as percentage change from 
baseline. When an overall analysis by Friedman two-way nonparametric analysis of 
variance (ANOVA) showed significant differences in responses (P<0.05, Chi-square 
test), the paired Wilcoxon signed rank test was used to find out which draflazine dosages 
were different from placebo. All results are expressed as median (95% confidence 
interval). 
RESULTS 
Figure 2 shows the effect of draflazine on breathing rate and tidal volume. 
Draflazine did not significantly affect breathing rate. Tidal volume changed by -7.2% 
(-36.5 to 49.1%) after placebo, and -8.7% (-35.4 to 47.8%), 38.4% (0.0 to 121.3%), 
35.0% (-10.5 to 70.4%) and 114.0% (38.3 to 184.8%) after 1, 2, 4 and 6 mg of 
draflazine, respectively (P<0.05 versus placebo for 2, 4 and 6 mg of draflazine). 
200 
180 
100 
60 
о 
-50 
10 
β 
Tidal Ышп« 
,-
(« chano«) 
* m 
Bruihing r a l · (changa) 
p-NS 
Figure 2. Effect of placebo (0 mg), 1, 2, 4 and 6 
mg draflazine on plethysmographically determi­
ned tidal volume (upper panel), breathing rate 
(middle panel) and ex-vivo nucleoside transport 
inhibition (NTI, lower panel) as determined by 
standardized incubation of erythrocytes with 
adenosine. Results are expressed as median with 
95% confidence interval. *, Statistically signifi­
cant differences from placebo (n=6). 
NTI (« changa) 
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Nucleoside transport was inhibited by 0% (0-1%) after placebo, and 70% (59 to 
74%), 81% (76 to 85%), 90% (86 to 93%) and 93% (90 to 96%) after the four 
increasing draflazine dosages, respectively (P<0.05 for each draflazine dosage versus 
placebo). Plasma adenosine concentrations did not significantly change: 0.0 μιηοΙ/L (-0.06 
to 0.03μηιο1/ί) after placebo and 0.0 μπιοΙ/L (-0.02 to 0.0 μπιοΙ/L), 0.02 μπιοΙ/L (0.0 to 
0.11 μηιοΙ/L), 0.02 μιποΙ/L (0.0 to 0.11 μιηοΙ/L) and 0.0 μΐηοΙ/L (-0.06 to 0.06 μπιοΙ/L) 
after 1, 2, 4 and 6 mg of draflazine (Friedman: P=0.12). 
DISCUSSION 
These results show that ventilation is increased by high grade nucleoside transport 
inhibition with draflazine. Until now, nucleoside transport inhibition has been the only 
known action of this drug [192,214,263,264]. 
Recently, we have shown that the hemodynamic and neurohumoral effects of high 
grade nucleoside transport inhibition with draflazine in humans can be antagonized with 
the adenosine receptor antagonist caffeine [265]. This supports the assumption that the 
effects of draflazine are mediated by endogenous adenosine. Additionally, draflazine is 
able to potentiate the vasodilator effect of intra-arterially-infused adenosine in humans 
[266] confirming the in vivo action of draflazine as a nucleoside transport inhibitor. 
Therefore, the present results suggest that endogenously released adenosine can play a 
role in the regulation of the ventilation. Plasma adenosine concentration was not signifi­
cantly affected by draflazine. This finding contrasts with the observations of others 
[244,251] who reported a doubling of adenosine concentrations after dipyridamole 
administration [244,251]. However, in these dipyridamole studies adenosine formation, 
uptake, and breakdown after blood sampling were not optimally antagonized. Therefore, 
in these studies baseline plasma adenosine concentrations may have been underestimated, 
and the administered dipyridamole may have affected adenosine uptake by erythrocytes 
after blood sampling. The present study does not rule out a small draflazine-induced 
increase in plasma adenosine levels, because intra-subject variability of the adenosine 
detection method is high. Additionally, we can not exclude a detectable increase in 
adenosine concentration during more sustained nucleoside transport inhibition. Alternati­
vely, nucleoside transport inhibition may transform the endothelium to a functional barrier 
preventing adenosine from leaving the interstitial space and resulting in an increase of 
adenosine in the interstitial compartment only. 
In conclusion, draflazine-induced high grade nucleoside transport inhibition 
stimulates ventilation in humans. We suggest that this effect is mediated by an increased 
extracellular adenosine concentration in the interstitial compartment only. 
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Presynaptic inhibition of norepinephrine release from 
sympathetic nerve endings by endogenous adenosine 
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Adenosine and norepinephrine release 
ABSTRACT 
Experimental data suggest that ATP (adenosine-5'-triphosphate) is coreleased with 
norepinephrine from sympathetic nerve endings. Breakdown of ATP to adenosine in the 
synaptic cleft may give rise to inhibition of norepinephrine release by stimulation of 
presynaptic adenosine receptors. We tested this mechanism of action in humans by using 
a specific nucleoside transport inhibitor (draflazine) as a pharmacological tool to allow 
accumulation of endogenous adenosine in the synaptic cleft. In a dose-finding study 
(n = 10), we first assessed the effect of local draflazine infusion into the brachial artery for 
five increasing dose steps: 100 to 2000 ng/100 ml forearm per min. Forearm blood flow 
and vascular resistance were registered at both sides by venous occlusion plethysmograp-
hy. Ex vivo levels of local nucleoside transport inhibition as determined from sequential 
blood samples showed a dose-dependent increase which resulted in a decrease in forearm 
vascular resistance in the infused arm only for the three highest draflazine dosages 
(P<0.05). Since the second dose of draflazine (250 ng/100 ml forearm per min) induced 
a considerable local nucleoside transport inhibition (=40%), without affecting vascular 
tone and without a relevant effect on the level of nucleoside transport inhibition at the 
contralateral side ( = 7%), this particular dose was used for the main study. 
In the main study, the effect of intra-arterial draflazine on sympathetic-mediated 
norepinephrine spillover during lower body negative pressure (LBNP, -25 mmHg, 15 
minutes) was studied by use of the 3H-norepinephrine (NE) isotope dilution technique 
(n=25). During placebo, LBNP induced a significant increase in the total body NE 
spillover (29±9%) as well as in the forearm NE appearance rate (45±13%), accompa-
nied by an increase in forearm vascular resistance (101 + 16%) and heart rate (5+2%). 
Draflazine infusion itself did not affect total body NE spillover or hemodynamics, but 
appeared to increase basal forearm NE appearance rate by 27+7%, possibly as result of 
afferent nerve stimulation. During draflazine, LBNP-induced increase in forearm NE 
appearance rate was significantly reduced as compared with placebo (16+11 versus 
45+13%, P<0.05), whereas the total body NE spillover and the systemic hemodynamic 
parameters responded similarly as during placebo. These observations suggest that during 
sympathetic stimulation, accumulation of endogenous adenosine in the synaptic cleft can 
inhibit the release of norepinephrine from sympathetic nerve endings. 
INTRODUCTION 
In vitro observations have indicated that adenosine-5'-triphosphate (ATP) is 
coreleased with norepinephrine from sympathetic nerve endings [15]. Extracellular ATP is 
rapidly degraded by ectophosphatases to adenosine-5'-monophosphate which is subse-
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quently dephosphorylated by 5'-nucleotidase to adenosine [82-84]. Then, endogenous 
adenosine is rapidly cleared from the interstitiurn, at least in part by cellular uptake 
through specific nucleoside transporters [254]. In a variety of in-vitro models, adenosine 
has been shown to inhibit norepinephrine (NE) release from sympathetic nerve endings 
[222,267,268]. Adenosine Α,-receptors are thought to be involved in this inhibitory effect 
[267]. In an elegant in vivo study in humans, Taddei et al. have provided indirect 
evidence for an adenosine-mediated reduction in NE release from sympathetic nerve 
endings in humans, by demonstrating an augmented forearm vasoconstrictor response to 
sympathetic stimulation during administration of the adenosine receptor antagonist 
theophylline [269]. However, NE release itself was not measured in these experiments 
and, in theory, their observations could have been explained by alterations or interactions 
at the postsynaptic level [50,223]. Apart from the putative inhibitory action of adenosine 
at the level of sympathetic nerve endings, it has to be emphasized that adenosine can 
increase sympathetic nervous system activity in humans by stimulating afferent nerve 
endings in the vessel wall as well as in the carotid body [207,270,271]. 
This study was performed to investigate the effect of endogenous adenosine on NE 
release from sympathetic nerve endings during stimulation of the sympathetic nervous 
system. To this end, a specific nucleoside transport inhibitor (draflazine) was used as a 
pharmacological tool to allow accumulation of endogenous adenosine in the synaptic cleft 
during sympathetic stimulation [254,271]. Appropriate pilot studies were performed to 
determine the dose of draflazine at which an optimal grade of nucleoside transport 
inhibition was induced. The current observations support the hypothesis that endogenous 
adenosine inhibits NE release at the sympathetic nerve ending. 
SUBJECTS AND METHODS 
After approval by the local ethics committee, a total number of 35 normotensive 
nonsmoking healthy male volunteers signed written informed consent statements before 
participation in the study. Their demographic characteristics are summarized in table 1. 
Ten of these subjects participated in the draflazine dose-finding study, and 25 participated 
in the main study. They had no history of hypertension, diabetes mellitus or drug allergy 
and did not use concomitant medication. In all volunteers, a physical examination and a 
twelve lead electrocardiography was performed to exclude cardiovascular, pulmonary or 
neurologic disease. The subjects were asked to abstain from caffeine-containing products 
for at least 24 hours since low concentrations of caffeine have shown to attenuate the 
effects of adenosine in the forearm vascular bed [221]. All experiments were performed 
in the moming hours after a ten-hour fasting period, in a temperature controlled room 
(24-25 'C) and with the subjects in supine position. Since all drug- and volume infusion 
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Dose-finding study 
10 
29.4 ± 11.9 
73.3 + 11.5 
180.5 ± 9.4 
22.4 + 2.0 
128 ± 8.0 
74.0 ± 9.6 
70.0 ±12 .1 
55 ± 11 
1.01 ± 0.16 
Main study 
25 
34.6 ± 16.8 
76.0 ± 10.4 
181.4 ± 6.6 
23.0 ± 2.5 
126 ± 8.9 
72.5 ± 8.9 
66.4 ± 9.7 
42 ± 15.6 
1.11 ± 0.13 
rates were calculated per deciliter of forearm tissue, the forearm volume was measured 
for each individual by water displacement. 
TABLE 1: Baseline characteristics of the study groups (mean ± SD) 
N 
Age (years) 
Weight (kg) 
Height (cm) 
Body mass index (kg/nr) 
Systolic blood pressure (mmHg)* 
Diastolic blood pressure (mmHg)* 
Heart rate (bpm)# 
Forearm vascular resistance (AU) 
Forearm volume (L) 
tt Blood pressure was measured in supine position with the Riva-Rocci technique using Korotkoff I and V 
for systolic and diastolic blood pressure respectively. Heart rate was measured by pulse frequency counting 
(radial artery). 
After local anesthesia (Xylocaine 2%), the left brachial artery was cannulated with 
a 20-gauge catheter (Angiocath, Deseret Medical, Becton Dickinson Sandy, UT, USA) 
for both intra-arterial drug infusion (automatic syringe infusion pump, type STC-521, 
Terumo, Tokyo, Japan) and blood pressure recording (Hewlett Packard GmbH, Böblin-
gen, Germany). In the same arm, a deep antecubital vein was cannulated retrogradely for 
venous blood sampling. In the opposite arm an antecubital vein was cannulated for blood 
sampling (dose-finding study) or infusion of tritiated norepinephrine (main study). 
Forearm blood flow (FBF) was recorded in both forearms by electrocardiography-
triggered venous occlusion plethysmography using mercury-in-silastic strain gauges 
(Hokanson EC4, D.E. Hokanson, Washington DC, USA). The upper arm collecting cuffs 
were simultaneously inflated using a rapid cuff inflator (Hokanson E-20). At least one 
minute before FBF measurements were made, the hand circulation was occluded by 
inflation of wrist cuffs to 200 mmHg. Forearm blood flow was recorded three times a 
minute. All experiments were started at least 30 minutes after intra-arterial cannulation. 
In all experiments total intra-arterial infusion rate was kept constant at 50 /Л/100 ml 
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forearm per min. Before the start of each experiment, venous blood was collected for the 
measurement of plasma caffeine concentration. 
Draflazine dose-finding study 
The aim of this dose-finding study was to determine the intra-arterial dose of 
draflazine which resulted in a sufficient level of nucleoside transport inhibition in the 
forearm vascular bed without causing systemic effects and without inducing regional 
vasodilation. We reasoned that prevention of draflazine-induced vasodilation was 
important because baseline vascular tone is an important determinant of the magnitude of 
the response to vasomotor stimuli [272]. 
In 10 subjects, the effect of five increasing dosages of draflazine, infused into the 
brachial artery, on forearm vascular tone and on local and systemic ex vivo nucleoside 
transport inhibition was studied. The experiment started with the measurement of baseline 
FBF, mean arterial pressure and forearm vascular resistance (FVR) during the last four 
minutes of a five minute saline infusion. The effect of five increasing dosages of 
draflazine (100, 250, 500, 1000 and 2000 ng/100 ml forearm per min) on FBF and FVR 
were compared with saline. Each draflazine dosage was infused for 20 minutes. At the 
end of saline infusion and each draflazine infusion, venous blood was sampled from both 
arms for ex vivo measurements of nucleoside transport inhibition (see 'analytical me-
thods'). Prolonged occlusion of the hand circulation can cause discomfort. Therefore, 
wrist cuffs were only inflated during the last 10 minutes of draflazine infusion, and FBF 
was measured during the last 8 minutes of each draflazine dose. 
Main study 
In 25 subjects, the lower body was sealed in an airtight Plexiglas™ box. The 
applied lower body negative pressure (LBNP) was recorded by a manometer connected to 
the inside of the box. In each subject, a 15-minute LBNP at -25 mmHg was applied 
twice. The second LBNP was performed 50 minutes after the first one. In a pilot study 
we have shown that the mean hemodynamic response to LBNP was identical when 
repeated within one day, with a fall in FBF of 1.3±1.0 and 1.1 ±0.8 ml/100 ml forearm 
per min for the first and second LBNP respectively (n=15, unpublished data). 
Intra-arterial infusion of placebo (NaCl 0.9%) started 10 minutes before each 
LBNP. The first LBNP was performed during ongoing intra-arterial placebo infusion. In 
contrast, five minutes before the second LBNP, intra-arterial placebo was switched to 
draflazine (250 ng/100 ml forearm per min) which was infused until the end of the 
LBNP. This draflazine dose was based on the results of the dose-finding study. The wrist 
cuffs were inflated during the ten minutes prior to each LBNP and during the last 10 
minutes of LBNP. Forearm blood flow was measured during the placebo infusions, 
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during the draflazine infusion and during the last 8 minutes of each LBNP. Venous and 
arterial blood samples were obtained from the infused arm immediately before and at the 
end of each LBNP for determination of NE kinetics. Additionally, arterial and venous 
blood was sampled at the end of the second placebo infusion to detect a possible effect of 
draflazine on baseline NE kinetics. 
Levo-[ring-2,5,6-3H]-norepinephrine (specific activity 30-60 Ci/mmol) was infused 
intravenously in order to assess plasma NE kinetics. The radiotracer was administered 
intravenously at a constant rate of 1.0 μΟϊ/ιτύη, and this infusion was started 20 minutes 
before the onset of each LBNP. Samples of the infúsate were taken at the end of the 
infusion in order to determine the exact infusion rate and the original activity of 3H-NE in 
1.0 ml plasma sample. 
Analytical methods 
Samples for determination of plasma caffeine concentration were analyzed with a 
reversed-phase HPLC method (limit of detection: 0.2 μg/ml), as described previously 
[218]. 
Blood samples for determination of plasma norepinephrine were collected in 
prechilled tubes containing glutathione (0.2 M) and EGTA (0.25 M). The tubes were 
centrifuged at 4 "C and the plasma was separated and stored at -20 *C. Measurements for 
concentrations of NE and 'H-NE of all plasma samples and infusâtes occurred within two 
months after sampling, using high performance liquid chromatography (HPLC) with 
fluorometric detection after precolumn derivatization with the fluorescent agent 1,2-
diphenylethylenediamine. A Gilson fraction collector (Model 201-202), which was 
connected to an automatic sample injector (Wisp 710B), was used for collecting [3H]-NE 
into scintillation vials, according to the retention time of the NE standard solution. 
Ex vivo nucleoside transport inhibition was measured by standardized incubation of 
erythrocytes with adenosine. Four ml of blood was drawn into a vial containing 1.0 ml 
acid/citrate/dextrose (85 mM tri-sodium citrate, 65 mM citric acid and 20 g/L glucose) 
and further handled as described before [271]. After incubation, the concentration of 
adenosine, inosine and hypoxanthine was determined in the supernatant with a chemolu-
miniscence technique. The percentage inhibition of nucleoside transport was calculated as: 
(Ax-A,) χ 100 I (1-Ag) in which A0 represents the adenosine concentration as proportion of 
the sum of the concentration of adenosine, inosine and hypoxanthine as determined in the 
sample collected just before the drug infusion and A, represents this proportion as 
determined in the sample collected after the start of the drug infusion. 
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Drugs and solutions 
Tritiated norepinephrine was obtained from Du Pont New England Nuclear ('s-
Hertogenbosch, The Netherlands). The radionuclide was sterilized using a 0.22 μπ\ filter 
and diluted in 0.9% NaCl containing acetic (0.2 M) and ascorbic (1 mg/ml) acid. 
Aliquots of approximately 70 μΟ/ιτιΙ of [JH]-NE were stored at -80 'C until use. 
Sterilization, dilution, and aliquoting were carried out under nitrogen. Just before use, an 
aliquot was diluted in 0.9% NaCl. 
Sterile draflazine solutions were freshly prepared from 10 ml vials containing 5 
mg draflazine diluted in NaCl 0.9% (Janssen Pharmaceutica Inc., Beerse, Belgium). The 
specificity of this drug as a nucleoside transport inhibitor, and the ability of this drug to 
increase endogenous adenosine levels in humans has extensively been described before 
[254,271]. 
Data analysis 
Mean arterial blood pressure was measured continuously during each recording of 
FBF and averaged per FBF measurement. Forearm vascular resistance (FVR) was 
calculated as the quotient of the simultaneously registered mean arterial blood pressure 
and the FBF, and was expressed as arbitrary units (AU). For the draflazine dose-finding, 
the hemodynamic registrations obtained during placebo infusion and the last 6 minutes of 
each draflazine infusion were each averaged to one value. Draflazine-induced effects were 
expressed both as absolute and percentage changes from the preceding placebo infusion. 
For the main study, the hemodynamic parameters were averaged to one value for the 
following consecutive periods: Placebo-1 / Placebo+LBNP / Placebo-2 / Draflazine / 
Draflazine+LBNP. The data obtained during the last 6 minutes of each LBNP were used. 
Arterial and venous concentrations of [3H]-NE and NE were used for calculations 
of the various parameters of norepinephrine kinetics, as previously described [273-275]. 
Total body NE spillover, the estimated rate of appearance of endogenous NE in arterial 
plasma, was calculated from arterial plasma NE concentration (NE,), the arterial steady-
state plasma concentration of [Ή]-ΝΕ (['Hl-NEJ and the infusion rate of [5H]-NE, 
according to the equation: 
Total body NE spillover (ng/min) = NE
a
 (ng/L) χ {Infusion rate (dpmmin')j I fH]-NEtt 
(dpm/L) 
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The local forearm NE appearance rate was estimated from: 
Forearm NE appearance rare (pg/100 ml forearm per min) = ((FPF χ NE
a
 xf^ + [FPF 
χ (NEV - NEJ]} I (1-f^ 
where fNE is the fractional extraction of the tracer across the forearm, calculated as 
([3H]NE. - [Ή1ΝΕ,) / [3H]NE„ and [Ή1ΝΕ, and [Ή]ΝΕ„ is respectively the venous and 
arterial plasma concentration of [3H]-NE, and FPF is the forearm plasma flow (ml/100 ml 
forearm per min), calculated from the forearm blood flow and the hematocrit as FBF χ 
(1-Ht). 
The changes in the hemodynamic and kinetic parameters induced by LBNP during 
placebo were compared to those induced by LBNP during draflazine. 
All results are presented as mean ±SE unless indicated otherwise. To avoid 
multiple comparison, within subject effects were assessed by ANOVA for repeated 
measurements first and further analyzed with the paired Student t-test if appropriate (dose-
finding study). The results of the main study were analyzed by paired Student t-tests. To 
minimize multiple comparisons, LBNP-induced changes from baseline were not tested 
statistically. For the same reason, only FVR, forearm norepinephrine appearance rate and 
total body spillover were included in the statistical analysis. Differences were considered 
to be statistically significant at a P-value < 0.05 (two-sided). NS means not significant. 
RESULTS 
Plasma caffeine levels were determined to check the compliance with respect to 
the caffeine abstinence. In all volunteers, plasma caffeine concentration was below the 
limit of detection indicating an excellent compliance to the caffeine free diet. No 
subjective side effects occurred during the intra-arterial infusion of draflazine. 
Dose Finding study 
Baseline FBF was 2.1+0.3 ml/100 ml forearm per min in the cannulated arm and 
increased to 2.2+0.4, 2.4+0.3, 3.0±0.4, 3.7+0.5 and 4.2±0.5 ml/100 ml forearm per 
min at the end of the five increasing draflazine dosages respectively. Expressed as percent 
change from baseline, FBF was increased by 4.9+7.4, 18.0+6.1, 51.1 ± 13.6, 
94.1 ±20.8, and 123.2+24.5 % at the end of the five increasing draflazine dosages 
respectively (n = 10; Ρ <0.05 for the four highest dosages). Forearm blood flow in the 
contralateral arm was not significantly affected during any of the infusions. Baseline FVR 
was 54.6± 10.7 AU in the cannulated arm. Draflazine decreased FVR by 5.3+10.1, 
5.7+5.7, 20.4±6.7, 34.8+7.1 and 41.7±6.7 % for 100, 250, 500, 1000 and 2000 ng 
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draflazine/100 ml forearm per min respectively (n = 10; P<0.05 for the three highest 
dosages). The FVR in the contralateral arm was not significantly affected (figure 1). 
In the infused arm ex vivo nucleoside transport inhibition was 7.0±2.4, 42.4±8.8, 
69.7+7.7, 80.8+4.8 and 87.1+2.5 % during the five increasing dosages respectively 
(n = 10, Ρ < 0.05 for each dosage versus baseline; see figure 1). Likewise, in the non-
experimental arm ex vivo NTI increased dose-dependently by 3.9 + 1.6, 6.8+3.4, 
11.9±3.7, 17.8±3.5 and 51.2+3.0 % respectively (n = 10, P<0.05 for each dosage 
versus baseline; see figure 1). 
NTI (% response) FVR (% response) 
1 • ι • > - 6 0 ' ' ' ' ' ' 
0 100 250 500 1000 2000 0 100 250 500 1000 2000 
Draflazine dose (ng/100 mi/min) Draflazine dose (ng/100 ml/min) 
Figure 1. Percentage changes (mean±SE) in nucleoside transport inhibition (lelt panel), and in the forearm 
vascular resistance (right panel) as induced by incremental dosages of draflazine, infused into the brachial 
artery. The solid line represents the data at the side ot dratlazme infusion, whereas the dashed line shows 
the data from the contralateral side. 
*, Ρ < 0.05 versus baseline. 
Based on these results, the draflazine dose of 250 ng/100 ml forearm per min was 
chosen for the main study because this dose induced a sufficient nucleoside transport 
inhibition in the forearm vascular bed ( = 40%) without a relevant increase in this 
parameter at the contralateral site ( = 7%), and without causing a significant vasodilator 
response at the side of infusion. 
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Main study 
Effect of sympathetic stimulation by LBNP 
Table 2 shows the hemodynamic and neurohumoral effects of LBNP with and 
without concomitant intra-arterial draflazine infusion. During placebo, LBNP induced a 
fall in FBF from 2.6±0.3 to 1.5+0.2 ml/100 ml forearm per min at the experimental 
side, and from 2.5±0.3 to 1.5±0.2 ml/100 ml forearm per min at the contralateral side. 
Mean arterial blood pressure did not change, but heart rate increased by 5.2±1.6 % as a 
result of the first and second LBNP respectively. Total body NE spillover increased by 
28.9±8.6%, whereas the forearm NE appearance rate increased by 45.3± 13.3%. Fifty 
minutes after stopping the first LBNP, all parameters had returned towards baseline level 
(placebo-1). 
Effects of draflazine infusion 
In accordance with the results of the dose-finding study, intra-arterial infusion of 
draflazine at a rate of 250 ng/100 ml forearm per min did hardly affect vascular tone 
(table 2). Although the total body NE spillover was not altered, draflazine caused an 
increase in forearm NE appearance rate of 26.6+7.2 % (P<0.01 versus baseline). 
Effects of draflazine on the response to sympathetic stimulation by LBNP 
Application of LBNP during draflazine exerted a hemodynamic response which did 
not differ from that to the first LBNP, with no change in mean arterial blood pressure and 
a significant increase in heart rate of 7.3 ±2.0 %. During draflazine infusion, LBNP 
induced a fall in forearm blood flow from 3.2±0.4 to 2.1 ±0.3 ml/100 ml forearm per 
min at the experimental side and from 2.8±0.3 to 1.9±0.2 ml/100 ml forearm per min at 
the contralateral side. Forearm vascular resistance showed a bilateral fall without 
difference between the experimental and contralateral arm, although response was lower 
as compared with the first LBNP, both on the experimental as well as on the contralateral 
side. 
Figure 2 shows the LBNP-induced percent changes from baseline for the data on 
norepinephrine. Again, total body NE spillover increased, on average by 45.6±9.3% as 
opposed to 28.9±8.6% during the first LBNP (first versus second LBNP: P=0.2). In 
contrast, the response of the forearm NE appearance rate to LBNP was almost abolished 
during draflazine (15.9± 10.5%), this response being significantly lower as compared 
with that to the first LBNP (15.9±10.5 versus 45.3 + 13.3%, P<0.05). In 16 subjects, 
the response to LBNP was reduced during draflazine infusion as compared with that to 
the first LBNP. 
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Figure 2. The percentage increase 
(mean ±SE) in the total body norepi-
nephrine (NE) spillover (left panel) 
and the forearm NE appearance rate 
resulting from sympathetic stimulati-
on by application of lower body 
negative pressure (LBNP), both 
during intra-arterial infusion of 
placebo or draflazine (250 ng/-
min/dl). 
+ + 
Draflazine (-/+) 
DISCUSSION 
The main observation of this study is that infusion of the specific nucleoside 
transport inhibitor draflazine into the forearm skeletal muscle vascular bed resulted in a 
blunted response of the local NE appearance rate during sympathetic stimulation. This 
attenuation only occurred at the side of draflazine infusion, as simultaneous measurements 
of the total body NE spillover convincingly showed that the overall response of the 
sympathetic nervous system to LBNP during draflazine (=45%) was certainly not lower 
than that to LBNP during placebo ( = 30%). The absence of an effect on total body NE 
spillover completely agrees with the almost negligible level of systemic nucleoside 
transport inhibition, which was far below the threshold for interference with the sympa-
thetic nervous system [271]. The specificity of draflazine has been tested in various in 
vitro systems [214]}. Intravenous infusion of draflazine in conscious humans elicits a 
hemodynamic, neurohumoral and ventilatory response that closely resembles the effects of 
intravenous infusion of adenosine [206,207,230,248,271,276]. This occurred at higher 
systemic draflazine blood concentrations than currently used locally, as assessed by ex-
vivo nucleoside transport inhibition. By use of caffeine as an adenosine receptor antago-
nist, we were able to show in a previous study that the circulatory effects of nucleoside 
transport inhibition by draflazine completely resulted from adenosine receptor stimulation 
[271]. Consequently, our current data provide evidence for an adenosine receptor-
mediated reduction in norepinephrine release from efferent nerve endings during sympa-
100 
80 
60 
40 
20 
Norepinephrine appearance rate 
(% response to LBNP) 
p-0.2 p=0.04 
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thetic stimulation. This reduction in the observed LBNP-induced norepinephrine release 
from the forearm vascular bed was expected to be accompanied by a parallel reduction in 
the local vasoconstrictor response to sympathetic stimulation. However, we did not find 
any evidence for an impaired forearm vasoconstrictor response at the side of draflazine 
infusion (table 2). This does not necessarily argue against our interpretation of the results, 
because the forearm vasoconstrictor response also depends on a variety of other factors, 
including the postsynaptic interaction between adenosine and norepinephrine [50,223], 
eventual alterations in receptor populations, and changes in the release of cotransmitters 
like ATP and/or neuropeptide Y [15,277,278]. 
Our interpretations are mainly based on assessment of the spillover of norepi-
nephrine according to the isotope dilution technique as described by Esler et al. [274]. 
The tracer 3H-NE is used for determining the amount of norepinephrine that is extracted 
during passage across a vascular bed, in this case that of the forearm skeletal muscles. 
However, forearm NE spillover as calculated from these parameters strongly depends on 
the forearm blood flow [273]. Recently, Chang et al. proposed a correction for this 
calculated forearm NE spillover by taking into account the amount of released norepi-
nephrine that is also extracted from the forearm vascular bed [275]. This so-called 
forearm NE appearance rate should be a more accurate measurement of the regional 
release from norepinephrine, especially for our study because of the induced changes in 
forearm blood flow as a result of sympathetic stimulation. 
In our dose-finding study, intra-arterial infusion of draflazine resulted in a 
significant dose-dependent inhibition of ex vivo nucleoside transport that was considerably 
higher in the infused arm as compared with the non-infused contralateral arm. Draflazine 
dosages of 500 ng/100 ml forearm per min or more elicited vasodilation in the infused 
arm that was not observed in the control arm indicating a local vasodilator action of 
draflazine in humans. As demonstrated previously, the effects of draflazine are mediated 
by adenosine accumulation in the extracellular space and subsequent adenosine receptor 
stimulation [271]. Therefore, the vasodilator action of draflazine indicates extracellular 
adenosine accumulation in the non-ischemic human forearm vascular bed. Possible 
sources of this endogenous adenosine include endothelium, vascular smooth muscle cells 
and sympathetic nerve endings where adenosine is formed extracellularly by enzymatic 
degradation of the neurotransmitter adenosine-5'-triphosphate (ATP) [85,279-281]. 
Unexpectedly, the main study showed that the baseline forearm NE appearance 
rate increased significantly during draflazine infusion without changes in total body NE 
spillover. Actually, the dose of 250 ng/100 ml forearm per min was chosen because it 
was expected to inhibit nucleoside transport inhibition to a sufficient extent without 
affecting baseline hemodynamic or humoral parameters. Of course, we realized that 
increasing endogenous adenosine levels may stimulate sympathetic nervous system activity 
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by stimulation of afferent nerves [207,270,271]. Recently, this has been shown in 
particular for the forearm skeletal muscle vascular bed [229]. However, dose response 
data on draflazine have suggested that this afferent stimulation should not occur at the 
level of nucleoside transport inhibition as reached in our main study [271]. Nonetheless, 
the present finding indicates that the baseline norepinephrine release from sympathetic 
nerve endings in the forearm can be slightly stimulated by low dosages of intra-arterially 
infused draflazine. We have no clear explanation for this observation. If stimulation of 
adenosine sensitive afferent nerve endings in the forearm vascular bed plays a role- in this 
observation, we must assume that the response of the efferent sympathetic nervous system 
was a differential side selective response because total body norepinephrine spillover and 
systemic hemodynamics were unaffected. Along these lines, the contrasting effects of 
draflazine on baseline versus stimulated forearm NE appearance rate may be mediated by 
interaction of endogenous adenosine with the sympathetic nervous system at two distinct 
levels. In figure 3 this hypothesis is summarized in a schedule. 
CENTRAL NERVOUS SYSTEM 
Sympathetic nerve ending 
Smooth muscle celts 
/^** u-iectplor 4 / 
Adenosine receptor 
NE ATP - > adenosine > 
V" V 
О · 
Р2
ж
-гесерЮг 
Vasoconstriction Vasodilation 
^ 
I Ad' 
Figure 3. Outline of the potential interactions between endogenous adenosine and the sympathetic nervous 
system. 
First, accumulation of continuously formed interstitial adenosine may increase 
sympathetic nervous system activity as a result of stimulation of afferent nerve endings in 
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the forearm vascular bed. Second, during sympathetic stimulation draflazine allows 
accumulation of endogenous adenosine, as a breakdown product of ATP coreleased in the 
synaptic cleft, that is able to reduce norepinephrine release from sympathetic nerve 
endings locally by presynaptic inhibition of neurotransmitter release. Apparently, the first 
effect of adenosine dominates during baseline conditions, when baseline sympathetic 
nervous system activity is low. However, the importance of the second interaction increa-
ses during sympathetic stimulation by LBNP as adenosine builds up in the synaptic cleft. 
It has to be emphasized that this dual action of adenosine has already extensively been 
described for exogenous adenosine [225]. The current results extrapolate this concept to 
the effects of endogenous adenosine. 
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NG-Monomethyl-L-Arginine reduces the forearm vasodilator 
response to acetylcholine but not to methacholine in humans 
G.A. Rongen, P. Smits, and Th. Thien 
Journal of Cardiovascular Pharmacology 1993;22:884-888 

L-NMMA and Methacholine 
ABSTRACT 
We compared the contribution of nitric oxide (NO) in methacholine (MCh)- and 
acetylcholine (ACh)-induced vasodilation using the NO-synthase inhibitor №-monome-
thyl-L-arginine acetate (L-NMMA-acetate) in two groups (A and B) of 6 healthy male 
volunteers. The left brachial artery was cannulated for drug infusion and recording of 
mean arterial pressure (MAP). Forearm blood flow (FBF) was measured on both sides by 
venous occlusion mercury-in-silastic strain gauge plethysmography. All measurements 
were performed with occluded hand circulation. Forearm vasodilator response to three 
increasing dosages of MCh (0.03, 0.3 and 1 ¿ig/100 ml forearm/min; group A) or ACh 
(0.5, 2 and 8 μg/100 ml forearm/min; group B) was studied first. Forty-five minutes 
later, these infusions were repeated (after and during local administration of L-NMMA). 
L-NMMA-acetate infusion alone increased basal forearm vascular resistance (FVR, 
mean+SE) by 86.2 + 14.5 % and 99.5±27.4 % in group A and B, respectively (P<0.05) 
without significant FVR changes in the control arm. MCh-induced vasodilation was not 
attenuated by concomitant L-NMMA-acetate infusion. In contrast, L-NMMA-acetate 
significantly reduced the averaged percentage decrease in FVR during infusion of ACh 
from 55.7±9.1 % to 35.4±11.8 % (P<0.05). 
L-NMMA-acetate increased basal vascular tone and reduced the vasodilator 
response to ACh. MCh induced vasodilation to a similar degree as compared to that 
obtained with ACh. Nevertheless, MCh-induced vasodilation could not be attenuated by 
L-NMMA suggesting that NO contributes differentially to MCh- and ACh-induced 
vasodilation in humans. 
INTRODUCTION 
The endothelium has important vascular tone-regulating properties mediated by en-
dothelium-derived relaxing and contracting factors (EDRF, EDCF) [73,282-284]. One of 
these is nitric oxide (NO), which is synthesized from L-arginine by nitric oxide (N0)-
synthase [32,285]. Nitric oxide has important vasorelaxing properties mediated by a 
soluble guanylate cyclase in vascular smooth muscle cell [32]. Both in vitro and in vivo 
studies have demonstrated that the effect of many endothelium-dependent vasodilators is 
mediated by NO [36,103,146,286]. Vallance and colleagues were first to show that 
infusion of N°-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of NO-syn­
thase, reduced basal blood flow and attenuated the response to the endothelium-dependent 
vasodilator acetylcholine (ACh) in the human forearm vascular bed [36]. These findings 
implicated that L-NMMA could be an important tool to investigate the role of NO in the 
human forearm in vivo. Methacholine (MCh), a relatively stable ACh analogue 
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[287,288], is often used as a substitute for ACh in human studies [196,197,289] but no 
data are available concerning the ability to reduce MCh-induced vasodilation by L-
NMMA in vivo Recently, Chowienczyk and co-workers have proposed that MCh- and 
ACh-mduced vasodilation in the human forearm is mediated by different mechanisms 
[290]. This hypothesis was based on the observed divergent effect of hypercholeste­
rolemia on ACh- and MCh-induced vasodilation, but some methodological problems may 
have biased the observations [291]. Therefore, we compared the contribution of NO in 
MCh- and ACh-induced vasodilation, using the commercially available L-NMMA-acetate. 
SUBJECTS AND METHODS 
After approval was obtained from the local ethics committee, two groups of six 
normotensive healthy male volunteers (group A and B) signed written informed consent 
statements before participating in the study Both groups were comparable for age (18-43 
years), weight (62 8-90 1 kg), height (172-202 cm), systolic blood pressure (106-130 
mmHg), and diastolic blood pressure (50-79 mmHg). Before the start of the study, the 
subjects were asked to abstain from caffeine-containing products for at least 36 hours and 
to refrain from smoking for 12 hours. Furthermore, subjects were asked to discontinue 
any food intake two hours before the experiment All tests were performed with the 
subject m supine position, starting at 2 00 ρ m After local anaesthesia (Xylocaine, 2%) 
was induced, the left brachial artery was cannulated with a 20-gauge catheter (Angiocath, 
Deseret Medical, Inc., Becton Dickinson, Sandy, UT, U S A ) for both lntra-artenal drug 
infusion (automatic syringe infusion pump, type STC-521, Terumo, Tokyo, Japan) and 
blood pressure recording (Hewlett Packard GmbH, Böblingen, Germany). Forearm blood 
flow (FBF) was registered on both forearms by electrocardiography-tnggered venous 
occlusion plethysmography using mercury-in-silastic strain gauges (Hokanson EC4, D E. 
Hokanson, Washington, D.C., U S A ) . The upper arm collecting cuffs were simultane-
ously inflated using a rapid cuff inflator (Hokanson E-20) At least one minute before 
FBF measurements were made, hand circulation was occluded by inflation of the wrist 
cuffs to 200 mmHg. Forearm blood flow was recorded three times a minute All 
experiments were started at least 30 minutes after intra-artenal cannulation. 
The experiment began with the measurements of baseline FBF during placebo 
infusion. Figure 1 shows the course of FBF and the schedule of the several drug infusions 
in group A. The effect of three increasing dosages MCh (0.03-0.3-1.0 ¿tg/lOO ml forearm 
per min) were compared with placebo (NaCl 0.9%) Because prolonged occlusion of the 
hand circulation can cause discomfort with subsequent effects on blood pressure and heart 
rate, a 10-minute rest was allowed between the first and second MCh infusion. Forty-five 
minutes after the last MCh infusion the vasoactive effect of L-NMMA-acetate infusion 
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(0.1 mg/100 ml forearm per min) was compared with placebo infusion. Subsequently, the 
lowest MCh dose was infused (0.03 mg/100 ml forearm per min) together with infusion 
of L-NMMA-acetate (0.05 mg/100 ml forearm per min). Ten minutes thereafter, L-
NMMA-acetate was infused again (0.1 mg/100 ml forearm per min), immediately 
followed by the middle and the highest MCh dosages (0.3-1.0 /tg/100 ml forearm per 
min) together with infusion of L-NMMA-acetate (0.05 mg/100 ml forearm per min). 
During all procedures, total infusion rate was kept constant at a rate of 100 μ1/100 ml 
forearm per min. Placebo and each drug dosage were infused during 5 minutes. In group 
B, ACh (0.5, 2 and 8 ¿tg/lOO ml forearm per min) was substituted for MCh. Otherwise 
the same protocol was performed. 
Forearm blood flow (ml/100tnl/min.) 
Figure 1. Forearm blood flow (ml/100 ml/min) 
during increasing dosages of methacholine 
(0.03-0.3-1 ftg/100 ml forearm/min) with and 
without L-NMMA-acetate (mean±SE) . P I , P2 and 
P3 represent first, second and third placebo infusi-
on respectively. 
Mch: methacholine 
" 40 60 " 115 135 155 
Time (min.) 
Drugs and solutions 
L-NMMA-acetate, acetylcholine chloride (Sigma Chemical Company, St. Louis, 
USA) and methacholine chloride (Aldrich Chemical Company, Inc., Bomem, The Ne-
therlands) were reconstituted on the morning of the study day from a sterile lyophilized 
powder, passed through a 0.2 μιτι millipore filter, and diluted in 0.9% NaCl. 
Statistical analysis 
Mean arterial pressure was measured continuously during each recording of FBF 
and averaged per FBF measurement. Forearm vascular resistance (FVR) was calculated 
from simultaneously measured MAP and FBF (MAP/FBF) and expressed as arbitrary 
units (AU). The calculated FVRs obtained during each 5 minutes of placebo infusion or 
during the last 2 minutes of each drug infusion were averaged to one value. Drug-induced 
effects were expressed as the percentage of change from preceding placebo infusion 
(effect of L-NMMA-acetate and MCh or ACh without L-NMMA-acetate) or from 
preceding L-NMMA-acetate infusion (effect of MCh or ACh with L-NMMA-acetate). To 
quantify the overall response to ACh or MCh, the percentage responses in FVR to the 
three dosages of ACh or MCh were averaged to one value, that was assumed to represent 
в Infused ami 
в Control arm 
• A rbo4 
_ Mch = E 3 Z=. EÍ3 
τ 0 El L-NMMA L-NMMA 
_ l l _ JL_ 
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the area under the curve (AUC) [292]. AUCs with and without concomitant L-NMMA 
infusion were compared to assess the effect of L-NMMA on the vasodilator response to 
MCh or ACh. All results are expressed as mean ±SE unless indicated otherwise and 
compared by the Wilcoxon's paired signed rank test; Ρ <0.05 was taken as statistically 
significant. 
RESULTS 
Figure 1 shows the course of the mean FBF throughout the several infusions in 
group A. In the infused arm in both groups, FVR did not significantly differ between the 
three consecutive placebo infusions: 50.1±11.6, 56.7+19.2 and 50.8±10.2 AU for 
group A and 46.8±8.3, 48.8+9.8 and 52.1 ±14.7 AU for group B. Figure 2 shows L-
NMMA-induced percentage changes in FVR for both control and infused arm. In the 
infused arm of group A, L-NMMA-acetate induced an increase in FVR of 36.7+15.7% 
(P=0.07) and 86.2± 14.5% (P<0.05) during the first and second infusion respectively. 
In theory, the effect of the second L-NMMA-acetate infusion could have been influenced 
by the preceding MCh infusion (0.03 ^g/100ml forearm per min). To assess this possible 
carry over effect, we calculated the percentage difference in FVR between the first and 
second placebo infusion. The percentage increase in FVR during the second L-NMMA 
acetate infusion differed significantly from the percentage difference in FVR between the 
first and second placebo infusion, indicating that a possible carry over effect has not 
played an important role (86.2+14.5% versus 3.1+9.5% for L-NMMA and placebo 
respectively; Ρ < 0.05). Comparable results were obtained in group B: L-NMMA-acetate 
induced an increase in FVR of 54.6± 16.6% (P<0.05) and 99.5+27.4% (P<0.05 versus 
baseline and versus placebo) during the first and second infusion, respectively. In the 
control arm, FVR did not change significantly as a result of L-NMMA-acetate infusion. 
Figure 3 shows the effect of L-NMMA on the vasodilator response to MCh and 
ACh. In the infused arm of group A, FVR decreased with 55.8+9.4%, 69.0+14.6% and 
86.9+3.7% during the three increasing MCh dosages. Concomitant L-NMMA-acetate 
infusion did not affect the vasodilator response to MCh significantly: The AUCs before 
and during L-NMMA infusion were -70.6±8.8 and -68.6+9.3%, respectively (P = NS). 
In the infused arm of group B, FVR decreased with 18.9+18.0%, 67.1±7.2% and 
81.0±5.3% during the three increasing ACh dosages. The AUCs before and during L-
NMMA infusion were -55.7±9.1% and -35.4+11.8% respectively (P<0.05). Again, no 
significant changes in FVR were observed in the control arm. 
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FVR infused arm Group A FVF{ c o r r t r o · a"n 
M l ***** feit 
Infusion order 
Figure 2. Effect of two consecutive L-NMMA-acetate infusions (0 1 my/100 ml/mm) on forearm vascular 
resistance (FVR) expressed as percentage change trom third placebo infusion (mean±SE). The course in 
FVR changes during the two L-NMMA-acetate infusions is compared with the course of these parameters 
during the first two consecutive placebo infusions preceding the methacholine (Group A) or acetylcholine 
(group B) infusions without L-NMMA-acetate. Solid line: L-NMMA; dashed line: placebo. *, Significant 
differences between placebo and L-NMMA-acetate intusion. #, Significant differences from baseline. 
DISCUSSION 
We compared the contribution of NO in MCh- and ACh-induced vasodilation. At 
present, in vivo measurements of NO release are not technically feasible. It is fortunate 
that production of NO can be reduced by L-arginine derivatives that competitively 
antagonize NO-synthase [27,28]. An example is №-monomethyl-L-arginine (L-NMMA). 
In vitro data suggest that L-NMMA also inhibits transmembrane transport of L-arginine 
[293]. Thus, a reduced intracellular concentration of the substrate of NO-synthase may 
further contribute to the inhibitory action of L-NMMA on NO production. 
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FVR infused arm FVR control arm 
- L -
Methacholine (microg/IOOml FAV/min) 
Acetylcholine (microg/100ml FAV/min) 
Figure 3. Effect of methacholine (top) and acetylcholine (bottom) infusions on forearm vascular resistance 
(FVR), expressed as percentage change (mean±SE) trom preceding placebo (methacholine or acetylcholine 
with placebo) or from preceding L-NMMA-acetate infusion (methacholine or acetylcholine with L-NMMA-
acetate). Dashed line: with concomitant placebo infusion, Solid line: with concomitant L-NMMA infusion. 
P-values indicate level of significance for the difference between the AUC's before and dunng L-NMMA 
infusion. If, Significant differences from baseline 
The L-NMMA-acetate infusion of 0.1 mg/100inl forearm per min induced a sig-
nificant increase in FVR, indicating that basal NO release was effectively inhibited [36]. 
The most striking result of the current study is the failure of L-NMMA-acetate to 
reduce the MCh-induced percentage reduction in FVR, although it caused a degree of 
vasodilation similar to that caused by ACh. This finding suggests that NO contributes 
differentially to MCh- and ACh induced vasodilation and supports the hypothesis of 
Chowienczyk and co-workers [290]. Our results may have been confounded by differen-
ces between the two study groups other than the vasodilator used. The existence of a con-
founding factor is not likely since both study groups consisted of healthy male volunteers 
very alike with respect to age, blood pressure, baseline FVR and effect of L-NMMA on 
basal vascular tone. 
Infusion of 0.1 mg L-NMMA-acetate/100ml per min was equimolar to the highest 
dosage of L-NMMA used by Vallance and colleagues (4 ^mol/min) [36], who infused this 
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dosage for 5 minutes just before giving ACh infusions. However, in the present study, L-
NMMA was also infused simultaneously with MCh and ACh to ensure that NO-synthase 
inhibition was effectuated. A reduced dosage of 0.05 mg L-NMMA-acetate was used to 
prevent possible serious side effects. MCh-induced vasodilation might be reduced by 
concomitant infusion of higher dosages of L-NMMA. 
The lowest ACh dosage did not affect FVR significantly. In contrast, the second 
ACh infusion induced a vasodilator response that was almost completely abolished by 
concomitant infusion of L-NMMA, confirming the important role of NO as mediator of 
the ACh-induced vasodilation. The vasodilator response to the highest ACh dose was not 
affected by L-NMMA, which can easily be explained by the competitive nature of the 
NO-synthase inhibition. Other mechanisms than endothelial release of NO may account 
for the vasodilator response to ACh in the presence of L-NMMA. According to the 
literature, ACh-induced vasodilation is mediated by at least three different mechanisms: 
presynaptic inhibition of norepinephrine release, release of NO from endothelial cells and 
stimulation of prostacyclin production from the blood vessel wall [65,282,294,295]. 
Furthermore, increasing evidence suggests that ACh is able to induce the release of an 
endothelium-derived hyperpolarizing factor that can induce vasodilation and is distinct 
from NO [64]. 
The divergent effect of L-NMMA on ACh- and MCh-induced vasodilation sug-
gests that NO contributes differentially to MCh- and ACh-induced vasodilation. Studies 
performed with MCh to assess the influence of various disease states on NO-mediated 
endothelium-dependent vasodilation, are not conclusive and should be repeated with ACh. 
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Characterization of ATP-induced vasodilation in the human fore-
arm vascular bed 
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ATP-induced vasodilation 
ABSTRACT 
Animal data indicate that adenosine-5'-triphosphate (ATP), derived from aggrega­
ting thrombocytes or endothelium, induces an endothelium-dependent vasodilator response 
that is mediated by P2y-purinergic receptors and is reduced when high dosages are 
administered. This reduced vasodilator response to high ATP doses has been associated 
with the concomitant release of endothelium-derived contracting factors. In contrast to the 
endothelium-dependent vasodilator response, ATP as released from sympathetic nerve 
endings induces a P2x-purinergic receptor-mediated vasoconstrictor response that may 
contribute to the attenuated vasodilator response to high dosages of luminally applied 
ATP. The dual action of ATP might be important in the pathophysiology of disease states 
characterized by an impaired endothelial function and increased thrombocyte aggregation. 
This study was performed to characterize the vascular response to ATP in humans. 
The brachial artery was cannulated in 50 healthy male volunteers (age, 18-44 
years) for drug infusion and measurement of mean arterial pressure. Forearm blood flow 
was recorded by venous occlusion strain-gauge plethysmography. ATP induced a dose-
dependent vasodilator response that was significantly higher than the effect of equimolar 
adenosine infusion and that was not reduced by concomitant infusion of the P, purinergic 
receptor antagonist theophylline. The infusion of the NO synthase antagonist №-monome-
thyl-L-arginine (L-NMMA) reduced the averaged fall in forearm vascular resistance 
(FVR) to acetylcholine (-59±6% [mean±SE] versus -42±8%; P<0.05; n=10) but did 
not affect the vasodilator response to ATP (-68±3% versus -64+6%; P>0.1 ; n = 10) or 
sodium nitroprusside (SNP; -53±3% versus -49+4%; P>0.1; n=6). The L-NMMA-
induced increase in FVR appeared to be related to the type of vasodilator pretreatment 
being 94.7+16.7%, 44.9±8.7% and 40.8±7.3% for acetylcholine, ATP and SNP 
pretreatment, respectively (P<0.01 for acetylcholine versus ATP and SNP; P>0.1 for 
ATP versus SNP). In contrast to animal data, high dosages of intra-arterially infused ATP 
(up to 1000 μg/lCЮ ml forearm per min) did not reveal a reduction in the forearm 
vasodilator response but appeared to be similar to the maximal forearm vasodilation as 
observed during postocclusive reactive hyperemia. 
These observations indicate that ATP induces a potent dose-dependent vasodilator 
response that is not mediated by P, purinergic receptor stimulation or by the release of 
nitric oxide. Moreover, in healthy volunteers the vasodilator response to high intra­
arterial dosages of ATP is not reduced by the release of endothelium-derived contracting 
factors or by the stimulation of P2x-purinergic receptors on the smooth muscle cells. 
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INTRODUCTION 
At the end of the 19th century, Heidenhain was probably the first to show that 
endogenous compounds, as extracted from freshly prepared organs, can elicit circulatory 
effects such as vasodilation and a fall in blood pressure (BP) when infused intravenously 
in animals [2]. In 1929, Drury and Szent-Gyorgyi recognized the importance of endoge­
nous nucleotides in this response [1] Their impressive early report on the pharmacology 
of nucleotides in rats is considered the beginning of modem research on purine pharmaco­
logy [102] After a detailed review of the existing literature and own observations, Burn-
stock et al. [6] proposed a subdivision of punnergic receptors The major subdivision is 
between Ρ,-punnergic receptors, with an endogenous agonist potency order of adenosine 
> adenosine-5'-monophosphate (AMP) >adenosine-V diphosphate (ADP) >adenosine-
5'-tnphosphate (ATP) and P2-punnergic receptors, with an endogenous agonist potency 
order of ATP > ADP > AMP > adenosine Based on a different potency order of 
synthesized adenosine analogues and divergent effects on intracellular cyclic adenosine-3'-
5'-monophosphate (cAMP) levels, an important second messenger of Ρ,-purinergic 
receptor stimulation, Ρ,-purinergic receptors are subdivided in A,- and Añádenosme 
receptors [6] In the vascular wall, Añádenosme receptors, located on endothelial and 
smooth muscle cells, are involved in the vasodilator response to adenosine [118] On 
sympathetic nerve endings, stimulation of the A, adenosine receptor results in a reduced 
release of norepinephrine [268] Methylxanthines like theophylline and caffeine are 
competitive antagonists on both Ρ,-purinergic receptor subtypes [206,221,247] Recently, 
this subdivision has been confirmed by molecular techniques [97] 
Largely on the basis of the rank order of agonist potency of structural analogues of 
ATP, two subtypes of the P2-punnergic receptor are generally accepted, the P2x- and the 
P2y-punnergic receptors [101,296,297] 
Under physiological circumstances, ATP is coreleased with norepinephrine from 
sympathetic nerve endings [15] The subsequent stimulation of P2x-punnergic receptors on 
vascular smooth muscle cells is thought to contribute to the sympathetic nervous system-
mediated vasoconstriction [15] Additionally, ATP is released from endothelial cells and 
aggregating thrombocytes, resulting in a P2y-punnergic receptor-mediated endothehum-
dependent vasodilator response that opposes the effect of thrombocyte-derived vasocon-
stncting agents like thromboxane A2 and serotonin [59,72,91] Thus, endogenously 
released ATP might have an important role in physiology and pathophysiology, and it is 
of interest to characterize the effects of ATP in vivo in humans Up to now, our pharma­
cological knowledge on ATP is largely based on in vitro data from animal studies 
Human in vivo data about the direct vascular effects of ATP are scarce Although the 
vasodilator effect of ATP in humans has been described before [298,299], the mechanism 
88 
ATP-induced vasodilation 
of action is largely unknown. Of course, endothelial P2y-purinergic receptors are expected 
to be involved in the vasodilator response to ATP, but this response may also be mediated 
by adenosine receptors [300], because ATP is rapidly degraded to adenosine [96,301] and 
because ATP has weak adenosine receptor agonist properties [301,302]. In this report, a 
series of experiments is presented to elucidate the mechanism of action of the vasodilator 
property of ATP in humans. This study focuses on three questions in particular: 
1) What is the involvement of P,-purinergic receptor stimulation in the ATP-induced 
forearm vasodilation? 
2) Is nitric oxide (NO) involved in the forearm vasodilator response to ATP? 
3) Is there evidence for an ATP-mediated release of endothelium-derived contracting 
factors (EDCF) or Pîx-purinergic receptor stimulation? 
SUBJECTS AND METHODS 
After approval from the local ethics committee, a total of 50 healthy male 
volunteers signed written informed consent statements before participation in the study. 
Their demographic characteristics are summarized in table 1. Before the start of the 
study, the subjects were asked to abstain from caffeine-containing products for at least 36 
hours and to refrain from smoking for at least 12 hours. Furthermore, subjects were 
asked to discontinue any food intake 2 hours before the start of the experiment. All 
experiments were performed in the afternoon with the subject in the supine position. After 
local anesthesia (Xylocaine 2%), the left brachial artery was cannulated with a 20-gauge 
catheter (Angiocath, Deserei Medical, Becton Dickinson, Sandy, UT, U.S.A.) for both 
intra-arterial drug infusion (automatic syringe infusion pump, type STC-521, Terumo, 
Tokyo, Japan) and BP recording (Hewlett Packard GmbH, Böblingen, Germany). 
Forearm blood flow (FBF) was registered in both forearms by electrocardiography-
triggered venous occlusion plethysmography using mercury-in-silastic strain gauges 
(Hokanson EC4, D.E. Hokanson, Washington DC, U.S.A.). The upper arm collecting 
cuffs were simultaneously inflated using a rapid cuff inflator (Hokanson E-20). At least 
one minute before FBF measurements were made, hand circulation was occluded by 
inflation of wrist cuffs to 200 mmHg. FBF was recorded three times per minute. All 
experiments were started at least 30 minutes after intra-arterial cannulation. In all 
experiments, total infusion rate was kept constant at 100 μ1/100 ml forearm per min. 
Saline and all drug dosages were infused for 5 minutes. 
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Involvement of Ρ,-pur'ine (adenosine) receptor stimulation in the ATP-induced 
forearm vasodilator response 
In 12 subjects, the vasodilator effect of equimolar dosages of intra-arterially-
infused adenosine and ATP were compared. Additionally, the effect of intra-arterially-
infused theophylline, a competitive P,-purinergic receptor antagonist, on the vasodilator 
response to ATP was studied. 
Forearm blood flow 
(ml/100 ml foreorm/m!n) 
N=6 J 
S 
;S*-e°- -2—0 
I I Placebo 
W\ Theophylline 
I I Adenosine 
Adenosine-5"-tnphosphate 
140 150 160 170 180 
N=6 
140 150 160 170 180 
Time after cannulatlon (min) 
Figure 1. A schematic presentation of the protocol aimed to study the involvement of P, purinergic 
receptors in the ATP-mediated vasodilator response. Adenosine was infused at a rate of 2 and 6 nmol/100 
ml forearm/ min and ATP was infused at a rate of 0.2, 0.6, 2 and 6 nmol/100 ml forearm/min. Additional­
ly, the course of the forearm blood flow is shown. 
Closed symbols indicate infused arm; open symbols, control arm. 
The experiment started with the measurement of baseline FBF during saline 
infusion (NaCL 0.9%). Figure 1 shows the course of FBF and the schedule of the several 
drug infusions. The effect of two increasing dosages of adenosine (0.5 and 1.5 /tg/100 ml 
forearm per min, equivalent to 2 and 6 nmol/100 ml per min) was compared with that of 
91 
Chapter 6 
saline infusion. Fifteen minutes after the last adenosine infusion, saline was infused again. 
Now, the effect of four increasing dosages of ATP (0.1, 0.3, 1.0, and 3.0 ¿tg/lOO ml 
forearm per min, equivalent to 0.2, 0.6, 2 and 6 nmol/100 ml forearm per min) were 
compared with saline infusion. Because prolonged occlusion of hand circulation can cause 
discomfort, with subsequent effects on BP and heart rate (HR), a 10-minute rest was 
allowed between the second and third ATP infusion. Forty-five minutes after the last ATP 
infusion, saline infusion and the four increasing ATP dosages were repeated in six 
subjects ("time control study"). In the other six subjects, saline infusion and the four 
increasing ATP dosages were repeated with concomitant infusion of theophylline (100 
μg/100 ml forearm per min). In previous reports, we and others have shown that this 
dosage of theophylline antagonizes the forearm vasodilator response to intra-arterially-
infused adenosine [221,303]. 
Involvement of nitric oxide (NO) in the ATP-iiiduced forearm vasodilator response 
We studied the effect of intra-arterially-infused NG-monomethyl-L-arginine (L-
NMMA), a competitive NO-synthase antagonist, on the vasodilator response to ATP 
(n = 10), to the NO-dependent vasodilator acetylcholine (n=10), and to sodium nitroprus-
side (SNP, η = 6), an NO donor that does not stimulate NO-synthase activity [304]. 
Acetylcholine, a proven NO-dependent vasodilator in the human forearm [36,305], was 
used to ascertain the effectiveness of our experimental setup to demonstrate antagonistic 
properties of L-NMMA (positive control experiment). L-NMMA reduced FBF which 
might nonspecifically affect the subsequent response to a vasodilator stimulus. Therefore, 
the interaction between SNP and L-NMMA was also studied (negative-control experi­
ment). Apart from the effect of L-NMMA on the aforementioned vasodilator response to 
acetylcholine, ATP, and SNP, the forearm vasoconstrictor response to L-NMMA itself 
was analyzed to find out whether this was related to the effect of the previously infused 
vasodilator substances on NO synthase. 
The experiment started with the measurements of baseline FBF during saline 
infusion. The effect of three increasing dosages of ATP (0.3, 3 and 10 μg/100 ml forearm 
per min) were compared with that of saline infusion. Because prolonged occlusion of 
hand circulation can cause discomfort, with subsequent effects on BP and HR, a 10-
minute rest was allowed between the first and second ATP infusions. Forty-five minutes 
after the last ATP infusion, the vasoactive effect of L-NMMA infusion (0.1 mg/100 ml 
forearm per min) was compared with that of saline infusion. Subsequently, the lowest 
ATP dose was infused (0.3 ^g/100 ml per min) together with infusion of L-NMMA (0.05 
mg/100 ml forearm per min). Ten minutes thereafter, L-NMMA was infused again (0.1 
mg/100 ml forearm per min), immediately followed by the middle and the highest ATP 
dosages (3 and 10 /tg/100 ml forearm per min), again together with the lower L-NMMA 
92 
ATP-induced vasodilation 
dose (0.05 mg/100 ml forearm per min). In the acetylcholine group, acetylcholine (0.5, 2 
and 8 ftg/100 ml forearm per min) was substituted for ATP. In the SNP group, SNP 
(0.02, 0.2 and 0.6 ¿ig/lOO ml forearm per min) was substituted for ATP. Since SNP is 
diluted in glucose 5%, in the SNP group glucose 5% was substituted for NaCl 0.9%. 
Otherwise, the same protocol was performed in the three groups. 
Effect of high dosages of intra-arterially infused ATP on forearm vascular tone 
In vitro data suggest that high dosages of ATP reveal a vasoconstrictor component 
compared with the effect of lower ATP dosages [306,307]. Both P2x-purinergic receptor 
stimulation as well as release of EDCFs may be involved in this response. To study these 
possible mechanisms in humans, the effects of high dosages of intra-arterially-infused 
ATP were studied in 12 subjects. The effect of four increasing intra-arterially-infused 
ATP dosages (10, 30, 100 and 300 μg/100 ml forearm per min) were compared with that 
of saline infusion. To avoid discomfort, a 10-minute rest was allowed between the second 
and third ATP infusions. After the first 6 experiments, an interim analysis was perfor­
med, revealing no decreased vasodilator response at the highest dosage. In the subsequent 
6 experiments, 1000 μg ATP/100 ml forearm per min was infused immediately after the 
fourth ATP infusion. To be sure that maximal vasodilation occurred in response to the 
ATP infusions, maximal vasodilation was measured during postocclusive reactive 
hyperemia according to the well-established method of Pedrinelli et al [308,309]. A cuff 
applied to the left upper arm was inflated to 300 mmHg for 13 minutes. During the last 
minute of ischemia, the subjects were asked to perform repeated hand contractions. 
Immediately after desufflation of the upperarm cuff, FBF measurements were started for 
at least 2 minutes with occluded hand circulation. The lowest forearm vascular resistance 
(MAP/FBF) was considered to represent maximal vasodilation. 
Drugs and solutions 
ATP solutions were freshly prepared from 2-ml ampoules containing 20 mg ATP 
as disodium salt (Striadyne, Wyeth Laboratories), and were diluted in NaCl 0.9%. L-
NMMA-acetate, and acetylcholine chloride (Sigma Chemical Co, St. Louis, MO, 
U.S.A.), were reconsituted on the morning of the study day from a sterile lyophilized 
powder, passed through a 0.2 μτη Millipore filter, and diluted in NaCl 0.9%. Adenosine 
(Sigma Chemical Co., St. Louis, MO, U.S.A.) was freshly prepared from 10-ml 
ampoules containing 20 mg adenosine with NaCl 0.9% as solvent. Theophylline solutions 
were freshly prepared from 10-ml ampoules containing 24 mg/ml aminophyllinum-
hydricum (EuphyllinR, BYK Nederland, Zwanenburg, The Netherlands), and diluted in 
NaCl 0.9%. SNP was reconstituted immediately before the start of the experiment from a 
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sterile lyophilized powder, diluted in glucose 5 % (Nipride, Roche Nederland, Mijdrecht, 
The Netherlands) and protected against light. 
Statistical analysis 
Mean arterial BP (MAP) was measured continuously during each recording of 
FBF and averaged per FBF measurement. Forearm vascular resistance (FVR) was 
calculated from simultaneously measured MAP and FBF (MAP/FBF) and expressed as 
arbitrary units (AU). The calculated FVRs obtained during each 5 min of saline infusion 
or during the last 2 min of each drug infusion were averaged to one value. Drug-induced 
effects were expressed as percentage of change from preceding saline infusion or 
antagonist infusion. The percentage changes in FVR to each dosage of a vasodilator 
substance were averaged to one value both before and during antagonist infusion. These 
two values were compared to assess the effect of an antagonist. All results are mean±SE 
unless indicated otherwise. To avoid multiple comparison, within-subject effects were 
assessed by Friedman two-way nonparametric ANOVA first and further analyzed with the 
Wilcoxon's paired signed rank test if appropriate. Likewise, differences between groups 
were assessed with the Kruskall-Wallis nonparametric one-way ANOVA and further 
analyzed with the Mann-Whitney-U test if appropriate; Ρ < 0.05 (two sided) was conside­
red statistically significant. 
RESULTS 
Involvement of Ρ,-purine (adenosine) receptor stimulation in the ATP-induced 
forearm vasodilator response 
Apart from the dosage schedule, figure 1 shows the course of FBF during infusion 
of adenosine and ATP. FBF in the control arm was not significantly affected during any 
of the infusions. 
Baseline FVR was 47±6 AU in the cannulated arm. In twelve subjects, the effect 
of two adenosine dosages and four ATP dosages were studied first. FVR of the infused 
arm during the first and second saline infusion did not significantly differ (47+6 and 
53+9 AU, respectively, P = NS; n=12). ATP decreased FVR by 17+12%, 37+11%, 
52+7% and 60±7% for 0.1, 0.3, 1 and 3 μg ATP/100 ml forearm per min respectively 
(n = 12; P<0.05 for the three highest dosages). The FVR in the control arm was not 
significantly affected. In figure 2, the forearm vascular effects of two equimolar adenosi­
ne and ATP dosages (2 and 6 nmol/100 ml per min) are compared. Both ATP dosages 
induced significantly more forearm vasodilation than their equimolar adenosine counter­
parts (37+11% versus 9±6% for 2 nmol/100 ml forearm per min, and 60±7% versus 
21+7% for 6 nmol/100 ml forearm per min; n = 12; P<0.05 for both comparisons). 
94 
ATP-induced vasodilation 
Forearm vascular resistance 
% response 
25 
0 
•25 
•50 
- 7 5 
Infused arm 
« * 
ι—ι ι—1 
¥ 1 
Control arm 
i 
p>0.1 
^ H Adenos¡ne-5'-tnphosphate 
I I Adenosine 
Purine dosage (nmol/100 ml f o r e a r m / m i n ) 
Figure 2. Bar graph comparing forearm vascular responses to two equimolar adenosine and ATP infusions. 
*, Statistically significant differences between adenosine and ATP. Ρ value indicates the level of significance 
for the vascular effects in the control arm. 
In 6 subjects, the ATP infusions were repeated 45 minutes later. The vasodilator 
response to ATP did not significantly differ between the two infusion periods: the 
averaged responses in FVR were -46±8% and -45 + 10 % in the infused arm for the first 
and second ATP infusions, respectively (P=NS). In the control arm, vascular resistance 
remained unchanged (averaged response in FVR, 2 ± 5 % and 8± 14 % during the first and 
second infusion period, respectively; n=6, P>0.1). In the other 6 subjects, the ATP 
infusions were repeated with concomitant infusion of theophylline. FVRs during the 
second saline infusion and the theophylline infusion were 54±16 and 54+17 AU, 
respectively (P=NS, η=6). FVR during theophylline infusion did not differ significantly 
from FVR during the third saline infusion of the time-control study group (54+17 versus 
62+8 AU; P=NS, n=6 for both groups). Thus, theophylline did not significantly affect 
FVR. Likewise, theophylline did not significantly affect the ATP-induced forearm 
vasodilator response: the averaged responses in FVR were -38±12% and -38+10% for 
ATP infusions with saline and theophylline, respectively (P=NS, n=6). In the control 
arm, no changes in FVR were observed. 
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Involvement οΓ NO in the ATP-induced forearm vasodilator response 
FBF in the control arm was not affected by the various drug infusions. 
Figure 3 depicts the effect of each dosage of the three vasodilator substances on FVR in 
the infused arm before and during L-NMMA infusion. 
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Figure 3. Graphs showing course of 
forearm vascular resistance in infu­
sed arm during the infusion ot three 
increasing dosages of ATP, acetyl­
choline (ACh) or sodium nitroprussi-
de (SNP). *, Ρ < 0.05 versus baseli­
ne, Ρ values indicate the level of 
siynificance for the effect of L-
NMMA on the vasodilator response. 
NS indicates not significant (P>0.1); 
solid line, before L-NMMA infusion; 
dashed line, during L-NMMA 
infusion. 
In the infused arm, for each vasodilator substance, a dose-dependent vasodilation 
was observed. Besides a smaller effect of the lowest SNP dosage, the three vasodilator 
substances induced a comparable vasodilator response. Only the acetylcholine-induced 
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vasodilator response could be antagonized significantly by L-NMMA. The effect was 
most pronounced for the lower dosages. Table 2 tabulates the effect of L-NMMA on 
forearm vascular tone and the averaged responses to vasodilator substances before and 
during L-NMMA infusion. The averaged percentage responses in FVR to the three 
vasodilator substances were -59±6%, -68+3%, and -53+3% for acetylcholine, ATP, 
and SNP, respectively. During concomitant infusion of L-NMMA, the averaged responses 
in FVR were -42±8%, -64+6%, and -49+4% for the acetylcholine, ATP, and SNP 
group, respectively (P<0.05 for effect of L-NMMA on acetylcholine; P=NS for the 
effect of L-NMMA on ATP and SNP). Besides a small increase during the second SNP 
infusion with L-NMMA (35.7± 14.8%; P<0.05 versus baseline), FVR in the control arm 
was not significantly affected for any of the vasodilators. 
TABLE 2: Effect of L-NMMA on baseline torearm vascular resistance and vasodilator response to ATP, 
ACh and SNP (mean ± SE) 
Infused 
arm 
Control 
arm 
Vasodilator 
ACh 
ATP 
SNP 
ACh 
ATP 
SNP 
% Rise in FVR to 
first 
L-NMMA infusion 
64±13*# 
37 ±10* 
3 3 ± U * 
5 ± 4 
-3±5 
5±2 
% Rise in FVR to 
second 
L-NMMA infusion 
95± I7*# 
45 ±9* 
41 ±7* 
I6±9 
6±5 
-8±11 
Averaged % 
response in FVR 
to vasodilator 
-59 ±6* 
-68±3* 
-53±3*@ 
1±5 
3±4 
6±5 
Averaged % 
response in FVR 
to vasodilator 
(+ L-NMMA) 
-42±8*§ 
-64 ±6* 
-49 ±4* 
5 ± 4 
1±3 
19±10 
L-NMMA indicates Nc-monomethyl-L-arj¡inine, ACh, acetylcholine, SNP, sodium nitroprusside, and FVR, 
forearm vascular resistance. Values are mean ±SE *, Statistically significant difference from baseline 
(P<0 05); §, Statistically significant effect of L-NMMA on vasodilator response (P<0.05); ft, Statistically 
significant difference from ATP and SNP group (P<0 05); 
@, Statistically significant difference with ATP group (P<0.05). 
Within each group, the vascular resistances during the three saline infusions were 
not significantly different, indicating that vascular tone had returned toward baseline 
levels before the second infusion of a vasodilator substance and before the first L-NMMA 
infusion. Additionally, baseline FVR did not differ significantly between the three groups. 
During the first L-NMMA infusion, FVR increased in all three groups (P<0.05 for 
acetylcholine [n = 10], ATP [n=10] and SNP [n=6] groups). In the acetylcholine group, 
this vasoconstrictor response differed significantly from the other two groups, being 
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64.3±12.7% versus 37.2±9.7%, and 33.3± 10.7% for the ATP and SNP groups, 
respectively (P<0.05 for the acetylcholine group versus each other group; P>0.1 for the 
ATP group versus the SNP group). These group differences were more pronounced for 
the second L-NMMA infusion. In the ATP group, the increase in FVR did not differ 
significantly from the SNP group, being 44.9 + 8.7% and 40.8±7.3% for the ATP and 
SNP groups, respectively (ATP versus SNP group, Ρ=1.0; first versus second L-NMMA 
infusion, P>0.1 for both groups). However, in the acetylcholine group, L-NMMA now 
tended to induce a more pronounced increase in FVR of 94.7+16.7% (P<0.01 versus 
ATP and SNP groups; Ρ=0.09 versus first L-NMMA infusion). 
Group differences in vasoconstrictor response to L-NMMA may have confounded 
the effect of L-NMMA on the response to vasodilator substances. To investigate this 
possibility, a correlation between the vasoconstrictor response to L-NMMA and the L-
NMMA-induced reduction in averaged percentage response in FVR to acetylcholine and 
ATP was analyzed for each agonist separately. This analysis revealed that with an 
increasing vasoconstrictor response to L-NMMA, the inhibition of agonist-induced 
vasodilation was reduced (r=-0.56; P=0.09 for acetylcholine and r=-0.66; P<0.05 for 
ATP). Therefore, it is unlikely that the reduced vasoconstrictor response to L-NMMA in 
the ATP-group masked a possible inhibitory effect of L-NMMA on ATP-induced 
vasodilation. 
Effect of high dosages of intra-arterially infused ATP on forearm vascular tone 
Baseline FVR was 73± 10 AU. Figure 4 shows the percentage response in FVR 
during the four increasing ATP dosages. In the control arm, FVR was not significantly 
affected (Friedman ANOVA, P>0.1; n=12). In the infused-arm, FVR was 9±2, 8±3, 
6+2 and 5+2 AU during infusion of 10, 30, 100 and 300 μg ATP/100 ml per min, 
respectively (P<0.01 versus baseline for all dosages, η = 12). These values are distorted 
because of one outlayer with a FVR in the infused arm of 77 AU during saline and 26, 
35, 32 and 28 AU during the four increasing ATP dosages, respectively. After exclusion 
of this outlayer, FVR was 8+2, 5 ± 1 , 4 + 1 , and 2±0.2 AU for the four increasing ATP 
dosages, repectively (P<0.01 versus baseline for all dosages, n = 11). Thus, up to 300 μ.% 
ATP/100 ml forearm per min, FVR was continuously reduced. In six subjects this dose-
response curve was extended to 1000 μg ATP/ 100 ml forearm per min, which was 
infused immediately after 300 μg ATP/100 ml forearm per min. On average, FVR was 
reduced to 3±1 AU during infusions of 1000 μg ATP/100 ml forearm per min, respec­
tively (P=NS for 300 versus 1000 μg ATP/100 ml forearm per min, n=6). In four of the 
6 subjects, FVR in the control arm increased slightly during the highest ATP dosage 
(P>0.1). The minimal FVR during postocclusive reactive hyperemia was 3+0.2 AU and 
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Figure 4. Graph showing effect of 
high dose of ATP on forearm vascu­
lar resistance. Solid line indicates 
infused arm; dashed line, control 
arm. 
*, Ρ<0.05 versus baseline; n » l l . 
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did not differ significantly from FVR during infusion of 300 (n = 12) or 1000 ^g ATP/100 
ml forearm per min (η=6). 
DISCUSSION 
In vitro studies have demonstrated pharmacological effects of ATP, that might 
have important physiological and pathophysiological implications. ATP released from 
sympathetic nerve endings at the adventitial side of a blood vessel, results in a vasocon­
strictor response, mediated by so-called P2k-purinergic receptors on smooth muscle cells. 
On the other hand, luminally released ATP from aggregating thrombocytes or the 
endothelium itself stimulate endothelial P2>-purinergic receptors, resulting in an NO-
mediated vasodilator response [50]. To assess the relevance of these in vitro observations, 
we now characterized the vascular in vivo effects of ATP in men. The perfused forearm 
technique was used because this model has been validated previously as a method to study 
direct vascular effects in humans [194,310]. In this model, the possibility of measuring 
FBF in the noninfused arm has methodological advantages because it enables us to detect 
systemic actions of the infused drugs, such as baroreflex activation, that could potentially 
counteract the local effects. 
Our results demonstrate that ATP induces vasodilation even at low concentrations 
in the nanomolar range, which are thought to occur under physiological conditions [311]. 
This vasodilator response appeared to be unrelated to P,-purinergic receptor stimulation 
and NO release. The vasodilator response was not reduced at high ATP infusion rates. 
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Involvement of P,-purine (adenosine) receptor stimulation in the ATP-induced 
forearm vasodilator response 
The vascular effects of equi molar dosages of ATP and adenosine, the degradation 
product of ATP with the highest P,-purinergic receptor agonist activity, demonstrate that 
Ρ,-purinergic receptor stimulation does hardly contribute to the ATP-induced vasodilation. 
This view is further supported by the fact that theophylline did not affect the vasodilator 
response to ATP. Since theophylline has been shown to antagonize the forearm vasodila­
tor response to adenosine [221,303], the present observation rules out that Ρ,-purinergic 
receptor stimulation is involved in the ATP-induced forearm vasodilator response. This is 
in agreement with most in vitro studies [62,105,117,297,312]. In theory, theophylline 
could have inhibited intracellular phosphodiesterase activity. Since cAMP is thought to be 
an important second messenger of A2 purinergic receptor stimulation, this effect could 
have counteracted the Ρ,-purinergic receptor antagonizing action of theophylline. This 
problem has been addressed by others using the forearm vasodilator response to theophyl­
line as a marker of phosphodiesterase inhibition [269,303]. They found that theophylline 
infusions up to 100 /tg/100 ml per min did not affect forearm vascular tone but signifi­
cantly antagonized the adenosine-induced vasodilation. In our study, the same theophylli­
ne dosage was used without any effect on vascular tone. Therefore, it is very unlikely that 
inhibition of phosphodiesterase has contributed to the results. 
In view of the extensive literature on in vitro vascular effects of ATP, the 
exclusion of Ρ,-purinergic receptor involvement strongly suggests the existence of the P^-
purinergic receptor in the human forearm vascular bed [102]. However, the involvement 
of a recently suggested "pyrimidine receptor" cannot be excluded [307]. Specific P2-
purinergic receptor antagonists are needed to resolve these problems in P2-purinergic 
receptor classification. 
Involvement of NO in the ATP-induced forearm vasodilator response 
L-NMMA, a competitive inhibitor of NO synthase without affinity for the musca­
rine receptor, was used in this study to inhibit the formation of vascular NO [28,313]. 
Acetylcholine is known to stimulate NO synthase both in vitro and in vivo in the human 
forearm [36,305]. Therefore, this agonist was used as a positive control. SNP is regarded 
as an NO donor that directly stimulates soluble guanylate cyclase without involvement of 
NO synthase [304], and therefore was a suitable negative control in this study part. 
The vasodilator response to acetylcholine was reduced significantly by L-NMMA, 
indicating that the L-NMMA dosage used in this study is able to inhibit NO synthase 
significantly. In contrast, the ATP-induced vasodilator response could not be inhibited by 
concomitant L-NMMA infusion, despite a similar degree of vasodilation induced by ATP 
and acetylcholine. This finding supports the argument that NO does not significantly 
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contribute to ATP-induced vasodilation. The SNP-induced forearm vasodilation was not 
affected by concomitant L-NMMA infusion, ruling out the possibility that agonist-induced 
vasodilation was affected by L-NMMA-evoked precontraction. During the second series 
of SNP infusions, FVR in the control arm increased temporarily. A possible systemic 
effect of the concomitant L-NMMA infusion is not likely, because it was not observed in 
the ATP and acetylcholine groups and because FVR in the control arm returned to 
baseline levels during the last administration of SNP with concomitant L-NMMA 
infusion. Whatever the cause might be, it did not seriously affect the results obtained 
from the infused arm, since it was only a small change in FVR that did not significantly 
differ from FVR fluctuations in the control arm during SNP administration with concomi-
tant saline infusion. 
In all three groups, L-NMMA induced a significant increase in FVR, confirming 
that L-NMMA in the dosages used was able to inhibit baseline NO production [36]. This 
effect of L-NMMA differed between the three groups, indicating an influence of agonist 
pretreatment on NO synthase activity. During the second L-NMMA infusion, ten minutes 
after the lowest agonist infusion, these between-group differences were more pronounced, 
supporting this view (see table 2). Since SNP does not stimulate NO synthase, the effect 
of L-NMMA in the SNP group can be regarded as unaffected by the previous infusions of 
SNP. In the acetylcholine group, the vasoconstrictor response to L-NMMA was signifi-
cantly higher than in the SNP group, indicating that NO synthase was still activated 50 
minutes after the last acetylcholine infusion, although FVR had returned to baseline 
levels. In the ATP group, L-NMMA-induced vasoconstriction was similar to that 
observed in the SNP group during both the first and second L-NMMA infusion. In 
combination with the lack of effect of L-NMMA on ATP-induced vasodilation these 
results indicate that ATP does not stimulate NO-synthase activity in the human forearm 
vascular bed. In theory, kinetic differences between acetylcholine and ATP could explain 
the between-group differences for the effect of L-NMMA on FVR. However, both 
acetylcholine and ATP have a short half-life of a few seconds because of rapid degradati-
on by choline esterase and ectonucleotidases, respectively. Furthermore, both substances 
induced a similar amount of vasodilation and in both the ATP and acetylcholine group, 
FVR had returned to baseline levels before L-NMMA was infused. Therefore, kinetic 
differences between the two agonists are not able to explain the divergent effect of L-
NMMA in the acetylcholine and ATP group. Probably, NO synthase remained activated 
after acetylcholine infusion without continuous muscarine receptor stimulation. 
One might argue that the group differences in L-NMMA-evoked contractions 
reflect group differences in NO synthase sensitivity to L-NMMA. However, this would 
assume a positive correlation between L-NMMA-induced vasoconstriction and the 
inhibitory effect of L-NMMA on the forearm vasodilator response to acetylcholine and 
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ATP. In contrast, a negative correlation was observed. Therefore, we believe that our 
results are not relevantly confounded by group differences in NO synthase sensitivity to 
L-NMMA. In addition, the existence of a confounding factor is not likely, because the 
study groups consisted of healthy male volunteers very alike with respect to age, BP, and 
baseline FVR. 
The present observation that ATP does not activate NO synthase in the human 
forearm contrasts with most in vitro studies [103,307,314]. An important question 
remains: How is the ATP-induced vasodilation mediated in the human forearm? With 
regard to the endothelium, in vitro studies indicate that besides NO, prostacyclin is also 
released after endothelial stimulation with ATP and may be involved in a vasodilator 
response [69,104]. Other, yet unidentified, endothelium-derived relaxing factors like the 
"endothelium-derived hyperpolarizing factor" may be involved as well [63,64]. Therefore, 
the present finding does not exclude the possibility that ATP induces its vasodilator 
response in the human forearm by an endothelium-dependent mechanism. On the other 
hand, some in vitro studies have demonstrated an endothelium-independent component in 
the ATP-induced vasodilator response [62,105,106]. The ATP-dependent potassium 
channel may be involved in ATP-induced vasodilation [315]. Further research is needed 
to determine the precise role of the endothelium in the ATP-induced forearm vasodilator 
response. 
Effect of high dosages of intra-arterially infused ATP on forearm vascular tone 
In vitro studies have shown a reduced vasodilator response to high dosages of ATP 
[297,306,307]. Two possible mechanisms have been proposed: simultaneous stimulation 
of P2x-purinergic receptors [307] and concomitant release of EDCFs [306]. In the present 
study, these in vitro observations could not be reproduced in the human forearm. 
Maximal ATP-induced vasodilation did not differ from post occlusive reactive hyperemia, 
confirming a previous observation [316]. Postocclusive reactive hyperemia can be 
regarded as a condition of maximal and total vascular relaxation [308,309]. The vasodila-
tor response to ATP was not reduced even at the very high dosage of 1000 ^g ATP/100 
ml forearm per min, indicating that the vasodilator effect of high intra-arterial dosages of 
ATP is not reduced by the release of EDCFs. The presence of an intact endothelium and 
the existence of a highly active vascular ectophosphatase system could have prevented 
ATP from reaching the vascular smooth muscle cells [82,317]. Therefore, the present 
observations do not exclude the existence of P2x-purinergic receptors in the human 
forearm vasculature. 
In conclusion, intra-arterial infusion of ATP induces a forearm vasodilator 
response that is not mediated by P,-purinergic receptor stimulation or by NO release. In 
healthy volunteers, the effect of high doses of ATP is not reduced by the potential release 
102 
ATP-induced vasodilation 
of EDCFs or stimulation of P2x-purinergic receptors. The exact mechanism of the 
vasodilator response to ATP in the human forearm remains to be elucidated. However, 
our results convincingly indicate that the intravascular release of ATP or ADP from 
thrombocytes is not expected to induce vasoconstriction in a healthy vascular system. 
This, of course, does not exclude a vasoconstrictor response to interstitially released 
ATP. 
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Adenosine and nitric oxide 
ABSTRACT 
The endogenous nucleoside adenosine plays an important role in the regulation of 
vascular tone, especially during ischemia. Experimental data derived from animal models 
suggest that nitric oxide (NO) contributes to the vasodilator effect of adenosine. The 
primary purpose of this investigation was to determine whether the endothelial release of 
NO contributes to adenosine-induced vasodilation in humans. 
Venous occlusion plethysmography was used to assess the forearm blood flow 
(FBF) responses to graded intra-arterial infusions of adenosine (1.5 - 500 /xg/min). Dose 
response curves were constructed before and during intra-arterial infusion of the NO-syn-
thase inhibitor NG-monomethyl-L-arginine (L-NMMA, 2 mg/min, η=6) or vehicle (n=6). 
Prior to L-NMMA, adenosine caused a dose-dependent increase in FBF from 2.3 to 15.9 
ml/min/dl. During concurrent infusion of L-NMMA, adenosine increased FBF from 1.7 
to 10.0 ml/min/dl, and this change from baseline was significantly reduced as compared 
with that before L-NMMA (P<0.05). L-NMMA also attenuated the FBF-response to 
adenosine when the basal constrictor effect of L-NMMA was prevented by co-infusion of 
the NO-donor nitroprusside (n=6, Ρ< 0.01). In contrast, L-NMMA did not affect the 
FBF-response to intra-arterial infusion of the endothelium-independent vasodilator 
verapamil (from 2.0 to 13.9 before L-NMMA and from 1.3 to 13.6 ml/min/dl during 
L-NMMA, n=6, P=NS). The second objective of this study was to determine whether 
the adenosine-induced release of nitric oxide is mediated by activation of endothelial 
potassium channels, putatively coupled to adenosine receptors. Thus, the FBF-response to 
adenosine was measured before and during infusion of the ATP-dependent K+-channel 
blocker tolbutamide (1 mg/min, η=6), or the K+-channel blocker quinidine (0.5 mg/min, 
η=6). The adenosine-mediated increments in FBF were not attenuated by either K+-chan-
nel blocker. 
Adenosine-induced vasodilation in humans is mediated, at least in part, by 
endothelial release of nitric oxide. The transducing mechanism of this phenomenon is not 
known, but does not appear to involve the activation of either ATP-dependent or 
quinidine-sensitive K+-channels. 
INTRODUCTION 
Apart from its role as a constituent of the intracellular energy source adenosine-'5-
triphosphate (ATP), the endogenous nucleoside adenosine also has important effects in the 
extracellular compartment. In the cardiovascular system, extracellular adenosine is a 
regulatory substance, matching blood flow to alterations in tissue oxygen supply and/or 
demand [318]. Until recently, the vasodilator effect of adenosine was thought to be based 
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on direct stimulation of A2-adenosine receptors on vascular smooth muscle cells, which 
mediate an increase in the second messenger, cyclic adenosine-3,5'-monophosphate 
(cAMP), via stimulation of adenylate cyclase. Therefore, this agent has been frequently 
used in animal as well as human studies to evaluate endothelium-independent vasodilation 
[319,320]. However, recent investigations have disputed the endothelium-independent 
character of adenosine-mediated vasodilation. Several vascular preparations have shown 
attenuated responses to adenosine or adenosine analogues after previous inhibition of 
endothelial nitric oxide synthesis [321,322], or after rubbing of the endothelium 
[122,323,324]. Also, infusion of large sized adenosine agonists (N6-octylamine-
adenosine coupled to carboxylated latex microspheres), which were assumed to be 
confined to the intravascular space, induced an obvious decrease in coronary vascular 
resistance in the saline-perfused guinea pig heart, presumably via an endothelium-derived 
mechanism [123]. Moreover, functional adenosine receptors have been identified on the 
endothelium, even in human aortic endothelial cells [122]. 
Several potential mechanisms could mediate the endothelial release of nitric oxide 
during adenosine administration. Stimulation of endothelial adenosine receptors may 
mobilize calcium and thereby activate endothelial NO-synthase [32]. Adenosine Α,-recep-
tors have been demonstrated to be coupled to ATP-dependent potassium channels by 
guanine nucleotide binding proteins, in particular by the Ga.-protein [325]. The 
Ga.-proteins can mobilize calcium by stimulating phosphoinositide-specific phospholipase 
С activity causing hydrolysis of phosphatidyl-inositol-4,5-biphosphate [326]. Also, 
adenosine can stimulate NO-release by the hyperpolarization of endothelial cells resulting 
from activation of ATP-dependent potassium channels [315,327]. In addition, potassium 
channel activation and NO-release can be triggered non-specifically by increments in 
shear stress related to the raised flow [328]. 
In the present study we evaluated whether the endothelial release of nitric oxide 
plays an important role in the vasodilating effects of adenosine in humans and, if so, 
whether the aforementioned potential mechanisms are involved in that NO-release. Human 
data on this subject are especially important because of the large inter-species differences 
in endothelial pharmacology [329]. To address these questions, the effects of adenosine 
were assessed in vivo by the perfused forearm technique, both before and during blockade 
of the production of nitric oxide by the NO-synthase inhibitor, N°-monomethyl-L-argini-
ne, and before and during blockade of potassium channels by the sulphonylurea derivati­
ve, tolbutamide, and by the antiarrhythmic drug, quinidine. These studies as well as 
appropriate control experiments allow us to conclude that the vascular effects of adenosine 
in humans are based, at least partly, on the endothelial release of nitric oxide. This 
adenosine-induced release of nitric oxide is not mediated by activation of ATP-dependent 
potassium channels or by quinidine-sensitive potassium channels. 
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SUBJECTS AND METHODS 
Thirty nine healthy volunteers participated in the study, and all signed a written 
informed consent before participation. The health status of each volunteer was assured by 
medical history and a physical examination as well as by laboratory investigations to 
assess lipid levels. Demographic data of the participants are shown in table 1. Subjects 
with high blood pressure (> 140/90 mmHg), high concentrations of serum cholesterol 
(low density lipoproteins above the 75"' percentile of their age group) and/or those who 
smoked cigarettes were excluded from participation because these features may interfere 
with the nitric oxide pathway [198,330-332]. 
TABLE 1: Demographic data for all participants 
Mean ± SD Range 
18-44 
1.50-1.83 
47.7-81.8 
17.0-30.3 
101-144 
47-86 
46-78 
2.9-5.5 
0.9-1.9 
1.6-3.6 
Each subject participated in one experiment of approximately 4 hours duration. 
The experiments were performed in a quiet and temperature-controlled room (22 *C). The 
participants were all asked to abstain from food, alcohol and caffeine for at least 12 hours 
before the test. Since caffeine acts as a potent adenosine receptor antagonist in the human 
cardiovascular system [221], we measured plasma caffeine levels at the time of the test to 
be sure of the subjects compliance with respect to the abstinence recommendations. The 
subjects remained in the supine position throughout the test. After arrival in the laborato-
ry, the left brachial artery was cannulated under local anesthesia with a 20-gauge catheter 
which was used for intra-arterial drug infusion as well as for blood pressure monitoring 
(Gould Ine, Cleveland, Ohio). Dnigs were delivered with an automatic syringe infusion 
pump (Harvard Apparatus, South Natick, Massachusetts). 
Age (years) 
Gender (male / female) 
Height (m) 
Weight (kg) 
Body Mass Index (kg/nr) 
Systolic Blood Pressure (mmHg) 
Diastolic Blood Pressure 
Heart Rate (bpm) 
Total Cholesterol (mg/dl) 
HDL-Cholesterol (mg/dl) 
LDL-Cholesterol (mg/dl) 
29.9±7.3 
17 /22 
1.71±0.09 
65.8±9.7 
22.5±3.0 
120±11 
62±8 
58±2 
4.3±0.6 
1.3±0.3 
2.6±0.6 
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Forearm blood flow (FBF) recordings were started after an equilibration period of 
at least 40 minutes. Forearm blood flow was measured in each arm by venous occlusion 
mercury-in-silastic strain gauge plethysmography (Hokanson EC4, D.E.Hokanson, 
Washington, U.S.A.) as previously described [198]. Both arms rested in slings on heart 
level, with the forearms slightly elevated to ensure a sufficient venous return. To be sure 
that FBF recordings referred predominantly to the forearm skeletal muscle circulation, the 
hand circulation was occluded during all FBF-recordings by a wrist cuff inflated 100 
mmHg above the systolic blood pressure [195]. 
Assessment of the role of nitric oxide in the vasodilator response to adenosine and 
verapamil 
In the first subgroup of 6 subjects, the vasodilator response to increasing dosages 
of adenosine was investigated. Baseline measurements were taken during infusion of 
placebo into the brachial artery (glucose 5 %). Then, adenosine was infused intra-arterial-
ly in six increasing dosages for 4 minutes per dose (adenosine dosages: 1.5 - 5 - 15 - 50 -
150- 500 /ig/min). Measurements were performed during the last two minutes of each 
infusion. After an equilibration interval of 60 minutes in which the FBF was allowed to 
return towards baseline levels, new baseline recordings were obtained during placebo-in-
fusion. Subsequently, infusion of N<!-monomethyl-L-arginine (L-NMMA) into the brachial 
artery was started in a dose of 2 mg/min. After 15 minutes of the L-NMMA-infusion 
alone, hemodynamic measurements were taken to evaluate the vaso-active effects of 
L-NMMA itself. Thereafter, the six increasing adenosine dosages were again 
administered and co-infused with L-NMMA. The total duration of L-NMMA infusion was 
approximately 40 minutes. In an additional series of three subjects, we ensured that the 
single infusion of L-NMMA of 2 mg/min for 40 minutes induced a steady state 
vasoconstrictor response, and did not progress over time. 
In the next group of 6 subjects similar experiments were performed, with a similar 
time schedule and the same dosages of adenosine and L-NMMA, but now the 
L-NMMA-infusion was accompanied by a low intra-arterial dose of the NO-donor sodium 
nitroprusside (SNP). Previous studies have shown that L-NMMA infusion induces a 
vasoconstrictor response in the forearm vascular bed by inhibiting the baseline release of 
nitric oxide from the endothelium [36]. From a methodological point of view, this change 
in baseline may complicate the interpretation of the results because the baseline vascular 
resistance is an important determinant of the response to a vasodilator stimulus [272], and 
also because the achieved concentrations of adenosine will be proportionally higher. We 
determined from pilot studies that an intra-arterial dose of sodium nitroprusside of 0.2 
/ig/min was appropriate to counteract the vasoconstrictor response to L-NMMA. Thus, 
this dose of nitroprusside was co-infused with L-NMMA. The "clamping" of the 
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NO-mediated vascular tone by the concomitant infusion of L-NMMA and nitroprusside 
has recently been shown to be a useful approach in animal experiments on this subject 
[333]. 
An additional six subjects were studied for a time control purpose. The same time 
schedule was used as in the other adenosine experiments, but instead the second dose 
response curve with adenosine was performed in the presence of placebo instead of active 
drug. This study was done to be sure that within one experimental session the forearm 
vasodilator response to adenosine did not change over time. 
In theory, nitric oxide release from the endothelium may have been triggered 
non-specifically by the adenosine-induced increase of shear stress resulting from the high 
forearm blood flows. In order to evaluate this non-specific stimulus of nitric oxide 
release, we measured FBF-responses to the endothelium-independent calcium entry 
blocker verapamil before and after L-NMMA (2 mg/min) in another six subjects. 
Verapamil was used in four dose steps of 5 minutes each (10 - 30 - 100 - 300 /*g/min). 
Since verapamil has a longer half life than adenosine, we waited for 90 minutes to wash 
out the drug after the first series of verapamil infusion. Apart from these details the time 
schedule was similar to the previous experiments. 
Assessment of the role of potassium channel activation in the vasodilator response to 
adenosine 
Recently, it has been shown that adenosine receptors are coupled to 
ATP-dependent potassium channels [325]. These channels can be blocked specifically by 
sulphonylurea derivatives, not only in the pancreatic beta cells, but also at the level of the 
vessel wall [334]. Therefore, adenosine dose response studies were performed in a fourth 
group of 6 volunteers before and during the intrabrachial infusion of tolbutamide (1 
mg/min). The infusion of tolbutamide started 15 minutes before the first adenosine dose. 
Since systemic dosages of tolbutamide may induce hypoglycemia by stimulating insulin 
release, and because insulin increases skeletal muscle blood flow and alters vascular 
responsiveness to drugs in the forearm model [335,336], arterial blood samples for 
glucose and insulin were taken just before and after tolbutamide to demonstrate that no 
systemic effects occurred at this low dose. 
In an additional 6 healthy volunteers, the vascular response to adenosine was 
assessed before and during the intra-arterial infusion of quinidine 0.5 mg/min. By use of 
the patch clamp technique, studies have shown that quinidine blocks several types of 
potassium channels [337-341], including those activated by adenosine. To limit the 
cumulative dose of quinidine in healthy volunteers, we only used the four highest instead 
of all six adenosine dosages in these subjects. Measurements of FBF, and subsequent 
administration of the four adenosine dosages were started after 10 minutes of 
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quinidine-infusion, and the total infusion time of quinidine was restricted to 30 minutes 
(cumulative dose 15 mg). 
Drugs and solutions 
Adenosine was prepared for each experiment by diluting Adenocard vials (6 mg / 
2ml, Fujisawa Pharmaceutical Co, Deerfield, Illinois) in saline. №-monome-
thyl-L-arginine acetate was purchased from Calbiochem, and diluted in glucose 5% just 
before the experiments. Sodium nitroprusside was purchased from Elkins-Sinn, Inc. 
(Cherry Hill, New Hampshire). Protected from light it was dissolved in glucose 5% just 
before administration. Verapamil HCl (American Regent Laboratories Inc., Shirley, New 
York) was diluted with glucose 5%. For the tolbutamide experiments, sterile tolbutamide 
sodium (Orinase Diagnostic, The Upjohn Company, Kalamazoo, Minnesota) was 
dissolved in saline (NaCl 0.9%). For the quinidine studies, we used quinidine gluconate 
vials (Eli Lilly, Indianapolis, Indiana) of 800 mg/10 ml diluted in glucose 5%. Depending 
on the experiment, glucose 5% or saline was used as placebo infusion. All drugs and 
placebo infusions were administered at the same infusion rate of 0.4 ml/min. 
Statistics and calculations 
The effects of adenosine itself were analysed by comparing the hemodynamic 
variables at baseline and at the six dose levels by one-way analysis of variance (ANOVA) 
with repeated measures. Post-hoc comparisons between the different dosages were made 
by Scheffé-F-tests. The paired t-test was used for the assessment of the effects of 
L-NMMA, tolbutamide or quinidine on baseline parameters. In order to evaluate the 
effect of the intervention (NO-synthase blockade, K+-channel blockade) on the adenosine 
or verapamil responses, two-way repeated measures ANOVA was performed on the 
changes from baseline. Since the mean arterial blood pressure was not affected by either 
drug infusion (see results), FBF-changes were assumed to represent changes in foream 
vascular tone. Differences were considered to be statistically significant at Ρ < 0.05 
(two-tailed). All results are presented as mean values+SE, unless indicated otherwise. 
RESULTS 
Vasodilator response to adenosine 
To assess the vascular response to graded adenosine infusion, the data of the first 
dose response curve for all experiments with the six adenosine dosages were pooled 
(n=24). Table 2 summarizes the results of this analysis. Adenosine induced a 
dose-dependent increase in FBF, which was significantly different from baseline for the 
third and higher dosages. The dose-dependency was supported by significant differences 
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between dosages (Scheffé-F-tests: Ρ <0.05). One hour after cessation of adenosine, the 
FBF was identical to the baseline level. As shown in table 2, there were no changes in 
TABLE 2: The results of graded intra-artenal adenosine infusion on hemodynamic parameters 
ADENOSINE 
DOSE 
Baseline 
(jig/nun) 
FBF-ex# 
(ml/min/dl) 
2.2 ±0.2 
FBF-conNS 
(ml/min/dl) 
1.8±0.2 
FVR# 
(arbitrary units) 
40.2±2.7 
MAPNS 
(mmHg) 
79.2±2.0 
HRNS 
(bpm) 
58.3± 1.8 
1.5 
5 
15 
50 
150 
500 
wash out 
2.3±0.2 
2.6±0.2 
4.4±0.5 
7.8±0.9* 
12.2±1.3* 
16.7±2.1* 
2.1 ±0.2 
l .8±0. l 
1.8±0.2 
1.8±0.1 
1.7±0.2 
1.8±0.l 
1.8±0.1 
1.8 + 0.1 
40.3±2.9 
34.0±2.5 
23.3±2.3* 
13.1±1.5* 
8.8±1.2* 
7.2±1.2* 
44.4±3.9 
78.8±1.7 
78.5±1.9 
78.7±1.9 
77.7±1.9 
78.6 + 2.0 
79.0 + 1.9 
81.1 ± 1.9 
57.8±1.7 
58.3±1.6 
58.4±1.8 
58.6±1.7 
57.9 ±1.9 
59.2±1.8 
57.9±1.8 
Values are presented as mean data ± SE (n=24). 
FBF: forearm blood flow at the experimental (-ex) as well as at the control side (-con) 
FVR: forearm vascular resistance at the experimental side (calculated as the quotient of mean arterial 
pressure and FBF) 
MAP: mean arterial pressure 
HR: heart rate. 
tt, P<0.001 by repeated measures ANOVA. NS Not significant by repeated measures ANOVA. 
*, Ρ<0.05 by Post-hoc Scheffé F-tests (significantly different versus baseline, versus the wash-out value as 
well as versus previous adenosine dose). 
flow in the non-infused forearm, or changes in blood pressure or heart rate during 
adenosine infusion, arguing against any systemic effect of the dosages used. In the subset 
of experiments where the adenosine infusions were repeated after one hour without any 
intervention (time controls), adenosine increased FBF the first time from 2.3+0.4 to 
15.2+4.7, and the second time from 1.9+0.7 to 16.0±7.2 ml/min/dl. There was no 
significant difference between the FBF-changes from baseline between this first and 
second series of measurements. 
Plasma caffeine levels could not be detected in 20 of 23 subjects in whome it was 
measured (lower limit of assay: 0.5 mg/l). In the remaining three subjects, caffeine 
concentration ranged from 1.8 to 4.0 mg/l. Despite detectable caffeine levels in these 
three subjects, each showed a vasodilator response to adenosine that was comparable to 
that observed in the others, justifying inclusion of their data in the results. Moreover, 
statistical analysis after exclusion of these particular individuals did not affect the outcome 
of the findings. 
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Vasoconstrictor response to NG-monomethyl-L-arginine 
To assess the effect of L-NMMA on basal forearm blood flow, the data of six 
L-NMMA-adenosine-, three single L-NMMA- and six L-NMMA-verapamil-experiments 
were pooled. After 15 minutes of intra-arterial L-NMMA infusion, FBF decreased 
significantly from 2.1±0.2 to 1.5±0.1 ml/min/dl (n = 15, paired t-test: P<0.01). In 
contrast, the FBF of the contralateral non-infused arm remained constant during this 
infusion (1.8±0.1 before versus 1.8+0.1 during L-NMMA). Moreover, L-NMMA-infu-
sion did not change the mean arterial blood pressure (81.3+2.3 vs 79.1 ±2.7 mmHg, 
P=NS) or heart rate (56.1 ±2.2 vs 54.9±2.1 beats/min, P = NS), indicating that local 
L-NMMA-infusion did not affect systemic hemodynamics. In the three subjects, in 
whome L-NMMA was the only drug given, the FBF fell from 1.8+0.3 at baseline to 
1.3±0.2 and 1.6±0.1 ml/min/dl after 15 and 40 minutes respectively, arguing against a 
progressive vasoconstrictor effect after 15 minutes of infusion. 
Effects of NO-synthase blockade on vasodilator responses 
Figure 1 illustrates the FBF response to the six increasing adenosine dosages 
during the placebo and L-NMMA-infusions. Adenosine in the presence of placebo 
induced a dose-dependent increase in FBF from 2.3±0.2 to 15.9+3.1 ml/min/dl. During 
co-infusion with L-NMMA, adenosine increased FBF from 1.7 to 10.0 ml/min/dl, this 
response being significantly reduced when compared with the first dose response curve. 
The concomitant infusion of L-NMMA and adenosine elicited no significant changes in 
contralateral FBF (from 1.8+0.2 at baseline to 2.3± 0.3 ml/min/dl at the highest 
adenosine dose), mean arterial pressure (from 80+4 to 83+4 mmHg) or heart rate (from 
55±2 to 54±2 beats/min) 
In the second series of experiments, the vasoconstrictor effect of L-NMMA was 
counteracted by concomitant infusion of sodium nitroprusside. Again, in the presence of 
placebo, adenosine caused a dose-dependent forearm vasodilator effect with an increase of 
FBF from 1.9±0.4 to 14.9±2.0 ml/min/dl (figure 2). After returning to baseline 
conditions, the combined infusion of L-NMMA and nitroprusside did not significantly 
change FBF (2.0±0.3 versus 2.2+0.3 ml/min/dl, n=6, P=NS). The subsequent 
administration of the six adenosine dosages elicited dose-dependent increments in FBF 
from 2.2+0.3 to 9.8±2.4 ml/min/dl; the changes from baseline were significantly 
reduced as compared with before adminstration of L-NMMA and nitroprusside (P<0.01) 
(figure 2). No significant changes occurred in contralateral FBF (from 1.7±0.3 at 
baseline to 1.8± 0.3 ml/min/dl at the highest adenosine dose), mean arterial pressure 
(from 79±4 to 81 ±3 mmHg) or heart rate (from 53±2 to 53±3 beats/min) 
The intra-arterial infusion of L-NMMA did not change the forearm vasodilator 
response to verapamil. 
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Forearm blood flow (ml/min/dl) 
20 
Placebo 
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P<0 05 
Forearm blood flow (ml/mm/dl) 
20 τ 
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10 
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Figure 1 (left) and figure 2 (right): The forearm blood flow (FBF) during graded infra-artenal adenosine 
infusion, both in the presence of placebo (squares/solid line) as well as during concomitant infusion of 
№-monomethyI-L-arginine (L-NMMA, urdes/dashed line, figure 1) or during the combined infusion of 
Nc-monomethyl-L-arginine and sodium nitroprusside (L-NMMA+ SNP, circles/dashed line, figure 2) is 
presented as mean ± SE The p-value reters to the statistical difference between conditions tor these dose-
responses as analyzed by repeated measures ANOVA 
Forearm blood flow (ml/min/dl) 
30η 
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Figure 3 (left) and figure 4 (right): The forearm blood flow (FBF) during graded intra-artenal adenosine 
infusion, both in the presence of placebo (squares/solid line) as well as during concomitant infusion of the 
potassium channel blocker, tolbutamide (figure 1) or quimdine (figure 4) Values are presented as 
mean±SE There were no significant dittereni.es in the dose-response relationship between placebo and 
tolbutamide or quimdine as analyzed by repeated measures ANOVA 
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Effects of potassium channel blockade on adenosine responses 
During placebo, the FBF-changes from baseline for the four increasing verapamil 
dosages averaged 2.3±0.5, 4.2+0.7, 8.6+1.9 and 11.9+2.8 ml/min/dl, whereas these 
numbers were 1.7±0.2, 3.5±0.9, 6.7±1.4 and 12.2+2.4 ml/min/dl during concomitant 
L-NMMA-administration. No significant effects on systemic hemodynamics were 
observed during the combined infusion of L-NMMA and verapamil. The contralateral 
FBF was 1.9±0.2 before and 1.6±0.3 ml/min/dl during the highest verapamil dose. 
Respective values for mean arterial blood pressure were 79+2 and 79±2 mmHg, and for 
heart rate were 56+4 and 58±4 beats/min. 
Figure 3 demonstrates the effects of tolbutamide on the vasodilator response to 
adenosine. Tolbutamide infusion into the brachial artery did not change the baseline FBF 
(2.3±0.3 versus 2.2±0.3 ml/min/dl). Moreover, the adenosine-induced increase in FBF 
was not reduced by tolbutamide. 
Figure 4 illustrates the effects of quinidine on the forearm vasodilator response to 
adenosine infusion. In this series, adenosine increased FBF from 1.6±0.3 to 9.0+0.8 
ml/min/dl. After equilibration, the FBF returned to a baseline value of 1.5 ml/min/dl. 
Ten minutes of quinidine-infusion increased the baseline FBF significantly to 2.9+0.7 
ml/min/dl (P<0.05). However, regional quinidine infusion did not significantly affect the 
adenosine-induced increase in FBF from baseline. 
Throughout these two series of experiments, there were no changes in contralateral 
FBF, blood pressure or heart rate. The plasma insulin concentrations averaged 4.4+1.2 
before and 4.5± 1.2 /¿U/ml after tolbutamide administration (P=NS), while the glucose 
levels were 84±3 and 81 ±2 mg/dl, respectively. 
DISCUSSION 
The results of this study enable us to conclude that the vasodilator response to 
adenosine in humans is mediated, at least in part, by the endothelial release of nitric 
oxide. The following evidence supports this conclusion: 1) blockade of NO-synthase by 
L-NMMA significantly reduced the forearm blood flow response to adenosine, 2) the 
vehicle control experiments ensured that this reduced response could not be attributed to 
time, 3) the observation that L-NMMA attenuated adenosine responses could not be 
attributed to a change in basal vascular resistance, because restoration of baseline 
conditions by the addition of a low dose of the nitroprusside did not change the results. 
We reasoned that the co-infusion of nitroprusside and L-NMMA was the most ideal 
approach to correct for the L-NMMA-associated change in baseline vascular resistance. 
Addition of exogenous NO by infusion of nitroprusside was thought to restore the 
baseline biology of the vascular wall, and to recondition its responsiveness to vaso-active 
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stimuli [333]. Also, the vasoconstrictor effect of L-NMMA (when infused alone) did not 
progress over time, and thus could not account for the L-NMMA-mediated reduction in 
adenosine responses. Apart from the pathophysiological consequences of our conclusion, 
it is obvious that the use of adenosine for the assessment of endothelium-independent 
vasodilation in peripheral resistance vessels is not a valid approach in human research. 
Several recent studies in animals support our observations [321,322,324,342], but 
others do not [319,343]. Species differences and different experimental conditions may 
contribute to this discrepancy. In the perfused forearm technique used in this study, the 
drug is administered into the vascular lumen, thus the exposure to adenosine is much 
higher for the vascular endothelium than for the underlying smooth muscle cell layer, 
especially because of the efficient uptake of adenosine by the endothelium [124,344]. In 
several in vitro vascular preparations the exposure is more balanced, and as such direct 
relaxant effects on smooth muscle cells mediated by stimulation of A2-adenosine receptors 
may have been more pronounced [124]. 
Shear stress as a mechanism of action 
A number of transducing mechanisms should be considered as mediators for 
adenosine's ability to release endothelium-derived nitric oxide. For example, the adenosi-
ne-induced release of NO might have been triggered non-specifically by the increase in 
flow (shear stress) rather than by the specific stimulation of endothelial adenosine 
receptors. However, in previous studies with the same technique, the intra-arterial 
infusion of L-NMMA reduced the relaxant effects of acetylcholine, but not those of 
nitroprusside, arguing against a contribution of flow-related NO-release during drug-indu-
ced elevations of forearm blood flow [345]. Furthermore, in the current experiment, 
L-NMMA did not attenuate the vasodilator response to the calcium entry blocker 
verapamil, an endothelium-independent vasodilator, despite achieving blood flow 
responses comparable to that observed in the mid dose range of adenosine. Our data 
therefore point towards a more specific interaction between L-NMMA and adenosine. We 
and others have shown previously that low intrabrachial dosages of the adenosine receptor 
antagonists caffeine and theophylline are able to block the forearm vasodilator response to 
adenosine [221,303], enabling us to postulate that the adenosine-mediated release of NO 
results from stimulation of endothelial adenosine receptors. Unfortunately, selective 
agonists and antagonists for the different subtypes of adenosine receptors are not available 
for human use, therefore it is not possible at this time to determine whether the adenosi-
ne-induced NO-release in humans is mediated by stimulation of endothelial A,- or 
A2-adenosine receptors. 
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Role of potassium channels 
We postulated that activation of potassium channels may serve as an intermediate 
step, transducing stimulation of adenosine receptors to the synthesis and/or release of 
nitric oxide from the endothelium. Since equipotent dosages of the related sulphonylurea 
derivative glibenclamide have been shown to attenuate the vasodilator response to 
pharmacological opening of KATP-channels in the forearm vascular bed [346,347], we think 
that our negative observation of tolbutamide can not be attributed to ineffective dosing. 
Consequently, our data support the conclusion that KATP-channel-opening does not 
contribute to the vasodilator response to intra-arterial adenosine infusion in humans. In 
theory, KATT-channel-opening might have contributed to the vaso-active effects of adenosi-
ne at two different levels. At the level of the endothelium, KATP-channel-opening may 
hyperpolarize endothelial cells [348], and as such may activate endothelial NO-release by 
increasing the influx of calcium [348]. In contrast to increases of calcium influx in 
endothelial cells after hyperpolarization, calcium influx decreases after membrane 
hyperpolarization in vascular smooth muscle cells [348]. Therefore, opening of potassium 
channels also results in vasodilation at the level of vascular smooth muscle cells. It must 
be emphasized that because of our intraluminal administration of adenosine, its effects 
may have been predominantly endothelium-dependent, and therefore we think that our 
tolbutamide data do not exclude a role of KAM.-channel activation in the smooth muscle 
relaxing effects of adenosine. 
Although we realize that quinidine has several pharmacological properties, 
including sodium channel blockade and anti-adrenergic effects, its recently established 
potassium channel blocking properties made this drug an additional tool for our study, 
especially because quinidine was able to attenuate the vasodilator response to adenosine in 
animal studies [349]. Quinidine increased basal forearm blood flow, but did not attenuate 
the vasodilator response to adenosine. The effect of quinidine on the baseline flow may 
well be explained by its alpha-adrenergic blocking properties. In line with the reasoning 
on tolbutamide, our data argue against a role of quinidine-sensitive potassium channels in 
the adenosine-mediated release of NO, but do not exclude an interaction between 
quinidine and adenosine at the level of vascular smooth muscle cells. 
Pathophysiologic Implications 
Apart from effects on vascular tone, adenosine has other important properties, 
including inhibition of platelet aggregation [350], inhibition of leukocyte activation [167], 
and presynaptic inhibition of norepinephrine release [268]. Furthermore, adenosine 
appears to mediate ischemic preconditioning in the myocardium [169]. The release of 
endogenous adenosine may also contribute to the reactive hyperemic response after 
ischemia [315,351], as well as to exercise-induced vasodilation [352]. In recent years, 
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nitric oxide has been demonstrated to affect several of these pathophysiological 
phenomena in a similar way [315,351,353-356]. Since adenosine is released from tissues, 
including the endothelium, during anoxia or ischemia [357], the currently observed 
relation between adenosine and endothelial nitric oxide release makes endogenous 
adenosine a likely candidate for triggering NO-release during ischemia. We think that our 
results create the foundation for future studies on the interrelationship between the release 
of endogenous adenosine and of nitric oxide during several pathophysiological conditions 
in humans. 
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ABSTRACT 
Experimental data derived from animal models suggest that the endogenous 
nucleoside adenosine has important cardioprotective properties. The potent vasodilator 
effects of adenosine may contribute to this cardioprotection as ischemia-induced release of 
endogenous adenosine has been suggested to adjust local blood flow to the metabolic 
demands of the tissue. Interestingly, the vascular effects of adenosine appeared to be 
impaired in animal models for diabetes mellitus. This observation may be of importance 
with respect to the increased cardiovascular mortality in diabetes. Therefore, we investi-
gated the in vivo vasodilator effects of adenosine in insulin-dependent diabetic patients. 
In twelve uncomplicated insulin-dependent male diabetic patients and twelve 
healthy male age-matched subjects, the brachial artery was cannulated for infusion of 
adenosine (0.15, 0.5, 1.5, 5, 15 and 50 /ig/100 ml/min) and for measurement of mean 
arterial pressure (MAP). Forearm blood flow (FBF) was measured by venous occlusion 
mercury-in-silastic strain gauge plethysmography. Maximal vasodilation was assessed by 
standardized post occlusive reactive hyperaemia (PORH). Baseline forearm blood flow 
was 2.7+0.4 and 1.8±0.2 ml/100 ml/min for the diabetic patients and control group 
respectively. In the diabetic patients, adenosine infusion raised forearm blood flow to 
2.4+0.4, 2.6+0.4, 4.4+0.7, 6.3+1.0, 9.8±1.5 and 14.2±2.1 ml/100 ml/min for the 
respective dosages. In the control group these values were 1.7+0.2, 1.9+0.3, 3.2±0.8, 
6.0+1.2, 10.9+2.1 and 17.1+3.4 ml/100 ml/min respectively (p>0.1 for between 
group comparison). Forearm blood flow at the contralateral side was not significantly 
affected by the placebo and adenosine infusions. Comparable results were obtained when 
results were expressed as changes in forearm vascular resistance or forearm blood flow 
ratio (FBF infused arm/FBF control arm). Maximal vasodilation did not differ between 
the two groups. 
We conclude that the forearm vasodilator response to adenosine is preserved in 
uncomplicated insulin-dependent diabetic patients. This observation argues against a 
primary role of a reduced adenosine responsiveness in the cardiovascular sequelae of 
diabetes. 
INTRODUCTION 
Adenosine has potentially important cardioprotective properties like inhibition of 
neutrophil activation with subsequent reduced free radical formation, inhibition of 
thrombocyte aggregation, vasodilation, presynaptic inhibition of norepinephrine release, 
and opening of potassium channels [204]. These effects are mediated by adenosine 
receptors, located on the outer cell membrane. In animals, myocardial infarct size is 
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reduced when adenosine is infused either before ischaemia or during the reperfusion 
period [168,169,202]. In addition, adenosine reduces the incidence of ischemia-induced 
arrhythmias [358]. Infusion of a selective adenosine receptor antagonist increases infarct 
size, indicating a role for endogenous adenosine as a cardioprotective autacoid [171]. 
Since the vasodilator action of adenosine is thought to play a role in the local adjustment 
of oxygen demand to oxygen supply [359,360], this may contribute to the cardioprotective 
properties of adenosine. 
Interestingly, an impaired responsiveness to the vasodilator effect of adenosine has 
been observed in animal models for diabetes mellitus [200,201]. Several mechanisms may 
be responsible for this reduced responsiveness to adenosine. Animal and human data have 
indicated both fascilitating as well as inhibiting interactions between adenosine and the 
sympathetic nervous system [206,222,223,229,269,271]. Furthermore, human and animal 
studies show that adenosine-induced vasodilation is at least partially mediated by the 
endothelium [123,361,362]. Since insulin alters sympathetic nervous system activity 
[363,364] and diabetes mellitus has been associated with reduced endothelium-dependent 
vasodilation [199,289,292,365], both neural and endothelial mechanisms may be involved 
in the reduced reactivity to adenosine in these descriptive animal studies. Additionally, 
direct actions of adenosine on cardiac and vascular muscle cells may be reduced in 
patients with diabetes mellitus. 
Although vascular reactivity in human diabetes has been studied extensively over the past 
few years [199,289,292,365], no human data are available on the responsiveness to the 
endogenous nucleoside adenosine. Since diabetes is an independent risk factor for 
developing cardiovascular disease [366], and is often associated with concomitant 
hypercholesterolaemia and hypertension which further attributes to an increased risk of 
ischaemic heart disease [367,368], an impairment in adenosine responsiveness may be of 
clinical interest. Pharmacological compounds are currently being developed to potentiate 
the action of endogenous adenosine at sites of ischemia [271]. In this context it is valuable 
to know if diabetic patients exhibit decreased responses to adenosine. Furthermore, a 
reduced vascular responsiveness to adenosine may also be of importance in the metabolic 
control of patients with diabetes mellitus since adenosine enhances glucose uptake in some 
animal models [369,370]. This metabolic effect of adenosine may in part be due to its 
effect on blood flow [371]. Therefore, we evaluated the vasodilator response to adenosine 
in patients with uncomplicated insulin dependent diabetes mellitus and compared these 
observations with a carefully matched control group. 
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PATIENTS AND METHODS 
Patients 
After approval of the local ethics committee, twelve normotensive nonsmoking 
Caucasian male patients with insulin-dependent diabetes mellitus were selected from our 
outpatient population. Diabetes mellitus was diagnosed at least 5 years before participation 
to this study. Patients with evidence of macro- or microvascular disease were excluded 
from the study because these vascular complications would result in a nonspecific 
impairment of the reactivity to any vasodilator substance. Macrovascular disease was 
assessed by taking their history (no coronary artery disease, heart failure, cerebrovascular 
disease, peripheral vascular disease or foot ulcers), physical examination and a twelve 
lead electrocardiogram. Microvascular disease was excluded by demonstrating the absence 
of orthostatic hypotension and peripheral loss of sensibility, by a normal fundoscopy, and 
by an albumin excretion ratio less than 20 μg/min. None of the patients used medication 
other than subcutaneous insulin injection. Only patients with a glycosylated haemoglobin 
concentration (HbAlc) between 7 and 10 % as measured during insulin treatment were 
included. 
Table 1: Demographic characteristics of the study groups (mean±SD) 
N 
Male/female 
Age (years) 
Body Mass Index (kg/nr) 
Systolic blood pressure (mmHg)* 
Diastolic blood pressure (mmHg)* 
Mean arterial pressure (mmHg)* 
Heart rate (beats per minute)* 
HbA l c(%) 
Time after diagnosis (years) 
Glucose (mmol/L)@ 
Diabetic subjects 
12 
12/0 
34.6±5.9 
23.6±2.4 
123 ±10.4 
63.2±8.6 
85.2±9.8 
67.3±16.8 
8.5±0.9 
16.2±8.3 
13.0±5.1 
Healthy subjects 
12 
12/0 
34.8±6.0 
23.3±2.4 
118±82 
62.4±4.9 
82.4±6.8 
57.4±9.6 
*, Intra-artenally measured during placebo infusion; #, Measured by electrocardiographic recordings during 
placebo infusion; @, Determined during the experiment; for each subject the 6 determinations were 
averaged to one value. 
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The control group consisted of twelve male non-smoking healthy Caucasian volunteers. 
These subjects were carefully matched for age, blood pressure and body weight. They 
had no history of diabetes mellitus and did not use concomitant medication. Physical 
examination and twelve lead electrocardiography did not reveal any abnormalities. 
Demographic data of the study groups are shown in table 1. 
Methods 
Before the start of the study, the subjects were asked to abstain from caffeine-
containing products for at least 24 hours, because caffeine is a potent adenosine receptor 
antagonist [221]. In all participating subjects, the plasma caffeine concentration was below 
the limit of detection as measured in a sample that was collected immediately before 
starting the experiments (reversed phase HPLC; minimal level of detection: 0.2 μg/ml 
[218]). All tests were performed in a temperature controlled laboratory (22-23 °C), with 
participants in the supine position, after an overnight fast, starting at 8.00 am. 
From a methodological point of view, the level of plasma insulin and glucose 
concentrations throughout the study is a very important issue. Recent studies have 
convincingly shown that baseline skeletal muscle flow in humans is not affected by 
hyperglycemia [372], whereas hyperinsulinemia induces an obvious increase in baseline 
skeletal muscle flow as well as in forearm vascular reactivity [335,373-375]. To avoid 
confounding of our results by insulin-mediated vasodilation, we instructed the diabetic 
subjects to skip their morning dose of insulin and not to use a breakfast. This was done in 
order to achieve low and steady state plasma insulin levels during the time of 
experiments. Although even lower insulin levels would have been reached by also 
skipping the long-acting insulin injection of the evening before the experiment, this would 
have introduced the risk of the development of ketosis or keto-acidosis, a factor which 
would certainly have affected the results. Since no insulin was administered in the 
morning hours, we had to accept the varying fasting glucose levels throughout the experi­
ments, since correcting the glucose levels would inevitably have increased insulin levels. 
As stated above, recent data have convincingly shown that plasma glucose levels up to 15 
mmol/1 do neither affect baseline forearm blood flow nor vascular reactivity of the 
forearm vascular bed [372]. 
After local anaesthesia (Xylocaine, 2%), the left brachial artery was cannulated 
with a 20-gauge catheter (Angiocath, Deseret Medical, Inc., Becton Dickinson and Co, 
Sandy, UT, U.S.A.) for both intra-arterial adenosine infusion (automatic syringe infusion 
pump, type STC-521, Terumo Corporation, Tokyo, Japan) and blood pressure recording 
(Hewlett Packard GmbH, Böblingen, Germany). Forearm blood flow was registered 
simultaneously on both forearms by electrocardiography-triggered venous occlusion 
plethysmography using mercury-in-silastic strain gauges (Hokanson EC4, D.E. Hokanson, 
126 
Adenosine and diabetes mellitus 
Inc., Washington, U.S.A). The upper arm collecting cuff was inflated using a rapid cuff 
inflator (Hokanson E-20, D.E. Hokanson, Inc., Washington, U.S.A.). At least one 
minute before the FBF measurements, the circulation of the left hand was occluded by 
inflation of a wrist cuff to 200 mmHg. Forearm blood flow was recorded three times per 
minute during the four minute placebo infusion and during the last two minutes of each 
adenosine infusion. 
The experiment started with the measurement of baseline forearm blood flow 
during placebo infusion (NaCl, 0.9%). Apart from the course in the forearm blood flow, 
figure 1 shows the schedule of the several drug infusions. The effect of six increasing 
dosages of adenosine (Sigma Chemical Co., St Louis, MO, U.S.A.; 0.15, 0.5, 1.5, 5, 15 
and 50 μg/100 ml forearm/min) were compared with placebo (NaCl 0.9%). Prolonged 
occlusion of the hand circulation can cause discomfort with subsequent effects on blood 
pressure and heart rate. 
FBF 
(ml/100 ml forearm/min) 
Time after cannulation (min) 
Figure 1. The course in forearm blood flow (FBF) before and during the intra-arterial infusion of adenosine 
is presented for the diabetic patients and the control group. There was no statistically significant difference 
between the groups (ANOVA for repeated measurements: Ρ =1.0). 
Therefore, a 5-minute rest period with desufflation of the wrist cuffs was allowed between 
the placebo infusion and the first adenosine dose and between the third and fourth 
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adenosine dose. During all procedures, total volume infusion was adjusted to forearm 
volume as measured by water displacement and kept at a constant rate of 100 μ\Ι 100 ml 
forearm/min. Placebo and each adenosine dosage were infused during 4 minutes. 
To exclude structural vascular changes in the diabetic patients, maximal vasodilati­
on was measured during post occlusive reactive hyperaemia (PORH) according to the 
well-established method of Pedrinelli et al [308,3091 twenty minutes after the end of the 
final adenosine infusion. A cuff applied to the left upper arm was inflated to 300 mm Hg 
for 13 minutes. During the last minute of ischaemia the subjects were asked to perform 
repeated hand contractions. Immediately after desufflation of the upperarm cuff, FBF 
measurements were started for at least 2 minutes with occluded hand circulation. The 
lowest forearm vascular resistance (MAP/FBF) was considered to represent maximal 
vasodilation. 
In the diabetic group, blood glucose concentrations were determined 6 times: 
immediately after arterial cannulation, after infusion of placebo, after the third and after 
the sixth adenosine dose, just before the test of maximal vasodilation and just before 
decannulation (Accutrend, type 1284851, Boehringer, Mannheim, Germany). Prior to the 
intra-arterial adenosine infusions, 10 ml arterial blood was collected with Li-heparin as 
coagulant in 9 diabetic patients and in 4 control subjects for the determination of plasma 
insulin and detection of insulin antibodies. Plasma insulin was measured by radioimmuno­
assay using a specific antiserum raised in a guinea pig against human insulin. A second 
antibody was used to separate the antibody-bound and free fractions. Insulin antibodies 
were detected by incubation of the samples with 12<I-insulin and subsequent precipitation 
with polyethyleneglycol [376]. 
Statistics 
Mean arterial pressure (MAP) was measured continuously during each recording 
of forearm blood flow (FBF) and averaged per FBF registration. Forearm vascular 
resistance (FVR) was calculated from simultaneously measured MAP and FBF 
(MAP/FBF) and expressed as arbitrary units (AU). Additionally, the ratio of each 
simultaneously measured FBF (FBF infused arm/FBF control arm) was calculated. 
Forearm blood flows, the calculated flow ratios and FVR's obtained during each four 
minutes of placebo infusion or during the last two minutes of each drug infusion were 
averaged to one value. Adenosine-induced effects were expressed both as absolute and 
percentage change from preceding placebo infusion. Differences in responses to adenosine 
between the two study groups were analysed with an ANOVA for repeated measurements 
with the adenosine dosage as within-subject factor and the presence of diabetes mellitus as 
between-subject factor. Differences in baseline values were assessed with the unpaired 
Student t-test. Correlations were performed using the Pearson correlation coefficient. 
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Since plasma insulin concentrations did not show a Gaussian distribution, group 
differences in insulin levels were analyzed by the Mann-Whitney U test. All results are 
expressed as mean+SE unless indicated otherwise; P<0.05 (two sided) was considered to 
indicate statistical significance. 
RESULTS 
Baseline FBFs in the infused arm were 2.7+0.4 and 1.8±0.2 ml/100 ml 
forearm/min for the diabetic patients and control group respectively (P=0.07). In the 
control arm these values were 2.4+0.4 and 1.5+0.1 ml/100 ml forearm/min (P=0.05). 
During the adenosine infusions, FBF in the infused arm of the diabetic patients amounted 
2.4±0.4, 2.6±0.4, 4.4+0.7, 6.3+1.0, 9.8+1.5 and 14.2±2.1 ml/100 ml forearm/min 
for the respective adenosine dosages of 0.15, 0.5, 1.5, 5, 15 and 50 μg adenosine/100 ml 
forearm/min. In the control group these values were 1.7±0.2, 1.9±0.3, 3.2±0.8, 
6.0±1.2, 10.9+2.1 and 17.1+3.4 ml/100 ml forearm/min, respectively (see figure 1). In 
both groups, FBF in the control arm was not significantly affected during the placebo and 
adenosine infusions. Overall, repeated measures ANOVA did not reveal a significant 
difference between the two groups (between subject effect: P=1.0). Comparable results 
were obtained when results were expressed as absolute or relative changes in FBF from 
baseline. 
Baseline FVRs in the infused arm were 39.6+5.2 and 57.5±7.6 AU for the 
diabetic patients and controls, respectively (P=0.07). In the control arm these values 
were 45.7±6.3 and 63.7±5.9 AU, respectively (P<0.05). During adenosine infusion, 
FVRs in the infused arm of the diabetic patients were 44.6+6.6, 41.9±5.4, 29.9+7.1, 
20.5±4.6, 16.6+5.7 and 12.2+5.7 AU for the six increasing adenosine dosages, 
respectively. In the controls, these values were 57.5±7.6, 58.5±7.2, 56.1 ±7.7, 
45.8±9.0, 24.6±5.5, 16.0+4.6 and 13.2+5.2 AU, respectively. Overall, the course of 
FVR in the infused arm did not significantly differ between the two groups (between-
subject effect: P=0.2). In both groups, FVR in the control arm was not affected. 
Comparable results were obtained when adenosine-induced changes in FVR were 
expressed as absolute or relative changes from baseline (see figure 2). 
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Figure 2. Adenosine-induced forearm vasodilation in controls (open symbols) and diabetic patients (closed 
symbols) expressed as absolute and permeiate change in forearm vascular resistance (FVR) from baseline. Ρ 
values indicate the level of significance for between group effects (ANOVA for repeated measurements). 
Because we observed slight differences in baseline FBF- and FVR-values between 
the diabetic patients and the control group, we also analyzed the results of the FBF-ratio 
(FBFmftutd .m, divided by РВР
С0ПІП1ІДІ1.Ы „ J . Assessment of the percent changes of this ratio 
has been shown to be an appropriate method to analyze dose response curves [292,377]. 
During placebo infusion, the FBF-ratio was equal in both groups and numbered 1.2±0.1. 
In the diabetic patients, the FBF-ratios increased to 1.0±0.1, 1.2+0.1, 2.1+0.4, 
4.4+1.0, 5.9+1.2 and 9.2±2.5 during the six increasing adenosine dosages, 
respectively. In the controls, these values were 1.3±0.1, 1.5±0.2, 2.2+0.4, 4.2±0.8, 
8.9± 1.5 and 14.7±2.1, respectively. Overall, the course of the ratio did not significantly 
differ between the two groups (between-subject effect: P=0.2). Comparable results were 
obtained when adenosine-induced changes in the ratio were expressed as absolute or 
relative changes from baseline. 
The minimal FVR that occurred during post-occlusive reactive hyperaemia did not 
differ between diabetic patients and controls: 3.2+0.2 versus 3.4±0.3 AU (P=0.6). 
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The individual courses of blood glucose concentration are shown in figure 3. Within each 
individual, glucose levels remained reasonably stable. However, between the patients a 
high variation in averaged glucose level existed ranging from 3.4 to 20.6 mmol/liter. 
There was no correlation between the individual plasma glucose concentration and the 
vascular responsiveness to adenosine in the diabetic patients (r=-0.2, P=0.5). Plasma 
insulin concentration was 21.8+2.5 mE/L (N=9) in the diabetic patients versus 6.5±1.3 
mE/liter (N=4) in the controls (P<0.01). In four diabetic patients, insulin antibodies 
could be detected. After exclusion of these patients, plasma insulin concentration was still 
significantly higher in the diabetic patients as compared with the control subjects 
(20.8±3.8 versus 6.5±0.9 mE/liter; P<0.05). 
Blood glucose 
( m m ОI / L ) Figure 3. Individual courses of blood 
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DISCUSSION 
This study was performed to investigate whether the forearm vasodilator response 
to adenosine is affected in patients with insulin-dependent diabetes mellitus. Normotensive 
non-smoking diabetic patients without evidence of macro- or microvascular complications 
were selected to prevent possible confounding by structural arteriolar or microvascular 
changes. Maximal forearm vasodilation in the diabetic patients appeared to be equal to 
that of the age-matched control group confirming the absence of structural abnormalities 
in the forearm vascular bed of the diabetic subjects. In these carefully selected patients, 
we observed a preserved vasodilator response to adenosine in the forearm vascular bed. 
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This observation argues against a primary role of reduced adenosine responsiveness in the 
cardiovascular sequellae of diabetes. 
The current results are in contrast with several observations in animal models for 
diabetes [200,201] that studied the responsiveness of the heart and coronary vasculature to 
adenosine. We can not exclude the possibility that diabetes mellitus differentially affects 
the coronary and forearm vascular bed in humans. However, other possible explanations 
should be discusses as well. 
It has to be emphasized that animal models for diabetes represent a true insulino-
penic state. In contrast, as a result of subcutaneous administration of insulin as opposed to 
the physiological release of insulin into the portal vein, the levels of insulin are elevated 
in treated patients with insulin-dependent diabetes mellitus. As such, treated patients with 
insulin-dependent diabetes do not represent an insulinopenic state, not even in the fasting 
state when plasma insulin concentrations reach their trough level. This may well explain 
the preserved adenosine responsiveness in our patients, because treatment of diabetic 
animals with insulin also restored the impaired responses to adenosine [201]. Since we did 
not study the effects of adenosine in a true insulinopenic state, our data do not exclude an 
interaction between insulin and adenosine. Nonetheless, our present results do allow the 
conclusion that the vascular responsiveness to adenosine is preserved in patients with 
diabetes mellitus who are regularly treated with insulin. 
In the diabetic patients, baseline forearm blood flow and forearm vascular 
resistance were slightly different from that of the control subjects. This interesting pheno-
menon has been described before [292] and is not only confined to the forearm but has 
also been shown for the retinal, renal and cutaneous circulation [378-380]. It already 
exists in the early course of the disease before diabetic complications have developed 
[292,380]. Although the exact mechanism of this 'hyperdynamic circulation' in diabetic 
patients is not known, it may be related to the development of complications like diabetic 
nephropathy and diabetic microangiopathy [380]. Especially because of this difference in 
baseline forearm blood flow, we also included the results on the FBF-ratio (see method 
section). For the FBF-ratio, the diabetic patients and the control group had exactly the 
same baseline values. Using this parameter, statistical analysis of the adenosine responses 
revealed no difference between the two groups. 
The main observation of the present study is that adenosine-mediated forearm 
vasodilation is not significantly affected in insulin-dependent diabetic patients. The 
response to the two highest adenosine dosages tended to be slightly reduced in the diabetic 
patients, but this difference did not reach statistical significance. In contrast to the two 
highest dosages, the responses to the lower dosages were very similar between the two 
groups. We regard these lower dosages more representative for the local physiological 
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increases in adenosine concentration which are probably needed for the small adjustments 
of local flow in order to constantly balance tissue oxygen demand and supply. 
The effect of intra-arterially supplied adenosine is determined by the adenosine 
concentration, adenosine receptor density and receptor function. Adenosine concentrations 
depend on the rate of cellular adenosine uptake. In theory, diabetes mellitus may impair 
this cellular uptake of adenosine [381]. Therefore, a reduced adenosine receptor density 
or function could have been masked by differences in adenosine kinetics between the two 
groups. However, the clinical significance of a possible receptor dysfunction is limited 
when the overall vasodilator effect of adenosine is not reduced in vivo as shown in the 
present study. 
In conclusion, the vasodilator response to adenosine is preserved in patients with 
insulin-dependent diabetes mellitus who are regularly treated with insulin. This observati-
on argues against a primary role of impaired adenosine responsiveness in the cardiovas-
cular sequelae of diabetes. 
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Summary and conclusions 
Based on in vitro studies and in vivo experiments in animals, adenosine has been 
shown to induce vasodilation, to reduce norepinephrine release from sympathetic nerve 
endings by a presynaptic mechanism and to exhibit negative inotropic, dromotropic and 
chronotropic actions. These effects of adenosine are mediated by stimulation of adenosine 
receptors (Ρ,-purinergic receptors) that are located at the outer cell membrane. In 
anesthetized animals, these effects occur both during local and systemic administration of 
adenosine. 
Studies in several animal models have demonstrated a cardioprotective effect of 
adenosine during ischemia by reducing the incidence of ischemia-induced arrhythmias and 
infarct size. Endogenous adenosine is thought to play an important role in ischemic 
preconditioning, defined as the increased tolerance of myocardium to a prolonged 
ischemic insult achieved by an initial brief exposure to ischemia and reperfusion. 
Exploitation of the cardioprotective effects of adenosine in humans would be of great 
therapeutic advantage. 
Unfortunately, in unanesthetized humans, intravenous infusion of adenosine results 
in an increase in systolic blood pressure, heart rate, plasma catecholamine levels and 
ventilation. These systemic effects are potentially deleterious in patients with ischemic 
heart disease and are thought to be mediated by afferent nerve activation and subsequent 
stimulation of the sympathetic nervous system. In contrast to these systemic effects of 
adenosine, local infusion of adenosine into the brachial or coronary artery induces 
vasodilation and counteracts sympathetic nerve-induced vasoconstriction. In humans, both 
local and systemic effects of adenosine are mediated by specific adenosine receptors and 
can be antagonized by adenosine receptor antagonists, such as theophylline and caffeine. 
Extracellular adenosine is rapidly taken up by various cells like endothelial cells, 
smooth muscle cells and erythrocytes. This process is mediated by facilitated diffusion 
and can be inhibited by nucleoside transport inhibitors like dipyridamole and draflazine. 
Nucleoside transport inhibition results in increased concentrations of adenosine at sites of 
adenosine formation only. Nucleoside transport inhibitors might circumvent the problems 
that are associated with intravenous adenosine to induce adenosine receptor-mediated 
cardioprotection. Additionally, it can be used to study the possible effects of 
endogenously formed adenosine. 
In vitro studies have shown a dual action of adenosine-5 'triphosphate (ATP) on 
the vessel wall: an endothelium-dependent vasodilator response and an endothelium-
independent vasoconstrictor response. Based on studies with stable ATP analogues, at 
least two distinct ATP receptors (Pj-purinergic receptors) are assumed to exist on the 
outer cell membrane: the P2y-purinergic receptor (on endothelial cells) and the P2x-
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punnergic receptor (on vascular smooth muscle cells), mediating vasodilation and 
vasoconstriction, respectively 
An increasing amount of in vitro studies show an ATP-dependent component in 
the sympathetic nervous system-induced vasoconstriction. Based on these observations, 
Bumstock hypothesized that ATP is a cotransmitter in the sympathetic nervous system, 
which induces vasoconstriction and which, after breakdown to adenosine, inhibits 
norepinephrine release presynaptically (see figure 1 of chapter 1). 
Apart from the sympathetic nervous system, extracellular ATP originates from 
aggregating thrombocytes. Endothelial damage, like in coronary atherosclerosis, promotes 
thrombocyte aggregation with subsequent ATP release In the absence of a functionally 
intact endothelium, ATP-evoked vasoconstriction may contribute to vasospasm and to 
induction of acute myocardial infarction. Therefore, demonstration of this dual action of 
ATP in humans would be of pathophysiological importance 
In this thesis, the role of adenosine and ATP in the regulation of vascular tone is 
investigated. In most of the described experiments, we used the perfused forearm 
technique to quantify vascular reactivity to vasoactive substances in vivo The brachial 
artery is cannulated for infusion of vasoactive substances The forearm vascular response 
is quantified by strain gauge plethysmography a method that accurately measures changes 
in blood flow. 
RESULTS AND DISCUSSION 
In chapter 2 and 3, the hemodynamic, neurohumoral and respiratory effects of the 
nucleoside transport inhibitor draflazine are characterized A double blind placebo-
controlled randomized cross-over trial was performed in twelve healthy male volunteers. 
Intravenous infusion of draflazine at dosages of 1 mg or higher, elicited the classical 
response as observed during intravenous adenosine infusion. Heart rate appeared to be the 
most sensitive marker of systemic effects. Forearm vascular tone was not affected by 
systemic nucleoside transport inhibition. All systemic effects of draflazine could 
significantly be antagonized by caffeine, indicating the involvement of P,-punnergic 
receptor stimulation After intravenous infusion of 0 5 mg draflazine, a dosage that did 
not elicit any systemic effect, the forearm vasodilator response to intra-arterially infused 
adenosine could still be potentiated, suggesting that low grade nucleoside transport 
inhibition is a feasable tool to potentiate adenosine-mediated cardioprotection in humans. 
Ex vivo nucleoside transport inhibition was used to quantify the grade of nucleoside 
transport inhibition. Before and after the infusion of draflazine, blood is collected to 
measure the rate of adenosine uptake by erythrocytes. Since erythrocyte membranes 
contain the draflazine sensitive nucleoside transporter, the ex vivo transport inhibition of 
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applied adenosine might reflect nucleoside transport inhibition in vivo. This assumption is 
supported by our observation that ex vivo nucleoside transport inhibition was significantly 
correlated with both whole blood draflazine concentration and the heart rate response to 
draflazine. No effect on heart rate was observed at levels of ex vivo nucleoside transport 
inhibition of 50% and lower. 
Thus, high grade nucleoside transport inhibition revealed the continuous formation 
of extracellular adenosine in healthy volunteers. Where is this endogenous adenosine 
produced and what is the physiological importance of this endogenous adenosine? Based 
on in vitro studies, we speculated that there are at least two potential sources of endoge-
nous adenosine: the endothelium and the sympathetic nervous system (see chapter 1, 
figure 1). Furthermore, we hypothesized that adenosine, as derived from sympathetic 
nerve endings (after breakdown of the cotransmitter ATP) inhibits norepinephrine release 
by stimulating presynaptic adenosine receptors. 
Two experiments were performed to get some answers to these fundamental 
questions (chapter 4). First, in ten healthy male volunteers draflazine was infused in the 
brachial artery at five increasing dosages. The intra-arterial route of administration was 
chosen to prevent the systemic effects that are associated with intravenous draflazine 
infusion. Forearm vascular resistance did not significantly change at levels of ex vivo 
nucleoside transport inhibition of 40% and lower. High graded locally induced nucleoside 
transport inhibition evoked a small vasodilator response. Although the physiological 
significance of this small vasodilator response (as compared with the effect of 
intraarterially infused adenosine) is uncertain, it indicates the local production of extracel-
lular adenosine in the forearm during baseline conditions. Second, in 25 healthy male 
subjects the effect of 250 ng draflazine/100 ml forearm/min was studied on forearm 
norepinephrine release at baseline conditions and during stimulation of the sympathetic 
nervous system using lower body negative pressure (LBNP). Both local (forearm) and 
systemic norepinephrine release were quantified using a tracer technique. Baseline 
forearm norepinephrine release increased during local draflazine infusion. In contrast, the 
LBNP-induced stimulation of forearm norepinephrine release was reduced during intra-
arterial infusion of draflazine. Systemic norepinephrine release was not affected by local 
draflazine infusion, indicating that the effects on forearm norepinephrine release were 
probably specifically related to the infusion of draflazine. The findings support the 
assumption that the formation of endogenous adenosine is increased during activation of 
the sympathetic nervous system, resulting in presynaptic inhibition of norepinephrine 
release. The increased baseline norepinephrine appearance rate can be explained by assu-
ming an increased firing rate of sympathetic nerves in the infused forearm in response to 
local forearm afferent nerve stimulation (see figure 3 of chapter 4). 
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In the next four chapters, the interaction between endothelium and purines are 
studied m more detail To study the involvement of nitric oxide in ATP and adenosine-
mediated forearm vasodilation we first performed a pilot study to find a dosage of L-
NMMA that was able to antagonize the vasodilator response to acetylcholine, a well 
known NO-dependent vasodilator During this process, we observed that methacholine, a 
muscarinic receptor agonist that was used frequently in our laboratory as a substitute for 
the more labile acetylcholine, induced a forearm vasodilation that could not be inhibited 
by L-NMMA, suggesting a differential contribution of NO to acetylcholine and 
methachohne-induced vasodilation (chapter 5) This observation is supported by the 
results of Chowienczyk et al [382] but contrasts with the findings of Bruning et al who 
were able to antagonize methacholine-induced vasodilation with concomitant L-NMMA 
infusion [383] These contrasting observations that became available to us after 
publication of our results will be discussed in perspective of the results of later 
experiments with L-NMMA (see below) 
In chapter 6, experiments are described that were performed to characterize the 
forearm vasodilator response to ATP The main purpose of these studies was to 
demonstrate a dual action of ATP on vascular tone (see above) First, the involvement of 
Ρ,-punnergic receptor stimulation in ATP-induced forearm vasodilation was investigated 
ATP appeared to induce much more vasodilation than equimolar dosages of adenosine 
Furthermore, the Ρ,-punnergic receptor antagonist theophylline could not antagonize 
ATP-induced vasodilation indicating that P,-purinergic receptor stimulation does not occur 
during intra-arterial infusion ot ATP Second, we tried to inhibit the ATP-induced 
vasodilator response by co-intusion with L-NMMA ATP induced vasodilation was not 
antagonized by L-NMMA suggesting that NO is not involved in the forearm vasodilator 
response to ATP The L-NMMA-induced vasoconstriction appeared to depend on the type 
of vasodilator substance that was infused 50 minutes prior to L-NMMA infusion After 
acetylcholine pretreatment, a substance that stimulates NO-synthase in the human 
forearm, L-NMMA-induced forearm vasoconstriction was significantly more pronounced 
than after sodium nitroprusside (SNP, a NO donor without a stimulating effect on NO 
synthase) or ATP pretreatment Probably, this pretreatment effect is caused by prolonged 
NO-synthase activation after acetylcholine infusion Interestingly, forearm blood flow had 
returned to baseline levels prior to L-NMMA infusion suggesting that other (endothelial9) 
factors counterbalanced the increased NO formation The similarity between SNP and 
ATP pretreatment with respect to L-NMMA-induced vasoconstriction further supports our 
conclusion that ATP-induced forearm vasodilation is not mediated by NO Third, we tried 
to overrule the vasodilator response to ATP by infusing extremely high dosages of ATP 
Based on in vitro data, we expected to find a reduced vasodilator response during infusion 
of the highest ATP dosages because of concomitant P2x-punnergic receptor activation 
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and/or release of endothelium-denved contracting factors. However, even at very high 
dosages the ATP-induced vasodilator response was not reduced. Endothelial 
metabolization of ATP, preventing luminally applied ATP from reaching the putative P2x-
purinergic receptor on vascular smooth muscle cells, probably explains our failure to 
demonstrate the existence of P2,-purinergic receptors in the forearm vascular bed. 
Urged by the previously mentioned conflicting results with respect to the 
interaction between L-NMMA and methacholine, we decided to reanalyse our data by 
comparing the vascular effects of acetylcholine, methacholine and sodium nitroprusside, 
focusing on the effect of vasodilator pretreatment on L-NMMA-induced vasoconstriction 
(Table 1). This analysis revealed a similar behaviour of acetylcholine and methacholine, 
indicating that both compounds are able to increase NO-synthase activity which is in 
agreement with the results of Bruning et al. [383]. However, we were not able to show 
an effect of L-NMMA on methacholine-induced vasodilation while Bruning et al. 
observed similar effects of L-NMMA on acetylcholine and methacholine-induced 
vasodilation. These conflicting observations are probably due to differences in the way 
that results were expressed. Bruning et al. calculated plasma drug concentrations from 
infusion rate and plasma flow, in order to correct for L-NMMA-induced reduction in 
baseline blood fow and subsequent effect on plasma drug concentrations by reduced 
dilution. This method assumes that local degradation of the infused drug is not affected by 
blood flow. However, this assumption is probably not true for labile substances like 
acetylcholine, ATP and SNP. For example, for ATP it has been reported that local 
degradation is augmented when flow is reduced [384]. Assuming the same effect of blood 
flow on degradation of acetylcholine in the forearm, the effect of a reduced dilution on 
final plasma acetylcholine concentration during L-NMMA infusion will (partially) be 
counterbalanced by an increased degradation. 
TABLE 1: Effect of L-NMMA on baseline forearm vascular resistance in the infused arm (mean±SE) 
Vasodilator 
pretreatment 
ACh 
MCh 
SNP 
Number of 
10 
6 
6 
subjects' 
Baseline 
FVR (AU) 
5 9 ± l l 
51 ± 10 
59±8 
% Rise in FVR to 
first 
L-NMMA infusion 
64±13* 
37± 16 
33±11* 
% Rise in FVR to 
second 
L-NMMA infusion 
95±17*# 
86±I4*# 
4I±7* 
L-NMMA indicates N^-monomethyl-L-arginine; ACh, acetylcholine; SNP, sodium nitroprusside; MCh, 
methacholine; and FVR, forearm vascular resistance. *, Statistically significant difference from baseline 
(P<0.05); It, Statistically significant difference from SNP group (P<0.05). In the control arm, FVR was 
not significantly affected by the drug infusions. For description of statistical analysis: see chapter 6. 
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Methacholine is less affected by degradation Therefore, Bruning et al have probably 
overestimated the effect of L-NMMA on acetylcholine-induced vasodilation, whereas we 
have underestimated the etrect ot L-NMMA on methachohne-induced vasodilation The 
advantage of the analysis as performed in table 1 is that baseline vascular tone was 
similar for the three groups Although this analysis indicates that both acetylcholine and 
methacholine are able to stimulate NO-synthase, it does not exclude a possible difference 
in vasodilator mechanism between the two compounds Further research is needed to 
address this question 
In chapter 7, the involvement of NO in the adenosine-mediated forearm 
vasodilator response was investigated L-NMMA significantly inhibited the adenosine-
induced vasodilator response indicating that this effect ot luminally applied adenosine is 
(partially) mediated by endothelial NO-synthase activation and subsequent NO formation 
Furthermore, the role of potassium channels in adenosine-induced forearm vasodilation 
was explored using tolbutamide and quinidine as potassium channel blockers Tolbutamide 
did not affect the vasodilator response to adenosine, indicating that ATP-dependent 
potassium channels are probably not involved in the vasodilator response to luminally 
applied adenosine Using quinidine, a less selective potassium channel blocker, similar 
results were obtained 
A reduced responsiveness to adenosine would be ot disadvantage during ischemia. 
In animal models ot insulin-dependent diabetes mellitus, a reduced adenosine-induced 
vasodilator response has been observed in the coronary vascular bed Since diabetes 
mellitus is an independent risk tactor tor cardiovascular disease, an impaired 
responsiveness to adenosine may be ot clinical interest Therefore, we evaluated the 
vasodilator response to adenosine in uncomplicated insulin-dependent diabetes mellitus 
and compared these observations with an age-matched control group (chapter 8) The 
forearm vasodilator response was not reduced in the patients with diabetes mellitus The 
difference between the animal data and our results can probably be explained by differen-
ces in insulin concentration in animal studies, a reduced responsiveness to adenosine was 
only observed in uisulinopenic animals while in our patient group high insulin concentra-
tions were measured in peripheral blood samples 
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CONCLUSIONS 
1. Systemic high grade nucleoside transport inhibition (ex vivo nucleoside transport 
inhibition > 50%) induces a dose-dependent increase in heart rate, systolic blood 
pressure, plasma catecholamine concentration and respiration The P,-punnergic 
receptor antagonist caffeine antagonizes the neurohumoral and hemodynamic 
effects indicating the involvement of adenosine receptor stimulation. 
2. Systemic low grade nucleoside transport inhibition augments the forearm vasodila-
tor response to intra-arterially infused adenosine without inducing systemic effects 
suggesting that low grade nucleoside transport inhibition is a feasable tool to 
potentiate the cardioprotective effects of endogenous adenosine. 
3 In contrast to systemic high grade nucleoside transport inhibition, forearm 
inhibition of nucleoside transport evokes a local vasodilator response, 
demonstrating counteracting systemic and local effects of endogenous adenosine 
4 Local low grade nucleoside transport inhibition in the forearm increases baseline 
forearm norepinephrine release probably by activation of forearm afferent nerve 
endings and subsequent stimulation of forearm sympathetic firing rate. In contrast, 
low grade nucleoside transport inhibition reduces the increase in forearm 
norepinephrine release in response to activation of the sympathetic nervous system 
supporting the hypothesis that endogenous adenosine inhibits norepinephrine 
release from sympathetic nerve endings in humans 
5. In healthy volunteers, local ATP infusion induces a dose-dependent forearm 
vasodilator response Vasodilation already occurs in the nanomolar range and is 
not reduced during infusion of extremely high ATP dosages 
6 Adenosine- but not ATP-induced forearm vasodilation is mediated by nitric oxide. 
7. The forearm vasodilator response to adenosine is preserved in patients with 
uncomplicated insulin-dependent diabetes mellitus who are treated with insulin. 
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Samenvatting en conclusies 
Door middel van m vitro en in vivo experimenten met dieren, heeft men aange-
toond dat adenosine vaatverwijding induceert, de afgifte van noradrenaline door sympathi-
sche zenuwuiteinden remt via een präsynaptisch mechanisme en tevens in staat is om de 
hartfrequentie te verlagen, de prikkelgeleiding in het hart te vertragen en de contractie-
kracht van het hart te verminderen Deze effecten van adenosine worden gemedieerd door 
stimulatie van adenosinereceptoren (P,-punnerge receptoren), gelokaliseerd op de 
celmembraan. BIJ dieren die onder narcose zijn gebracht, treden deze effecten zowel na 
locale (artenele) als systemische (veneuze) toediening van adenosine op 
Dierexperimenteeel onderzoek heeft aangetoond dat adenosine een beschermend 
effect heeft ten aanzien van myocardischemie, zowel door het verlagen van de kans op 
hartntmestoornissen als door het reduceren van de infarctgrootte. Endogeen adenosine 
wordt een belangrijke rol toegedacht in 'ischemic preconditioning' Ischemic preconditio-
ning wordt gedefinieerd als een toegenomen tolerantie van het hartspierweefsel voor de 
gevolgen van langdurige afsluiting van een kransslagader door een eerdere kortdurende 
blootstelling aan ischemie en reperfusie. Het uitbuiten van de cardioprotective eigen-
schappen van adenosine bij de mens zou van groot therapeuthisch nut kunnen zijn. 
Helaas geeft intraveneus toegediend adenosine bij mensen, die niet onder invloed 
zijn van anesthetica, aanleiding tot een stijging van bloeddruk, hartfrequentie, plasma-
catecholamineconcentratie en ademtrequentie. Deze systemische effecten van adenosine 
zijn potentieel schadelijk voor patiënten met een ischemische hartziekte. Men veronder-
stelt dat deze eltecten worden teweeggebracht door stimulatie van afferente zenuwvezels 
leidend tot stimulatie van het sympathisch zenuwstelsel. In tegenstelling tot deze systemi-
sche effecten van adenosine, geeft lokale infusie van deze stof in de armslagader of een 
kransslagader aanleiding tot lokale vaatverwijding en vermindert het de vasoconstictieve 
werking van het sympathisch zenuwstelsel. Bij de mens worden zowel de systemische als 
de lokale effecten van adenosine veroorzaakt door stimulatie van specifieke adenosinere-
ceptoren. Deze effecten kunnen worden geantagoneerd door adenosinereceptorantagoms-
ten zoals theophylline en Coffeine 
Extracellulair adenosine wordt snel opgenomen door diverse celtypen zoals 
endotheelcellen, gladde spiercellen en rode bloedcellen. De opname van adenosine wordt 
versneld door een proces van gefacihteerde diffusie en kan worden geremd door nucleosi-
detransportremmers zoals dipyndamol en draflazine. Remming van het nucleosidetrans-
port leidt alleen tot verhoging van de adenosineconcentratie op die plaatsen waar 
adenosine ook gevormd wordt. Hierdoor is het wellicht mogelijk om het cardioprotectief 
effect van adenosine te versterken zonder gehinderd te worden door de problemen die 
verbonden zijn aan het systemisch toedienen van adenosine of adenosine-analogen. 
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Daarnaast kunnen nucleosidetransportremmers gebruikt worden om de mogelijke effecten 
van endogeen gevormd adenosine te bestuderen. 
In vitro onderzoek heeft aan het licht gebracht dat adenosine-5'-trifosfaat (ATP) 
twee tegengestelde effecten heeft op de vaatwand: een vaatverwijdend effect dat teweeg 
wordt gebracht met tussenkomst van het endotheel (dit is de één cellaag dikke binnenbe-
kleding van een bloedvat) en een vasoconstnctief effect dat ontstaat wanneer ATP direkt 
in kan werken op de gladde spiercellen van de vaatwand. Op basis van studies met 
stabiele ATP-analogen wordt verondersteld dat er tenminste twee verschillende ATP 
receptoren (P2-punnerge receptoren) in de vaatwand aanwezig zijn: de P2y-punnerge 
receptor (op endotheelcellen) en de PN-punnerge receptor (op de gladde spiercellen van 
de vaatwand) die na stimulatie respectievelijk vaatverwijding en vaatvernauwing veroorza-
ken. 
Een toenemend aantal studies laat zien dat ATP een rol speelt in de regulatie van 
de vaattonus door het sympathisch zenuwstelsel. Op basis van deze studies, postuleerde 
Burnstock dal ATP een rol speelt als cotransmitter in het sympathisch zenuwstelsel. 
Hieronder wordt verstaan dat naast noradrenaline ook ATP door de zenuwuiteinden van 
het sympathisch zenuwstelsel wordt afgegeven. Dit ATP induceert in de vaatwand 
vasoconstnctie en remt, na afbraak tot adenosine, presynaptisch de afgifte van noradrena-
line (zie figuur 1 van hoofdstuk 1). 
Behalve uit het sympathisch zenuwstelsel, komt ATP ook vrij uit aggregerende 
thrombocytes Beschadiging van endotheel, zoals bij athérosclérose in coronair artenen, 
bevordert thrombocytenaggregatie resulterend in afgifte van ATP. In afwezigheid van een 
functioneel intact endotheel, zou dit ATP vasoconstnctie teweeg kunnen brengen die zou 
kunnen bijdragen aan vasospasme en inductie van een hartinfarct Daarom zou het 
aantonen van het tweeledig effect van ATP op de vaatwand bij de mens van groot 
pathofysiologisch belang kunnen zijn 
In dit proefschrift wordt de betekenis onderzocht van adenosine en ATP voor de 
regulatie van de vaattonus. In de meeste experimenten die in dit boek beschreven worden, 
wordt gebruik gemaakt van het 'onderarmsmodel' om de vasculaire reactiviteit van 
vasoactieve stoffen in vivo te kunnen kwantificeren. De onderarmsslagader (a. brachialis) 
wordt bij deze methode gecannuleerd voor infusie van vasoactieve stoffen. De vasculaire 
respons in de onderarm wordt gekwantificeerd met behulp van kwiktouwtjes plethysmo-
grafie: een methode waarmee nauwkeurig veranderingen in bloeddoorstroming kunnen 
worden vastgelegd. 
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RESULTATEN EN DISCUSSIE 
In hoofdstuk 2 en 3 worden de hemodynamische, neurohumorale en ventilatoire 
effecten van draflazine gekarakteriseerd. Een dubbelblind, placebo-gecontroleerd en 
gerandomiseerd cross-over experiment werd uitgevoerd bij twaalf gezonde mannelijke 
vrijwilligers. Intraveneuze infusie van draflazine in een dosering van 1 mg of hoger, gaf 
aanleiding tot een klassieke respons zoals die in het verleden ook werd gezien na 
toediening van adenosine. De hartfrequentie bleek de meest gevoelige parameter om 
systemische effecten te detecteren. De vaattonus in de onderarm werd door systemische 
nucleosidetransportremming niet beïnvloed. Voorbehandeling met Coffeine antagoneerde 
alle systemische effecten van draflazine, wijzend op de betrokkenheid van Ρ,-purinerge 
receptorstimulatie. Na de intraveneuze toediening van 0,5 mg draflazine, een dosering die 
niet leidde tot systemische effecten, kon het vaatverwijdend effect van intra-arteriëel 
toegediend adenosine in de onderarm nog steeds worden versterkt. Dit suggereert dat 
geringe remming van het nucleosidetransportsysteem het cardioprotectief effect van 
adenosine bij de mens zou kunnen potentiëren. 
Ex vivo metingen werden gebruikt om de mate van nucleosidetransportremming te 
kwantificeren. Voor en na draflazine-infusie werd bloed afgenomen om de snelheid te 
meten waarmee adenosine wordt opgenomen door erythrocytes Aangezien het membraan 
van erythrocyten de draflazine-gevoelige nucleosidetransporter bevat, is ex vivo transport-
remming van toegediend adenosine wellicht een weerspiegeling van de mate van nucleosi-
detransportremming in vivo. Deze veronderstelling wordt ondersteund door onze 
observatie dat ex vivo resultaten correleren met zowel de draflazineconcentratie in bloed 
alsook met de stijging van de hartfrequentie die optreedt na toediening van draflazine. De 
hartfrequentie werd niet door draflazine beïnvloed zolang de ex vivo nucleosidetransport-
remming onder de 50% bleef. 
Bovenstaande experimenten brachten aan het licht dat bij gezonde vrijwilligers 
continu extracellulair adenosine wordt gevormd. Waar wordt dit adenosine geproduceerd 
en wal is de fysiologische betekenis van dit endogeen adenosine? Gebaseerd op in vitro 
onderzoek, speculeerden we dat er tenminste twee mogelijke bronnen van endogeen 
adenosine beslaan: het endotheel en het sympathisch zenuwstelsel (zie hoofdstuk 1, figuur 
1). Vervolgens veronderstelden we dat adenosine, zoals dat afkomstig is uit sympathische 
zenuwuiteinden (na afbraak van de cotransmitter ATP) de noradrenaline-afgifte remt door 
stimulatie van presynaptische adenosinereceptoren. 
Twee experimenten werden uitgevoerd om antwoord te vinden op deze fundamen-
tele vragen (hoofdstuk 4). Ten eerste werden bij tien gezonde vrijwilligers vijf opklim-
mende doseringen draflazine in de a. brachialis geïnfundeerd. De intra-arteriële wijze van 
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toediening werd gekozen ter voorkoming van systemische effecten die verbonden zijn aan 
de systemische toediening van draflazine Tot het niveau van 40% lokale ex vivo 
nucleosidetransportremming (250 ng draflazine/100 ml onderarm/min) werd de vaatweer-
stand in de onderarm niet significant beïnvloed Sterkere remming van het nucleoside-
transport in de onderarm gaf aanleiding tot een geringe vaatverwijding In vergelijking 
met het effect van intra-arterieel toegediend adenosine, is het vaatverwijdend effect van 
nucleosidetransportremming slechts gering en de fysiologische betekenis ervan is 
onduidelijk Echter, het optreden van enige vaatverwijding toont wel aan dat er ook in de 
onderarm extracellulair adenosine wordt gevormd onder normale (= niet ischemische) 
condities In het tweede experiment, werd bij 25 gezonde mannelijke vrijwilligers het 
effect van 250 ng draflazine/100 ml onderarm/min bestudeerd op de afgifte van noradre-
naline in de onderarm onder basale condities en tijdens stimulatie van het sympathisch 
zenuwstelsel door het aanbrengen van een onderdruk om het onderlichaam (LBNP) 
Zowel de lokale (onderarm) als systemische noradrenaline-afgifte werden bepaald met 
behulp van een tracer-techmek De basale afgifte van noradrenaline in de onderarm nam 
roe tijdens de lokale intusie van draflazine Echter, de LBNP-geinduceerde toename van 
de noradrenaline afgifte in de onderarm nam af tijdens intra-arteriele toediening van 
draflazine De systemische noradrenaline-afgifte werd niet beïnvloed door de lokale'draf-
lazine' toediening, hetgeen aantoont dat de effecten op de afgifte van noradrenaline in de 
onderarm waarschijnlijk specifiek gerelateerd zijn aan de infusie van draflazine Deze 
bevindingen ondersteunen de veronderstelling dat de vorming van endogeen adenosine is 
toegenomen tijdens activatie van het sympathisch zenuwstelsel, resulterend in een 
presynaptische remming van de noradrenaline afgifte De toegenomen basale afgifte van 
noradrenaline kan worden verklaard door aan te nemen dat de vuurfrequentie van 
sympathische zenuwvezels in de geintundeerde onderarm is toegenomen ten gevolge van 
de stimulatie van lokale afterente zenuwvezels (zie figuur 3 van hoofdstuk 4) 
In de volgende vier hoofdstukken wordt de interaktie tussen endotheel en purines 
bestudeerd. We wilden de betekenis vaststellen van stikstofoxide (NO), een vaatverwij-
dende substantie die geproduceerd wordt door het endotheel, voor de vaatverwijding die 
tot stand komt onder invloed van ATP en adenosine Hiertoe werd eerst een pilot studie 
uitgevoerd om een dosering te vinden van de NO-synthase remmer L-NMMA, die in staat 
was om het vaatverwijdend effect van acetylcholine te verminderen Acetylcholine is 
namelijk het prototype NO-afhankelijke vaatverwijder Tijdens het uitvoeren van deze 
inleidende studie ontdekten we dat methacholine, een muscannereceptoragonist die 
regelmatig door onze onderzoeksgroep werd gebruikt als substituut voor het meer labiele 
acetylcholine, een vaatverwijding in de onderarm veroorzaakt die niet door L-NMMA 
geremd kon worden Deze bevinding suggereert dat de bijdrage van NO aan het vaatver-
wijdend effect van methacholine en acetylcholine verschilt voor deze twee stoffen 
150 
Samenvatting en conclusies 
(hoofdstuk 5) Deze observatie wordt ondersteund door de bevindingen van Chowienczyk 
et al. [382] maar verschilt van de resultaten van Bruning et al. die in staat waren om ook 
het vaatverwijdend effect van methacholine te remmen met behulp van L-NMMA-infusie 
[383]. Deze tegengestelde observaties, die voor ons beschikbaar kwamen na publicatie 
van onze resultaten, zullen worden bediscussieerd in het licht van de resultaten van onze 
latere experimenten met L-NMMA (zie onder). 
In hoofdstuk 6 worden de experimenten beschreven die werden uitgevoerd om het 
vaatverwijdend effect van ATP in de onderarm te typeren De belangrijkste doelstelling 
van deze experimenten was het aantonen van een tweeledig effect van ATP op de 
vaattonus (zie boven) Ten eerste werd de betekenis van Ρ,-purinerge receptorstimulatie 
voor de ATP-geinduceerde vaatverwijding in de onderarm vastgesteld. ATP bleek een 
veel sterker vaatverwijding te induceren dan equi molaire adenosinedosenngen Verder 
bleek dat de Ρ,-purinerge receptorantagonist theophylline de ATP-geinduceerde vaatver­
wijding niet kon antagoneren Deze resultaten tonen aan dat tijdens intra-arteriele 
toediening van ATP geen stimulatie optreedt van P,-punnerge receptoren. Vervolgens 
probeerden we de ATP-geiduceerde vaatverwijding te remmen met gelijktijdige infusie 
van L-NMMA. De ATP-geinduceerde vaatverwijding werd niet door L-NMMA geantago-
neerd Dit suggereert dat NO niet is betrokken m het vaatverwijdend effect van ATP. De 
L-NMMA-geinduceerde vasoconstnctie bleek afhankelijk te zijn van het type vaatverwij-
der dat 50 minuten voor de L-NMMA infusie werd geinfundeerd Na voorbehandeling 
met acetylcholine, een stof die NO-synthase stimuleert in de onderarm, was de L-
NMMA-geinduceerde vasoconstnctie significant sterker dan na voorbehandeling met 
natrium nitroprusside (SNP, een NO donor zonder stimulerend effect op NO-synthase) of 
voorbehandeling met ATP. Waarschijnlijk wordt dit effect van voorbehandeling veroor­
zaakt door aanhoudende activatie van NO-synthase na acetylcholine-infusie. Interessant is 
dat de onderarmsdoorbloeding was teruggekeerd naar het uitgangsniveau voordat L-
NMMA werd geinfundeeerd Dit suggereert dat andere (endotheliale9) factoren het effect 
van toegenomen NO-produktie tegenwerken De overeenkomst tussen SNP- en ATP-
voorbehandeling op de L-NMMA-geinduceerde vasoconstnctie ondersteunt onze conclusie 
dat NO niet is betrokken in de ATP-geinduceerde vaatverwijding Tenslotte probeerden 
we het vaatverwijdend effect van ATP te reduceren door infusie van extreem hoge 
doseringen ATP. Gebaseerd op de resultaten van m vitro experimenten, verwachtten we 
een gereduceerde vaatverwijding te vinden tijdens infusie van de hoogste ATP-dosenngen 
vanwege gelijktijdige activatie van P24-punnerge receptoren en/of afgifte van endotheliale 
vasoconstrictive factoren Echter, zelfs tijdens infusie van zeer hoge ATP-dosenngen 
was het vaatverwijdend eftect niet gereduceerd. De afbraak van ATP door het endotheel 
voorkomt dat luminaal toegediend ATP de veronderstelde P2,-purmerge receptor op 
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gladde spiercellen bereikt en dit verklaart waarschijnlijk waarom wij niet in staat waren 
om het bestaan van P2x-punnerge receptoren in het vaatbed van de onderarm aan te tonen 
Aangespoord door de eerder genoemde tegengestelde resultaten met betrekking tot 
de interaktie tussen L-NMMA en methachohne, besloten we onze gegevens opnieuw te 
analyseren door de vasculaire effecten van acetylcholine, methachohne en natrium 
nitroprusside met elkaar te vergelijken waarbij we ons concentreerden op het effect van 
voorbehandeling met deze vaatverwijdende stoffen op het vasoconstnctief effect van L-
NMMA (tabel 1) Deze analyse bracht aan het licht dat het vasoconstnctief effect van L-
NMMA na voorbehandeling met methachohne niet significant verschilt met het effect van 
L-NMMA na voorbehandeling met acetylcholine Deze bevinding wijst erop dat beide 
stoffen in staat zijn tot activatie van NO-synthase hetgeen overeenstemt met de gegevens 
van Brumng et al [383] Hoe is dan het verschil tussen beide studies te verklaren voor 
wat betreft het effect van L-NMMA op de methacholine-geinduceerde vaatverwijding'* 
Waarschijnlijk wordt dit verschil verklaard door een verschil in de wijze waarop de 
resultaten worden gepresenteerd Brumng et al berekenden plasmaconcentraties van 
acetylcholine en methacholine op basis van infusiesnelheid en bloeddoorstroming (plasma 
flow) Zij deden dit om te corrigeren voor het effect van L-NMMA op de uitgangsflow 
waardoor de concentratie van de vaatverwijdende stof in de bloedbaan wordt beïnvloed (er 
treedt minder verdunning op) Daarbij veronderstelt men dat de afbraak van de geinfun-
deerde stof in de onderarm niet wordt beïnvloed door de stroomsnelheid van het bloed 
Echter, deze aanname is, met name voor labiele stoffen zoals acetylcholine, ATP en SNP, 
waarschijnlijk niet juist Bijvoorbeeld, voor ATP is beschreven dat lokaal meer ATP 
wordt afgebroken wanneer de doorbloeding afneemt [384] Wanneer we een zelfde effect 
van de doorbloeding veronderstellen op de lokale afbraak van acetylcholine, dan zal, 
onder invloed van L NMMA, het effect van de verminderde verdunning op de uiteindelij-
ke acetylcholineconcentratie (gedeeltelijk) worden tegengegaan door de toegenomen 
afbraak Aangezien methachohne stabieler is dan acetylcholine, wordt de uiteindelijke 
concentratie van methachohne minder door degradatie beïnvloed Hierdoor hebben 
Brumng et al het ettect van L-NMMA op de acetylcholine-geinduceerde vaatverwijding 
waarschijnlijk overschat, terwijl wij het effect van L-NMMA op de methacholine-
geinduceerde vaatverwijding hebben onderschat Het voordeel van de analyse zoals 
beschreven in tabel 1 is dat de uitgangswaarde van de onderarmsdoorbloeding gelijk was 
voor de drie groepen Hoewel deze analyse aantoont dat zowel methachohne als acetyl-
choline de produktie van NO stimuleren, kan niet worden uitgesloten dat het vaatverwij-
dend mechanisme verschillend is voor deze twee stoften Er is meer onderzoek nodig om 
deze vraag te kunnen beantwoorden 
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TABEL 1: Ettect van L-NMMA op de vaatweerstand van de geïnfundeerde onderarm (gemiddelde ± SE) 
Vaatverwijder % Staging in FVR % Stijging in FVR 
waarmee werd Uitgangs ti|dens eerste li|dens tweede 
voorbehandeld Aantal proefpersonen FVR (AU) L-NMMA infusie L-NMMA infusie 
ACh 10 59 ±11 64 ±13* 95±I7*# 
MCh 6 51 ±10 37± 16 86±14*# 
SNP 6 59±8 33±11* 41±7* 
L-NMMA betekent Nl--monomelhyl-L-arginine; ACh, acetylcholine; MCh, methacholine; SNP, natrium 
nitroprusside; en FVR. onderarm;· vaatweerstand. *, Statistisch significant verschil met uitgangswaarde 
(P<0.05); #, Statistisch significant verschil met SNP groep (P<0.05). In de controle arm werd de FVR 
niet significant beïnvloed door de infusie van vasoactieve stoften. Voor een beschri|ving van de statistische 
analyse: zie hoofdstuk 6. 
In hoofdstuk 7 werd de rol van NO in de adenosine-geïnduceerde vaatverwijding 
onderzocht. L-NMMA remde het vaatverwijdend effect van adenosine. Dit betekent dat 
het vaatverwijdend effect van luminaal aangeboden adenosine (gedeeltelijk) wordt 
gemediëerd door activatie van NO-synthase waardoor het endotheel meer NO gaat 
afgeven. Tevens werd de rol van kaliumkanalen in de adenosine-geïnduceerde vaatverwij-
ding bestudeerd met behulp van de kaliumkanaal-blokkerende middelen tolbutamide en 
kinidine. Tolbutamide had geen effect op de vaatverwijding tijdens adenosineinfusie. 
ATP-afhankelijke kaliumkanalen spelen dus waarschijnlijk geen rol in het vaatverwijdend 
effect van luminaal aangeboden adenosine. Met kinidine, een minder selectief kaliumka-
naal-blokkerend middel, werden vergelijkbare resultaten verkregen. 
Een verminderde respons op adenosine zou nadelig kunnen zijn tijdens ischemic 
In diermodellen van insuline-afhankelijke diabetes mellitus is een verminderd vaatverwij-
dend effect van adenosine in de coronairvaten gevonden. Aangezien diabetes mellitus een 
onafhankelijke risikofaktor is voor het krijgen van hart- en vaatziekten, zou een vermin-
derde gevoeligheid voor adenosine bij de mens van klinische betekenis kunnen zijn. 
Daarom evalueerden we het vaatverwijdend effect van adenosine bij patiënten met 
ongecompliceerde insuline-afhankelijke diabetes mellitus en vergeleken we de resultaten 
met een leeftijd-gewogen controlegroep (hoofdstuk 8). Het vaatverwijdend effect van 
adenosine in de onderarm was bij de patiënten met suikerziekte níet verminderd. Het 
verschil tussen de dierexperimentele gegevens en onze resultaten kan waarschijnlijk 
worden verklaard door verschillen in insulineconcentratie: in de dierexperimentele studies 
werd een verminderde gevoeligheid voor adenosine alleen vastgesteld bij insulinopene 
dieren terwijl in onze patiëntengroep hoge insulineconcentraties werden gemeten in 
perifere bloedmonsters. 
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CONCLUSIES 
1. Een hoge mate van systemische nucleosidetransportremming (ex vivo nucleoside-
transportremming > 50%) induceert een dosis-afhankelijke verhoging in hartfre-
quentie, systolische bloeddruk, plasmacatecholamineconcentratie en ventilatie. De 
P|-purinerge receptorantagonist Coffeine antagoneert de neurohumorale en hemody-
namische effecten, hetgeen de betrokkenheid van adenosinereceptorstimulatie 
aantoont. 
2. Systemische matige nucleosidetransportremming versterkt het effect van intra-
arteneel toegediend adenosine op de onderarmsdoorbloeding. 
3. In tegenstelling tot systemische nucleosidetransportremming, induceert lokale 
remming van het nucleosidetransport in de onderarm een lokale vaatverwijdende 
respons. Dit toont aan dat de lokale effecten worden tegengewerkt door de 
systemische effecten van endogeen adenosine. 
4. Wanneer een matige nucleosidetransportremming lokaal in de onderarm wordt 
toegepast, dan blijkt de basale afgifte van noradrenaline in de onderarm toe te 
nemen. Dit etteci ontstaat waarschijnlijk door lokale activatie van afferente 
zenuwvezels resulterend in een toename van de vuurfrequentie van efferente 
sympathische zenuwvezels in de onderarm. Hier staat tegenover dat matige 
nucleosidetransportremming in de onderarm de toename van noradrenaline-afgifte 
onder invloed van activatie van het sympathisch zenuwstelsel vermindert Deze 
bevinding ondersteunt de hypothese dat endogeen adenosine de afgifte van 
noradrenaline door sympathische zenuwuitemden bij de mens remt 
5. Bij gezonde vrijwilligers induceert lokale ATP infusie een vaatverwijdend effect 
dat al optreedt bij ATP concentraties in het nanoinolaire bereik Deze vaatverwij-
ding is niet verminderd tijdens infusie van extreem hoge doseringen ATP 
6 Adenosine- maar niet ATP-geinduceerde vaatverwijding in de onderarm wordt 
gemedieerd door stikstofoxide (NO). 
7. Het effect van adenosine op de doorbloeding van de onderarm blijft in stand bij 
patiënten met ongecompliceerde insuline-afhankelijke diabetes mellitus die 
behandeld worden met insulme-injecties 
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Dankwoord 
Velen hebben aan de totstandkoming van dit proefschrift bijgedragen. Graag maak ik van 
deze gelegenheid gebruik om hen hiervoor te bedanken. 
Alle vrijwilligers: sommigen waren bereid om zelfs 9 maal de koffie voor 24 uur te laten 
staan en steeds weer prompt op tijd naar het ziekenhuis te komen om zich voor enkele 
uren aan slangen en electroden te laten binden. Jullie inzet was voor mij zeer motiverend! 
Wilhbrord Hoefnagels, bij jou heb ik als keuzevakker mijn eerste schreden als 
onderzoeker gezet Je hebt me gemotiveerd om verder te gaan 'in het onderzoek' en je 
wist me ervan te overtuigen dat dit met ten koste hoeft te gaan van mijn klinische 
vorming. Eugenie Olde Riekennk- dankzij jou was de 'klinische fysiologie' een plaats 
waar ik me thuis voelde Je zorgde altijd voor een kop koffie, ondanks soms grote drukte. 
Achter de schermen zorgde je ervoor dat de schappen altijd gevuld waren met alles wat 
nodig was om de experimenten soepel te laten verlopen. Dankzij je gastvrijheid waren de 
vrijwilligers bereid om terug te komen voor nóg een meting Zonder jou had ik het 
onderzoek dat in hoofdstuk 2 wordt beschreven, nooit dubbelblind kunnen uitvoeren 
Dankzij je assistentie kon 'de eerste meting' ook altijd in de statistische analyse betrokken 
worden. Marie Cecile Jacobs: samen hebben we heel wat 'ups en downs' van het doen 
van onderzoek beleefd. De frustratie van het mispnkken, van de vrijwilligers die zich niet 
afmelden, van het 'kaken'.. . Je bleef altijd lachen. Joost den Arend: mede door jouw 
inzet heb ik nooit een meting hoeven afzeggen vanwege een technisch mankement. Jouw 
kennis van de computermarkt, zowel van software als hardware, heeft me enorm 
geholpen. Mark Massa: jouw 'flow programma' was essentieel voor het welslagen van de 
metingen aan de onderarm. Door jouw hulp bij de automatisering konden ook 
ingewikkelde protocollen tot een goed einde worden gebracht en werd de data-invoer 
kinderspel Jorgo Lambrou en Egidia van Ginneken· als keuzevakkers hebben jullie me 
een hoop werk uit handen genomen zodat ik in staat was om het grootste deel van dit 
proefschrift nog at te werken voordat mijn klinische opleiding begon. Matthijs 
Blankesteijn en Frans Rüssel, jullie gaven mij de benodigde kennis en programmatuur om 
de regressie-analyses van hoofdstuk 2 tot een goed einde te brengen. Ik heb veel geleerd 
van jullie kommentaar en discussies. Henk van Lier. vanaf mijn prilste begin in de 
wetenschap, heb je me begeleid in het oerwoud van statistiek. Het gaf me steeds een 
veilig gevoel dat ik ook in een latere fase van het onderzoek toch altijd op jou terug kon 
vallen voor raad en bijstand. Jacqueline de Graaf, Henne Kleinveld, Magda Hectors en 
Bas Bredie: samen met Matthijs vormden jullie de 'vaste kern' van de lunch-ploeg. Jullie 
gezelligheid vormde steeds een belangrijk rustpunt in een werkdag Mare Mol en Peter 
Bijlstra: als kamergenoten voelden we ons afwisselend typist, (toekomstig) nobelpnjswin-
naar en cabaretier. Wat hebben we samen veel gelachen! De overige leden van de 
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'circulatie-groep': Hub, Cor, Cees, Mane Louise, Paetrick, Frans, bedankt voor de 
collegiale werksfeer en de opbouwende kritiek tijdens de werkbesprekingen. Ronney de 
Abreu, John van Baal, Addy de Graaf, Irma Versieyen en Jenneke Gamtsen: dankzij 
jullie flexibiliteit en organisatievermogen konden de ingewikkelde adenosinebepahngen 
volgens de regels van de kunst verricht worden. Nooit deed ik tevergeefs een beroep op 
jullie. Dick Lozekoot, Betty van Raay en Leon Swinkels: met grote toewijding hebben 
jullie de cGMP, L-Citrulline en angiotensine II bepalingen verricht. Hoewel het resultaat 
van deze bepalingen niet was zoals we hadden gehoopt, heeft het zeker mijn inzicht in de 
fysiologie/biochemie vergroot. Het ontbreken van deze gegevens in dit proefschrift ligt 
zeker niet aan jullie. Sjaak Willemsen: jouw enthousiasme is spreekwoordelijk. Als 
'koning van de catecholaminebepaling' was je inzet een voorwaarde om de experimenten 
die beschreven worden in hoofdstuk 2 en 4, tot een succes te maken. Je betrokkenheid 
heeft de kwaliteit van het onderzoek zeker verhoogd Ita Baars: de snelheid en precisie 
waarmee JIJ Coffeine in plasma hebt bepaald is niet te evenaren. José Benneker: samen 
met je medewerkers van de afdeling klinische farmacie, zorgde je er steeds voor dat de 
benodigde L-NMMA ot acetylcholine op het juiste moment bereid waren. Herman Van 
Belle, Kris Ver Donck (Janssen Research Foundation, Beerse, België), Albrecht de Vries, 
Johan Arends en Jos van Gorp (Janssen Pharmaceutica, Tilburg, Nederland): van jullie 
heb ik geleerd dat er ook veel overeenkomsten bestaan tussen 'de Farmaceut' en 'de 
Academie'. Dhr. Ross (ziekenhuisapotheker, Bennekom) en Dhr. Duyn (Wyeth 
Laboratories, Hoofddorp) wil ik bedanken voor het belangenloos ter beschikking stellen 
van adenosine en adenosine-5'-tnfosfaat. 
Familie en vrienden, bedankt voor jullie begrip en geduld 
Henny, zonder jouw steun en vermogen tot relativeren had ik deze klus nooit kunnen 
klaren. 
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Curriculum vitae 
Gerard Rongen werd geboren op 5 maart 1965 in Breda Na het behalen van zijn 
Gymnasium В diploma (Norbertus College, Roosendaal), begon hij in 1983 de studie 
Geneeskunde aan de Medische Faculteit van de Katholieke Universiteit in Nijmegen In 
1987 behaalde hij daar het Doctoraal Examen Geneeskunde. In 1988 begon hij zijn co-
assistenlschappen in het Academisch Ziekenhuis Nijmegen, St Radboud en geaffilieerde 
ziekenhuizen In 1990 behaalde hij het artsexamen (Cum Laude) Direkt daarna vervolgde 
hij zijn loopbaan in de kliniek voor Inwendige Ziekten, afdeling Algemeen Interne 
Geneeskunde van het Academisch Ziekenhuis Nijmegen (Hoofd Prof Dr. A. van 't 
Laar) Aanvankelijk was hij hier kortdurend werkzaam als arts-assistent geneeskundige. 
Vanaf december 1990 was hij aan deze afdeling verbonden als wetenschappelijk 
medewerker Na een onderzoek naar de effecten van renine-remming bij patiënten met 
essentiële hypertensie (onder leiding van Dr J W M Lenders) begon hij op 1 augustus 
1991 aan het het onderzoeksproject getiteld 'de rol van ATP als cotransmitter in het 
sympathisch zenuwstelsel van de mens' dat uiteindelijk heeft geleid tot dit proefschrift. 
Op 1 augustus 1994 is hij begonnen aan de opleiding tot internist in de Kliniek voor 
Inwendige Ziekten van het Rijnstate ziekenhuis te Arnhem (opleider Dr L Verschoor) 
Van 1 september 1995 tot 31 augustus 1996 is hij als research fellow verbonden aan de 
afdeling Cardiologie van het Mount Sinai Hospital in Toronto (Hoofd Dr. John S. 
Floras) HÍJ IS gehuwd met Henny Hesselmans Samen hebben zij een zoon, Sjoerd 
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STELLINGEN 
behorende bij het proefschrift: 
Vascular pharmacology of adenosine and 
adenosine-5'-triphosphate in humans 
Gerard Rongen 
Nijmegen, 5 januari 1996 
1 Bij toediening van een selectieve remmer van het nucleosidetransport in het 
vaatbed van de onderarm worden de lokale effecten van endogeen adenosine geca-
moufleerd door een reflexmatige activering van het sympathisch zenuwstelsel (dit 
proefschrift, hoofdstuk 2 en 4) 
2 De nucleosidetransportremmer draflazine is in staat om het effect van endogeen 
interstitieel adenosine te potentieren, zelfs indien draflazine zo laag gedoseerd 
wordt dat er geen systemische hemodynamische effecten optreden (dit proefschrift, 
hoofdstuk 2 en 4) 
3 Het toegenomen ademminuutvolume na draflazine-infusie (dit proefschrift, 
hoofdstuk 3) suggereert dat deze nucleosidetransportremmer slechts matig de 
bloedhersenbarnère van de mens passeert Gezien het potentieel groot klinisch 
belang van cerebrale nucleosidetransportremming bij de preventie van cerebrale 
infarcten dient deze suggestie geverifieerd te worden door bijvoorbeeld de 
draflazineconcentratie te bepalen in de liquor cerebrospinalis 
4 In het vaatbed van de onderarm wordt de afgifte van noradrenaline uit sympathi-
sche zenuwvezels presynaptisch geremd door endogeen adenosine (dit proefschrift, 
hoofdstuk 4) 
5 Stimulatie van het sympathisch zenuwstelsel door endogeen adenosine draagt bij 
aan een optimale aanpassing van de circulatie aan situaties van ischemie of 
zuurstotgebrek 
6 Іп-мпо hebben hoge concentraties draflazine of dipyndamol een dodend effect op 
de erytlirocytaire stadia van de malaria parasiet Plasmodium Falciparum (eigen 
waarneming, in samenwerking met Ton Lensen, afdeling Medische Parasitology, 
Academisch Ziekenhuis Nijmegen) Gezien het wereldwijde belang van een goede 
malariabestrijding behoort deze waarneming in-vivo geverifieerd te worden 
7 Tot tenminste 50 minuten na infusie van acetylcholine in de arteria brachialis van 
de mens dient met carry-over effecten rekening gehouden te worden (dit proef­
schrift, hoofdstuk 6) 
8 In klinisch farmacologisch onderzoek is het proefdier een onacceptabel substituut 
voor de mens (du proefschrift, hoofdstuk 2 en 6) 
9 Bij een onverwachte observatie dient altijd eerst de kwaliteit van het meetinstru­
ment te worden onderzocht (Rongen GA, Janssen RWMM, Hoefnagels WHL 
Neth J Med 1991, 39 A69 (abstract) en Rongen GA, Bos WJW, Lenders JWM, 
van Monttrans GA, van Lier HJJ, van Goudoever J, Wesseling KH, Thien Th 
Am J Hypertens 199*5, 8 237-248) 
10 Zowel ten gevolge van tarmacodynamische als farmacokinetische tekortkomingen 
zullen de huidige renineremmers in de dagelijkse patiëntenzorg nooit een plaats 
krijgen als antihypertensivum (Rongen GA, Lenders JWM, Smits P, Thien Th. 
Chn Pharmacokmet 1995, 95 658-668) 
11 Onderzoekers kun je zien als een tikje neurotische mensen die het leven niet 
helemaal aankunnen en het daarom verkleinen tot een onderzoeksprobleempje Als 
het opgelost is, denken ze dat ze iets belangrijks gedaan hebben (P. Borst, uit 
rubriek 'Gezegd', Gelderlander, 29 augustus 1992) 
12 De ïmpacttactor van een wetenschappelijk tijdschrift is een slechte indicator voor 
de kwaliteit van het daarin gepubliceerd onderzoek 
13 Violisten met hypermobiliteit van vinger- en polsgewrichten hebben minder 
klachten van deze gewrichten dan hun collega's zonder deze hypermobiliteit 
(Larsson L-G, Baum J, Mudholkar GS, Kollia GD N Engl J Med 1993,329 1079-
1082) De mobiliteit van deze gewrichten is door frequent bespelen van een viool 
te verhogen (eigen waarneming) Dit is als een vorm van 'preconditioning' te 
beschouwen 
14 Een computer is een essentieel werktuig bij het uitvoeren en publiceren van 
wetenschappelijk onderzoek Daarom dient iedere promovendus de beschikking te 
hebben over een computer die gefinancierd wordt door de werkgever en die de 
promovendus in bruikleen heett gedurende de periode van onderzoek en bewerking 
van het proefschrift 
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